
<html lang="en"     class="pb-page"  data-request-id="242f1f15-2268-48f2-9e51-6d4f06b9447c"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2016.59.issue-13;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.6b00374;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery and Rational Design of Pteridin-7(8H)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants" /></meta><meta name="dc.Creator" content="Deheng  Sun" /></meta><meta name="dc.Creator" content="Yu  Yang" /></meta><meta name="dc.Creator" content="Jiankun  Lyu" /></meta><meta name="dc.Creator" content="Wei  Zhou" /></meta><meta name="dc.Creator" content="Wenlin  Song" /></meta><meta name="dc.Creator" content="Zhenjiang  Zhao" /></meta><meta name="dc.Creator" content="Zhuo  Chen" /></meta><meta name="dc.Creator" content="Yufang  Xu" /></meta><meta name="dc.Creator" content="Honglin  Li" /></meta><meta name="dc.Description" content="FLT3 has been validated as a therapeutic target for the treatment of acute myeloid leukemia (AML). In this paper, we describe for the first time, pteridin-7(8H)-one as a scaffold for potent FLT3 in..." /></meta><meta name="Description" content="FLT3 has been validated as a therapeutic target for the treatment of acute myeloid leukemia (AML). In this paper, we describe for the first time, pteridin-7(8H)-one as a scaffold for potent FLT3 in..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 22, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00374" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00374" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00374" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00374" /></link>
        
    
    

<title>Discovery and Rational Design of Pteridin-7(8H)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00374" /></meta><meta property="og:title" content="Discovery and Rational Design of Pteridin-7(8H)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/large/jm-2016-00374p_0007.jpeg" /></meta><meta property="og:description" content="FLT3 has been validated as a therapeutic target for the treatment of acute myeloid leukemia (AML). In this paper, we describe for the first time, pteridin-7(8H)-one as a scaffold for potent FLT3 inhibitors derived from structural optimizations on irreversible EGFR inhibitors. The representative inhibitor (31) demonstrates single-digit nanomolar inhibition against FLT3 and subnanomolar KD for drug-resistance FLT3 mutants. In profiling of the in vitro tumor cell lines, it shows good selectivity against AML cells harboring FLT3-ITD mutations over other leukemia and solid tumor cell lines. The mechanism of action study illustrates that pteridin-7(8H)-one derivatives suppress the phosphorylation of FLT3 and its downstream pathways, thereby inducing G0/G1 cell cycle arrest and apoptosis in AML cells. In in vivo studies, 31 significantly suppresses the tumor growth in MV4–11 xenograft model. Overall, we provide a structurally distinct chemical scaffold with which to develop FLT3 mutants-selective inhibitors for AML treatment." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00374"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00374">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00374&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00374&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00374&amp;href=/doi/10.1021/acs.jmedchem.6b00374" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 13</span><span class="cit-fg-pageRange">, 6187-6200</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/13" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b00297" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b00390" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery and Rational Design of Pteridin-7(8<i>H</i>)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Deheng++Sun">Deheng Sun</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yu++Yang">Yu Yang</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jiankun++Lyu">Jiankun Lyu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Zhou">Wei Zhou</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wenlin++Song">Wenlin Song</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhenjiang++Zhao">Zhenjiang Zhao</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhuo++Chen">Zhuo Chen</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yufang++Xu">Yufang Xu</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Honglin++Li">Honglin Li</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science & Technology, Shanghai 200237, China</span></div><div class="corresp-info"><strong>*</strong>Z.C.: phone/fax, +86-21- 64250213; e-mail, <a href="/cdn-cgi/l/email-protection#e6858e83889c8e9389a68385939592c8838293c88588"><span class="__cf_email__" data-cfemail="44272c212a3e2c312b0421273137306a2120316a272a">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>Y.X.: phone/fax, +86-21- 64251399; e-mail, <a href="/cdn-cgi/l/email-protection#0e7768767b4e6b6d7b7d7a206b6a7b206d60"><span class="__cf_email__" data-cfemail="f58c938d80b59096808681db909180db969b">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>H.L.: phone/fax, +86-21- 64250213; e-mail, <a href="/cdn-cgi/l/email-protection#cca4a0a0a58ca9afb9bfb8e2a9a8b9e2afa2"><span class="__cf_email__" data-cfemail="741c18181d3411170107005a1110015a171a">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00374&amp;href=/doi/10.1021%2Facs.jmedchem.6b00374" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 13</span><span class="cit-pageRange">, 6187–6200</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 7, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>11 March 2016</li><li><span class="item_label"><b>Published</b> online</span>22 June 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 July 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00374" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00374</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6187%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DDeheng%2BSun%252C%2BYu%2BYang%252C%2BJiankun%2BLyu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D13%26contentID%3Dacs.jmedchem.6b00374%26title%3DDiscovery%2Band%2BRational%2BDesign%2Bof%2BPteridin-7%25288H%2529-one-Based%2BInhibitors%2BTargeting%2BFMS-like%2BTyrosine%2BKinase%2B3%2B%2528FLT3%2529%2Band%2BIts%2BMutants%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6200%26publicationDate%3DJuly%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00374"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2120</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">16</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00374" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery and Rational Design of Pteridin-7(8H)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Deheng&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Yu&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Jiankun&quot;,&quot;last_name&quot;:&quot;Lyu&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Wenlin&quot;,&quot;last_name&quot;:&quot;Song&quot;},{&quot;first_name&quot;:&quot;Zhenjiang&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Zhuo&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Yufang&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Honglin&quot;,&quot;last_name&quot;:&quot;Li&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;22&quot;,&quot;issue&quot;:&quot;13&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;6187-6200&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00374&quot;},&quot;abstract&quot;:&quot;FLT3 has been validated as a therapeutic target for the treatment of acute myeloid leukemia (AML). In this paper, we describe for the first time, pteridin-7(8H)-one as a scaffold for potent FLT3 inhibitors derived from structural optimizations on irreversible EGFR inhibitors. The representative inhibitor (31) demonstrates single-digit nanomolar inhibition against FLT3 and subnanomolar KD for drug-resistance FLT3 mutants. In profiling of the in vitro tumor cell lines, it shows good selectivity against AML cells harboring FLT3-ITD mutations over other leukemia and solid tumor cell lines. The mechanism of action study illustrates that pteridin-7(8H)-one derivatives suppress the phosphorylation of FLT3 and its downstream pathways, thereby inducing G0/G1 cell cycle arrest and apoptosis in AML cells. In in vivo studies, 31 significantly suppresses the tumor growth in MV4–11 xenograft model. Overall, we provide a structurally distinct chemical scaffold with which to develop FLT3 mutants-selective inhibitors for AML &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00374&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00374" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00374&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00374" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00374&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00374" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00374&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00374&amp;href=/doi/10.1021/acs.jmedchem.6b00374" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00374" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00374" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00374%26sid%3Dliteratum%253Aachs%26pmid%3D27266526%26genre%3Darticle%26aulast%3DSun%26date%3D2016%26atitle%3DDiscovery%2Band%2BRational%2BDesign%2Bof%2BPteridin-7%25288H%2529-one-Based%2BInhibitors%2BTargeting%2BFMS-like%2BTyrosine%2BKinase%2B3%2B%2528FLT3%2529%2Band%2BIts%2BMutants%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D13%26spage%3D6187%26epage%3D6200%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291352" title="Screening assays">Screening assays</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/13" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/jmcmar.2016.59.issue-13/20160714/jmcmar.2016.59.issue-13.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/medium/jm-2016-00374p_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/large/jm-2016-00374p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00374&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">FLT3 has been validated as a therapeutic target for the treatment of acute myeloid leukemia (AML). In this paper, we describe for the first time, pteridin-7(8<i>H</i>)-one as a scaffold for potent FLT3 inhibitors derived from structural optimizations on irreversible EGFR inhibitors. The representative inhibitor (<b>31</b>) demonstrates single-digit nanomolar inhibition against FLT3 and subnanomolar <i>K</i><sub>D</sub> for drug-resistance FLT3 mutants. In profiling of the in vitro tumor cell lines, it shows good selectivity against AML cells harboring FLT3-ITD mutations over other leukemia and solid tumor cell lines. The mechanism of action study illustrates that pteridin-7(8<i>H</i>)-one derivatives suppress the phosphorylation of FLT3 and its downstream pathways, thereby inducing G<sub>0</sub>/G<sub>1</sub> cell cycle arrest and apoptosis in AML cells. In in vivo studies, <b>31</b> significantly suppresses the tumor growth in MV4–11 xenograft model. Overall, we provide a structurally distinct chemical scaffold with which to develop FLT3 mutants-selective inhibitors for AML treatment.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44035" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44035" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">FLT3, a member of the class III receptor tyrosine kinase family, plays a pivotal role in the development of immature hematopoietic cells.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Normally, through binding to its ligand, dimerization and activation of FLT3 lead to phosphorylation of downstream signaling pathways,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> involving the Ras/mitogen-activated protein kinase (Ras/MAPK) and phosphatidylinositol 3-kinase/Akt (PI3K/Akt) pathways.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Mutated FLT3, however, causes constitutive ligand-independent activation of the target. Commonly, internal tandem duplication (ITD) mutations of FLT3 are harbored in approximately 30% of acute myeloid leukemia (AML) patients and are associated with poor prognosis.<a onclick="showRef(event, 'ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6">(4-6)</a> FLT3-ITD mutations prefer to activate the downstream effector signal transducer and activator of transcription 5 (STAT5), which results in aberrant proliferation of leukemia cells.<a onclick="showRef(event, 'ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9">(7-9)</a> In addition, subsequent point mutations in the activation loop in the FLT3 kinase domain (KD), such as D835Y, D835H, are identified as primary mechanisms of resistance to most FLT3 inhibitors which have been developed as clinical-stage drug candidates.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Thus, inhibition of FLT3 kinase and its mutants is a promising therapy for AML.</div><div class="NLM_p">As FLT3 inhibitors represent a promising modality for AML treatment, discovery of novel scaffolds for selective FLT3 inhibitors has been an attractive research area in recent years.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a> Several potent drug candidates have been advanced to clinic trials, including midostaurin (PKC-412),<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> lestaurtinib (CEP-701),<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> tandutinib (MLN-518),<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> sunitinib (SU11248),<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> sorafenib (BAY 43-9006),<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> quizartinib (AC220),<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and crenolanib.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19, 20)</a> However, the rapid development of secondary drug-resistant KD mutations of FLT3 in AML patients was found to limit the clinical R&D of the majority of FLT3 inhibitors with the exception of crenolanib, which retains activity against ITD mutants and most resistance-conferring KD mutants of FLT3 in in vitro and in vivo models.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21, 22)</a> Consequently, discovery of efficacious inhibitors with novel scaffolds against FLT3 and its mutants is an unmet need for AML monotherapy.</div><div class="NLM_p last">In our previous studies, the pteridin-7(8<i>H</i>)-one derivative (<b>1</b>) was identified as a highly potent irreversible inhibitor targeting epidermal growth factor receptor (EGFR) tyrosine kinases through a computational scaffold hopping protocol.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Recently, we unexpectedly found that <b>1</b> shows 99% and 82% inhibition of FLT3 at 10 μM and 1 μM, respectively, in a panel of 26 kinases (see <a href="/doi/suppl/10.1021/acs.jmedchem.6b00374/suppl_file/jm6b00374_si_001.pdf" class="ext-link">Figure S1 in Supporting Information</a>). However, this inhibition corresponded to only a moderate half maximal inhibitory concentration (IC<sub>50</sub>) of 312 nM. We began our study of pteridin-7(8<i>H</i>)-one derived FLT3 inhibitors by analyzing the structure–activity relationships of previously synthesized pteridin-7(8<i>H</i>)-one irreversible EGFR inhibitors. Then, with the assistance of a FLT3 homology model and a subsequent docking study, we carried out a series of structural modifications on these lead compounds to improve FLT3 inhibition activities and growth inhibition potency of pteridin-7(8<i>H</i>)-ones against AML cells. Subsequently, we explored the antitumor mechanism of representative compounds in AML cell lines and investigated their kinome profiling, binding affinities for drug resistance related mutants, in vitro antiproliferative activities against leukemia and solid tumor cell lines, pharmacokinetics (PK) properties in rats, and in vivo efficacy in MV4–11 tumor xenografts models. We were able to convert previously studied irreversible EGFR inhibitors into highly potent FLT3 inhibitors and for the first time introduce this novel and unique pteridin-7(8<i>H</i>)-one scaffold into the family of FLT3 inhibitors.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14004" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14004" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The pteridin-7(8<i>H</i>)-one analogues used in this study were synthesized as shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Details of the synthetic method were reported previously.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Condensation of commercially available 2,4-dichloro-5-nitropyrimidine (<b>I</b>) with a 3′- or 4′-substituted arylamine in 1,4-dioxane containing <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA) gave compound <b>II</b>. Compound <b>III</b> was then obtained by nucleophilic substitution of compound <b>II</b> with a second substituted arylamine. The nitro group in <b>III</b> was reduced by hydrogenation with Pd/C in ethanol to provide <b>IV</b> containing a nucleophilic amino group in good yield. The diaminopyrimidine compound (<b>IV</b>) was cyclized with ethyl glyoxalate and acetic acid in refluxing ethanol to form the pteridin-7(8<i>H</i>)-one core in compound <b>V</b>. Finally, compound <b>V</b> was deprotected in trifluoroacetic acid (TFA) to generate the aminopteridin-7(8<i>H</i>)-ones (<b>VI</b>), which was further acylated with the corresponding acyl chloride or sulfonyl chloride to obtain the target compounds (<b>VII</b>).</div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/medium/jm-2016-00374p_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/large/jm-2016-00374p_0009.jpeg" id="GRAPHIC-d639e364-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Pteridin-7(8<i>H</i>)-one Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/large/jm-2016-00374p_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00374&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagent and conditions: (a) ArNH<sub>2</sub>, DIPEA, 1,4-dioxane, rt; (b) ArNH<sub>2</sub>, DIPEA, 1,4-dioxane, rt; (c) Pd/C, H<sub>2</sub>, EtOH; (d) EtOOC–CHO, HOAc, EtOH, reflux; (e) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt; (f) acyl chloride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt or CH<sub>3</sub>SO<sub>2</sub>Cl, 1-methyl-2-pyrrolidinone, CH<sub>3</sub>CN, 0 °C to rt.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23281" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23281" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Binding Mode Analysis</h3><div class="NLM_p">Previously, we reported the discovery of the lead compound <b>1</b> as a potent and irreversible EGFR inhibitor. Reviewing its profile against a panel of 26 kinases, we found that it showed only moderate inhibition against FLT3. An explanation of this observation could be that the interaction modes of the lead compound with FLT3 and EGFR share a high degree of similarity (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>A). The predicted binding mode shown in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>A was obtained through docking the lead compound into FLT3 homology model built in an active conformation. The structure of EGFR (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>) was aligned to the FLT3 homology model. In both structures, the aminopyrimidine ring interacts with the residue (FLT3, Cys694; EGFR, Met793) at hinge region through classical bidentate hydrogen bonding. A hydrophobic sandwich with the pteridin-7(8<i>H</i>)-one core and a floor leucine residue and a ceiling alanine residue (FLT3, Ala642 and Leu818; EGFR, Ala743 and Leu844) is formed, further stabilizing the binding interactions between lead scaffold and target. The most noticeable difference within the two inhibitor–kinase complexes is the distinct interaction between the Michael acceptor and the target. The electrophilic group forms a covalent bond with the thiol of Cys797 of EGFR, and this has been widely reported<a onclick="showRef(event, 'ref24 ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26 ref27">(24-27)</a> as a vital contribution to EGFR binding affinity and selectivity. On the contrary, compound <b>1</b> binds to FLT3 noncovalently, for the corresponding location in FLT3 is occupied by a larger aspartic acid (Asp698), and the acrylamide group has to swing away from it and forms a hydrogen-bond interaction with the main chain carbonyl group of Arg815.</div><figure id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/medium/jm-2016-00374p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/large/jm-2016-00374p_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Compound <b>1</b> at the active site of the FLT3 homology model (template PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG">1PKG</a>) with the P-loop hidden for clarity. The green-colored compound <b>1</b> is presented as a ball and stick model. The contacting residues in the active site are depicted as stick, and the backbone of hinge region is shown as stick. The EGFR crystal structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>) is aligned to the homology model of FLT3, and residues in EGFR are highlighted in pink stick presentation. (B) SAR overview. (C) FLT3 inhibition IC<sub>50</sub> curves of compounds <b>1</b> and <b>31</b>. (D) Compound <b>31</b> docked into the active site of the FLT3 homology model with the P-loop hidden for clarity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/large/jm-2016-00374p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00374&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> In Vitro Structure–Activity Relationship (SAR) Interpretation and Structural Modification</h3><div class="NLM_p">The initial SAR analysis was based on the reported pteridin-7(8<i>H</i>)-one derivatives (compounds <b>1</b>–<b>21</b>; see <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). At first, with the same Michael acceptor group (R<sup>2</sup>) in the 3′-position we compared the variations of R<sup>1</sup> on the substituted aniline at the C2 position (<b>1</b>–<b>10</b>). Of all these structures, the lead compound with a 4-methylpiperazinyl group (<b>1</b>) displayed the best FLT3 inhibitory activity. This experimental observation agrees significantly with the computational results. The charged 4-methylpiperazinyl group is oriented toward the solvent channel and forms a hydrogen bond with the side chain of Asn701. Absence of that interaction leads to significant loss of activity (<b>1</b> vs <b>8</b>), further emphasizing that a key H-bond contact in this region has a positive effect on FLT3 inhibition. Next, we turned our attention to the impact of Michael acceptors on the FLT3 potency. Comparing the compounds in pairs with the same R<sup>1</sup> substitution but varied Michael acceptor at the 3′ or 4′-position (<b>1</b> vs <b>11</b>, <b>7</b> vs <b>12</b>, <b>8</b> vs <b>13</b>, <b>9</b> vs <b>14</b>, <b>10</b> vs <b>15</b>), we found that the Michael acceptor at 4′-position was more favorable for FLT3 inhibition. Increasing the length of the acrylamide fragment with the addition of a dialkylaminomethyl group (<b>7</b> vs <b>16</b>, <b>12</b> vs <b>17</b>) produced no detectable variation in FLT3 inhibition, but when the acrylamide group was replaced by a smaller amino group (<b>7</b> vs <b>18</b>, <b>12</b> vs <b>19</b>), the analogs displayed a dramatic improvement in potency. When compared with compound <b>7</b>, compound <b>18</b> showed a >50-fold enhancement in FLT3 inhibitory activity. These observations indicate that the Michael acceptor is detrimental to FLT3 inhibitory activity. In addition, the FLT3 potency decreased when the group in R<sup>3</sup> at the 2-position was methoxy (<b>1</b> vs <b>20</b>, <b>11</b> vs <b>21</b>). For new round of chemical modification, a smaller substituent could be introduced at this position where it might eliminate a possible steric clash with the hinge region. This initial SAR analysis therefore paved the way for the next round of rational lead optimization.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro Enzymatic Inhibitory and Cellular Antiproliferative Activities of Pteridin-7(8<i>H</i>)-one Compounds<a class="ref internalNav" href="#t1fn1" aria-label="g">g</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/medium/jm-2016-00374p_0010.gif" alt="" id="GRAPHIC-d639e606-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/medium/jm-2016-00374p_0011.gif" alt="" id="GRAPHIC-d639e607-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/medium/jm-2016-00374p_0012.gif" alt="" id="GRAPHIC-d639e608-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/medium/jm-2016-00374p_0013.gif" alt="" id="GRAPHIC-d639e609-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn2"><div class="footnote" id="t1fn2"><sup>Table a</sup><p class="last">MV4–11, cell lines harboring FLT3-ITD mutation and characterized by a ligand-independent FLT3 receptor activation.</p></div><div class="footnote" id="t1fn3"><sup>Table b</sup><p class="last">K562, chronic myeloid leukemia cell lines without FLT3 expression.</p></div><div class="footnote" id="t1fn4"><sup>Table c</sup><p class="last">WI-38, normal embryonic lung tissue cell lines.</p></div><div class="footnote" id="t1fn5"><sup>Table d</sup><p class="last">Data from  <cite>Blood</cite> <span class="NLM_year">2009</span>, <em>114</em> (14), 2984–2992.</p></div><div class="footnote" id="t1fn6"><sup>Table e</sup><p class="last">Data from  <cite>Cancer Cell</cite> <span class="NLM_year">2002</span>, <em>1</em> (5), 421–432.</p></div><div class="footnote" id="t1fn7"><sup>Table f</sup><p class="last">Not determined.</p></div><div class="footnote" id="t1fn1"><sup>Table g</sup><p class="last">Data are averages of at least three independent determinations and reported as the mean ± SD (standard deviation).</p></div></div><div></div></div><div class="NLM_p">In the light shed by the previous docking study, new SAR explorations were devised to guide synthesis of the following analogs. A schematic representation is shown in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>B. In detail, the R<sup>1</sup> group is a binary option (methylpiperazinyl or methoxy), while the Michael acceptor group (R<sup>2</sup>) and R<sup>3</sup> group on the aniline segment are substituted with diverse groups for a second round of lead optimization.</div><div class="NLM_p">In the new round of structural modification, R<sup>2</sup> substituents were investigated first. The initial SAR study suggested that removal of the Michael acceptor in R<sup>2</sup> should be beneficial to FLT3 inhibition. The binding mode shown in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>A also implied that when the acrylamide group is converted into an amino substituent, the nearby Asp698 residue becomes accessible and available to interact with the R<sup>2</sup> group.</div><div class="NLM_p">We applied this rationale to analogs bearing a 4-methylpiperazinyl group in R<sup>1</sup> (<b>1</b> vs <b>22</b>, <b>11</b> vs <b>23</b>). Biological testing showed 50-fold and 5-fold improvements in FLT3 inhibition, respectively, supporting this hypothesis (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00374/suppl_file/jm6b00374_si_001.pdf" class="ext-link">Figure S2</a>). The docking scores for these four compounds are also consistent with the experimental observations (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00374/suppl_file/jm6b00374_si_001.pdf" class="ext-link">Table S1 and Figure S3B</a>). We attempted to acetylate the amino group at the 4′-position of R<sup>2</sup> to investigate whether the amino was crucial to the activity. When R<sup>1</sup> is methoxy, further substitution at the R<sup>2</sup> position with free amino (<b>19</b>), acetamide (<b>24</b>), or methanesulfonamide (<b>25</b>) displayed decreased FLT3 IC<sub>50</sub> values of 29, 127, 255 nM, respectively. A similar tendency was also observed with compounds <b>23</b>, <b>26</b>, and <b>27</b>. These results confirmed that the exposed amino in this position is more favorable for FLT3 inhibition. Given the modeled structure of FLT3, a possible explanation is that the amino group in R<sup>2</sup> might form a hydrogen-bond interaction with the deprotonated carboxyl group of Asp698. If the amino group is substituted with electron withdrawing group, the strength of the favorable electrostatic interaction will be greatly diminished. Comparison of <b>23</b> with <b>28</b> (8.7 nM vs 37.2 nM) demonstrated that one more degree of freedom (DOF) caused by the additional methylene (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00374/suppl_file/jm6b00374_si_001.pdf" class="ext-link">Figure S4A and Figure S4C</a>) may increase the difficulty of maintaining optimal hydrogen bond geometries with Asp698, leading to a 4-fold loss in activity. Besides, the binding potency of compound <b>29</b> is similar to <b>23</b> (8.2 nM vs 8.7 nM). This is probably due to the unchanged DOF and piperazine ring’s hydrogen bond with Asp698 (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00374/suppl_file/jm6b00374_si_001.pdf" class="ext-link">Figure S4B</a>). After all, the hydrogen bond between the R<sup>2</sup> substituted group and the deprotonated carboxyl group of Asp698 plays an important role in FLT3 inhibition.</div><div class="NLM_p last">As was mentioned in the overall SAR, a methyl group was introduced to the 2-position in R<sup>3</sup> on substituted aniline at C2 position, but like the early analogs, the FLT3 potency was also reduced (<b>19</b> vs <b>30</b>). According to the predicted binding mode (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>A), the methyl or methoxy group at 2-position should increase the possibility of a steric clash with the residues at the hinge region, such as the side chain of Tyr693, thereby attenuating the stability of the hinge binder. However, the R<sup>3</sup> group at 3-position fell into a different situation. On the one hand, the hydrophobic slot formed by Leu616 and Gly697 (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00374/suppl_file/jm6b00374_si_001.pdf" class="ext-link">Figure S5</a>) is exposed to solvent,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> which leaves limited space for small substitutions at 3-positon in R<sup>3</sup>. On the other hand, consistent with the docked model (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>D), introduction of a small group at the 3-position can increase the torsion angle between phenyl and 4-methylpiperazinyl ring, further stabilizing the hydrogen-bond contact between 4-methylpiperazinyl and Asn701. Moreover, it may also affect the perpendicular orientation of the two phenyl-ring system within the scaffold, leading to a favorable T-shaped intramolecular π–π stacking interaction. As expected, when the methyl or methoxy group is transferred from the 2-position (<b>30</b>) to the 3-position (<b>31</b>), the FLT3 inhibitory potency increases immediately. Compound <b>31</b> in fact displays the most potent FLT3 inhibitory effect (IC<sub>50</sub> = 1.56 nM) in this series. Additionally, introduction of a halogen atom such as chlorine at this position did not obviously decrease the FLT3 activity (<b>23</b> vs <b>33</b>, <b>19</b> vs <b>34</b>). But when a fluorine atom is placed at the 3-position, the corresponding analogues present declining potency (<b>23</b> vs <b>35)</b>, suggesting that strong electron-withdrawing groups are not suitable at the 3-position of R<sup>3</sup>. All the SAR exploration at the 3-position underlines the fact that introduction of a methyl or methoxy at the 3-position in R<sup>3</sup> is an important contribution to improvement of the inhibitory activity against FLT3 of this series.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> In Vitro Antiproliferative Activities of Pteridin-7(8<i>H</i>)-one Derivatives</h3><div class="NLM_p last">The antiproliferative potency of pteridin-7(8<i>H</i>)-one derivatives against selected cell lines was measured using MTT or SRB assays. The target compounds were first evaluated against the FLT3-driven AML cell line MV4–11 containing an FLT3-ITD-activating mutation. The antiproliferative activities against MV4–11 cells of targeted compounds normally correspond with their FLT3 enzymatic inhibitory activities, ranging from 51 nM to more than 10 000 nM. Some of these were 5 times more potent than the positive control MLN518 and comparable with the positive control AC220. Introduction of a Michael acceptor at the R<sup>2</sup> position leads to reduced potency. For the majority of compounds, the IC<sub>50</sub> values were >1 μM in MV4–11 cell lines, further confirming that Michael acceptor is relatively unfavorable for FLT3 targeting (<b>1</b> vs <b>22</b>, <b>11</b> vs <b>23</b>). In addition, at the R<sup>1</sup> position, the 4-methylpiperazinyl moiety significantly contributes to cellular growth inhibition more than does a methoxy group. For example, the 4-methylpiperazinyl-group-bearing derivatives <b>22</b> and <b>23</b> were 8–22 times more potent than the methoxy derivatives <b>18</b> and <b>19</b> (383 nM vs 3487 nM, 297 nM vs 6887 nM). Furthermore, the introduction of a methyl group at the R<sup>3</sup>-position greatly enhances the antiproliferative activity. For instance, compound <b>31</b> was a 5 times more potent antiproliferative agent (51 nM vs 297 nM) than <b>23</b> as a result of introduction of the methyl group. Almost all the tested pteridin-7(8<i>H</i>)-one derivatives, including the potent MV4–11 growth inhibition agents, were ineffective against the FLT3-independent chronic myelogenous leukemia (CML) cell line K562. In the normal cell line WI-38, compounds such as <b>23</b> and <b>31</b>, which target FLT3 efficiently, were 33- to 81-fold less potent than they were in MV4–11 cells. We therefore concluded that the efficient FLT3-targeting pteridin-7(8<i>H</i>)-one derivatives exhibit selective antiproliferative activities against FLT3-driven cells rather than normal toxicity.</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Inhibition of FLT3 Phosphorylation and Downregulation of Downstream Signal Proteins in the MV4–11 Cell Line</h3><div class="NLM_p">To investigate further whether the anti-AML activity is associated with inhibitory activation of FLT3 and its downstream signaling proteins, the representative compound <b>31</b> was assessed and quantified by Western blot analysis (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). After a 2 h treatment, <b>31</b> at a concentration of 10 nM inhibits FLT3 phosphorylation by more than 50% and down-regulates the phosphorylation of the downstream signaling proteins, AKT, ERK1/2, and STAT5 in a dose-dependent manner in MV4–11 cells, which are comparable with the known FLT3 inhibitor MLN518. The representative compound from the first round of optimization, <b>23</b>, exhibits less potent inhibition of FLT3 and downstream cell signaling proteins than <b>31</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00374/suppl_file/jm6b00374_si_001.pdf" class="ext-link">Figure S6</a>), which are consistent with the SAR on the FLT3 enzymatic inhibitory activities and antiproliferative activities in MV4–11 cells.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/medium/jm-2016-00374p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/large/jm-2016-00374p_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Western blot analysis. (A) Compound <b>31</b> inhibits FLT3 autophosphorylation and the phosphorylation of downstream signaling effectors STAT5, ERK, and AKT in 2 h. (B) Immunoblots quantification of p-FLT3, p-STAT5, p-AKT, and p-ERK, respectively. All bands were quantified and normalized by GAPDH. The data are expressed as the mean ± SEM from at least three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/large/jm-2016-00374p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00374&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Induction of Cell Cycle Arrest and Cell Apoptosis</h3><div class="NLM_p">Cell cycle analysis of MV4–11 cells treated with compound <b>31</b> showed dose-dependent increases in the G<sub>0</sub>/G<sub>1</sub> and subG<sub>1</sub> populations, indicating both cell cycle arrest and cell death (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A). The percentage of cells in the G<sub>0</sub>/G<sub>1</sub> and sub-G<sub>1</sub> populations increased from 70% to 86% and 0% to 12%, respectively, after treatment with 100 nM compound <b>31</b> for 48 h. As detected by annexin V staining, a dose-dependent increase in the percentage of apoptotic and dead cells was also seen, which is consistent with the increased sub-G<sub>1</sub> cell population observed in MV4–11 cells treated with compound <b>31</b>. (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B). In the presence of vehicle alone for 48 h, 9% of the cells were in apoptosis. Treatment with 100 nM compound <b>31</b> for 48 h led to an increase in the degree of apoptosis by a factor of 4.5 (40%). Remarkable cell cycle arrest and apoptosis were also observed for compound <b>23</b> at a concentration of 1000 nM (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00374/suppl_file/jm6b00374_si_001.pdf" class="ext-link">Figure S7</a>). Accordingly, this series of pteridin-7(8<i>H</i>)-one derivatives was able to block the G<sub>0</sub>/G<sub>1</sub> cell cycle, trigger apoptosis and inhibit the growth of FLT3 mutant MV4–11 cells by modulating the FLT3 signaling pathways.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/medium/jm-2016-00374p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/large/jm-2016-00374p_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. After a 48 h treatment, compound <b>31</b> induces dose-dependent cell cycle G<sub>0</sub>/G<sub>1</sub> phase arrest (A) and apoptosis (B) in MV4–11 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/large/jm-2016-00374p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00374&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Binding Affinity against Wild-Type and Activated Mutations of FLT3 Kinase</h3><div class="NLM_p">By profiling compound <b>31</b> in a panel of 468 kinases at a concentration of 1 μM using DiscoverX’s KINOMEScan technology, we identified the kinase selectivity of compound <b>31</b>. The <i>S</i>(10) selectivity score, which is calculated by dividing the number of nonmutant kinases which are <10% of control can be determined by the total number of nonmutant kinases. From the 403 nonmutant kinases there were 34 hits, giving a selectivity score of 0.084 (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.6b00374/suppl_file/jm6b00374_si_001.pdf" class="ext-link">Tables S2 and S3</a>). Clinically relevant FLT3-resistant mutants, such as ITD, D835V, ITD/D835V, are inhibited with percent control values of ≤1%. This was further confirmed by <i>K</i><sub>D</sub> determination. As shown in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>, compound <b>31</b> binds wild-type FLT3 and FLT3 variants with high affinity (<i>K</i><sub>D</sub> = 0.25–6.9 nM). In particular, compound <b>31</b> revealed good binding affinity for drug-resistance mutants<a onclick="showRef(event, 'ref29 ref30 ref31 ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref31 ref32 ref33 ref34">(29-34)</a> such as D835V (<i>K</i><sub>D</sub> = 0.25 nM), ITD/D835V (<i>K</i><sub>D</sub> = 0.79 nM), and ITD/F691L (<i>K</i><sub>D</sub> = 5.7 nM). The relatively lower binding affinity of compound <b>23</b> was consistent with these results. In addition, compound <b>31</b> showed comparable binding affinity for wild-type FLT3 and FLT3-ITD mutant with AC220.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/medium/jm-2016-00374p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/large/jm-2016-00374p_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Profiling of compound <b>31</b> at a 1 μM concentration versus a panel of 468 kinase targets. The blue circles label the FLT3 and its related mutants. The red circles label the off-targets. FLT3, five main FLT3-related mutants, and seven main off-targets (inhibition with percent control values of ≤1%) are labeled in bold font style.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/large/jm-2016-00374p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00374&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Binding Affinity to Wild-Type and Mutant FLT3 of Compounds <b>23</b>, <b>31</b>, and AC220</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="8" align="center">binding affinity <i>K</i><sub>D</sub>, nM</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">wild type</th><th class="colsep0 rowsep0" align="center">ITD</th><th class="colsep0 rowsep0" align="center">D835H</th><th class="colsep0 rowsep0" align="center">D835Y</th><th class="colsep0 rowsep0" align="center">D835V</th><th class="colsep0 rowsep0" align="center">ITD/D835V</th><th class="colsep0 rowsep0" align="center">ITD/F691L</th><th class="colsep0 rowsep0" align="center">autoinhibited</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">75</td><td class="colsep0 rowsep0" align="left">270</td><td class="colsep0 rowsep0" align="left">44</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">nd<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">nd<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">nd<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">nd<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">6.9</td><td class="colsep0 rowsep0" align="left">1.8</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.79</td><td class="colsep0 rowsep0" align="left">5.7</td><td class="colsep0 rowsep0" align="left">79</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AC220<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">8.8</td><td class="colsep0 rowsep0" align="left">3.7</td><td class="colsep0 rowsep0" align="left">7.1</td><td class="colsep0 rowsep0" align="left">nd<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">nd<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">nd<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">nd<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Not determined.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Data from supporting information of  <cite>Nat. Biotechnol.</cite> <span class="NLM_year">2011</span>, <em>29</em> (11), 1046–1051.</p></div></div></div></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> In Vitro Antiproliferative Activities of Compound <b>31</b> against Leukemia and Solid Tumor Cell Lines</h3><div class="NLM_p last">The antiproliferative activity of compound <b>31</b> was tested against various cell lines, including leukemia and solid tumor cell lines, and the results are listed in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>. Compound <b>31</b> potently inhibits the growth of AML cell lines MV4–11 and the Molm13-harboring FLT3-ITD mutant, with IC<sub>50</sub> values of 51 nM and 33 nM, respectively. It shows much weaker growth inhibition activities against leukemia RS4;11, Molt4, HL60 cells, lung cancer H1299, H1975 cells, colorectal cancer RKO, HCT116, HT29, SW620 cells, neuroblastoma SH-SY5Y cells, with IC<sub>50</sub> values of 925, 2119, 1377, 4876, 4464, 1928, 2358, 3021, 2529, and 5566 nM, respectively). For other leukemia and solid tumor cell lines, including THP1, A549, DMS79, H146, H187, H209, and MCF7, compound <b>31</b> failed to exhibit a distinct growth inhibition effect at a concentration of 10 000 nM.</div></div><div id="sec3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> PK Properties in Rats of Compound <b>31</b></h3><div class="NLM_p">The PK properties of <b>31</b> were evaluated in rats following intravenous and oral administration (<a class="ref internalNav" href="#tbl3" aria-label="Table 03">Table 03</a>). Compound <b>31</b> was administered at a dose of 1 mg/kg in saline mixture (DMSO/PEG400/saline = 5:40:55) (iv) or 10 mg/kg in 0.5% methlcellulose (po), respectively. Its bioavailability was determined to be ∼26%, and the half-life of <b>31</b> was 3.1 h (iv) and 4.5 h (po). It had a volume distribution (27.69 L/kg) and clearance at 8.51 L h<sup>–1</sup> kg<sup>–1</sup>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. PK Properties of Compound <b>31</b> in Rats<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="6" align="center">(A) Intravenous Administration</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center">Cl (L h<sup>–1</sup> kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center">AUC<sub>(0–∞)</sub> (ng·h/mL)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">55.23 ± 9.80</td><td class="colsep0 rowsep0" align="left">8.51 ± 1.07</td><td class="colsep0 rowsep0" align="left">27.69 ± 6.72</td><td class="colsep0 rowsep0" align="left">3.11 ± 1.2</td><td class="colsep0 rowsep0" align="left">118.72 ± 13.93</td></tr></tbody></table><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="6" align="center">(B) Oral Administration</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center">AUC<sub>(0–∞)</sub> (ng·h/mL)</th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">2.17 ± 1.76</td><td class="colsep0 rowsep0" align="left">40.98 ± 17.79</td><td class="colsep0 rowsep0" align="left">4.49 ± 3.35</td><td class="colsep0 rowsep0" align="left">311.11 ± 49.23</td><td class="colsep0 rowsep0" align="left">26.42 ± 4.69</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Data are averages of three independent determinations and reported as the mean ± SD (standard deviation).</p></div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Antiproliferative Activity of Compound <b>31</b> against Various Cell Lines<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cancer type</th><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">acute myeloid leukemia</td><td class="colsep0 rowsep0" align="left">MV4–11</td><td class="colsep0 rowsep0" align="left">51 ± 9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">acute myeloid leukemia</td><td class="colsep0 rowsep0" align="left">Molm13</td><td class="colsep0 rowsep0" align="left">32.9 ± 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">acute monocytic leukemia</td><td class="colsep0 rowsep0" align="left">THP1</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">acute lymphoblastic leukemia</td><td class="colsep0 rowsep0" align="left">RS4;11</td><td class="colsep0 rowsep0" align="left">925 ± 224</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">acute lymphoblastic leukemia</td><td class="colsep0 rowsep0" align="left">Molt4</td><td class="colsep0 rowsep0" align="left">2119 ± 76</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">acute promyelocytic leukemia</td><td class="colsep0 rowsep0" align="left">HL60</td><td class="colsep0 rowsep0" align="left">1377 ± 326</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">small cell lung cancer</td><td class="colsep0 rowsep0" align="left">DMS79</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">small cell lung cancer</td><td class="colsep0 rowsep0" align="left">H146</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">small cell lung cancer</td><td class="colsep0 rowsep0" align="left">H187</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">small cell lung cancer</td><td class="colsep0 rowsep0" align="left">H209</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">lung carcinoma</td><td class="colsep0 rowsep0" align="left">A549</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">non-small-cell lung cancer</td><td class="colsep0 rowsep0" align="left">H1299</td><td class="colsep0 rowsep0" align="left">4876 ± 1329</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">non-small-cell lung cancer</td><td class="colsep0 rowsep0" align="left">H1975</td><td class="colsep0 rowsep0" align="left">4464 ± 1645</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">colon carcinoma</td><td class="colsep0 rowsep0" align="left">RKO</td><td class="colsep0 rowsep0" align="left">1928 ± 869</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">colorectal carcinoma</td><td class="colsep0 rowsep0" align="left">HCT116</td><td class="colsep0 rowsep0" align="left">2358 ± 224</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">colorectal adenocarcinoma</td><td class="colsep0 rowsep0" align="left">HT29</td><td class="colsep0 rowsep0" align="left">3021 ± 801</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">colorectal adenocarcinoma</td><td class="colsep0 rowsep0" align="left">SW620</td><td class="colsep0 rowsep0" align="left">2529 ± 271</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">neuroblastoma</td><td class="colsep0 rowsep0" align="left">SH-SY5Y</td><td class="colsep0 rowsep0" align="left">5566 ± 176</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">breast adenocarcinoma</td><td class="colsep0 rowsep0" align="left">MCF7</td><td class="colsep0 rowsep0" align="left">>10000</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Data are averages of at least three independent determinations and reported as the mean ± SD (standard deviation).</p></div></div></div></div><div id="sec3_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> In Vivo Effects of <b>31</b> against MV4–11 Tumor Xenografts</h3><div class="NLM_p">The in vivo antitumor efficacy of compound <b>31</b> was evaluated in MV4–11 xenograft models. When the tumor grew to a mean volume of around 200 mm<sup>3</sup>, the mice were treated orally with vehicle, 10, 25, 50 mg/kg of <b>31</b> and 10 mg/kg of AC220 once daily for 14 days. As shown in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A, <b>31</b> showed dose-dependent in vivo efficacy, with TGI = 28% (<i>p</i> < 0.01), 87% (<i>p</i> < 0.001), and 128% (<i>p</i> < 0.001) at 10, 25, and 50 mg/kg, respectively. It could induce tumor regression (TGI = 128%) upon oral administration at 50 mg/kg, which was comparable with AC220 at 10 mg/kg (TGI = 139%). No obvious body weight changes were observed (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B). When treated with <b>31</b> intraperitoneally, significant tumor shrinkage was also induced with TGI = 129% and 136% at 25 and 50 mg/kg (<i>p</i> < 0.001) (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00374/suppl_file/jm6b00374_si_001.pdf" class="ext-link">Figure S8</a>). Immunohistochemical (IHC) analyses were performed to evaluate the time course of the antitumor activity of compound <b>31</b> in the MV4–11 xenograft model. As shown in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>C, compound <b>31</b> (50 mg kg<sup>–1</sup> day<sup>–1</sup>, po) suppresses proliferation and induces late stage apoptosis in xenograft models compared with vehicle-treated tumors.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/medium/jm-2016-00374p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/large/jm-2016-00374p_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. In vivo effects of compound <b>31</b> against MV4–11 tumor xenografts via oral administration. (A) Compound <b>31</b> and AC220 were administered orally at concentrations ranging from 10 to 50 mg kg<sup>–1</sup> d<sup>–1</sup>. <i>N</i> = 5 for each group. Data are shown as the mean ± SEM. (B) Body weight change in mouse xenograft model for each daily dosing group. (C) After 1 and 3 days of compound <b>31</b> once daily oral treatment, Ki67 and TUNEL were detected in MV4–11 tumors (three per group).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/large/jm-2016-00374p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00374&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01632" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01632" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Guided by a docking study based on a homology model of FLT3 in an active conformation, we explored structural modifications on irreversible EGFR inhibitors. This resulted in this first report of pteridin-7(8<i>H</i>)-one derivatives acting as potent FLT3 inhibitors. In our model, the 4-methylpiperazinyl group in the R<sup>1</sup> substituent promotes the enzymatic and cellular activity of the compound by forming a hydrogen-bond interaction with Asn701. Conversion of the former Michael acceptor into an amino group at the 4′-position in R<sup>2</sup> led to a noticeable improvement in FLT3 inhibition and selectivity against FLT3 over EGFR (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00374/suppl_file/jm6b00374_si_001.pdf" class="ext-link">Table S4</a>) because of the hydrogen-bond interaction between the amino group and Asp698. Substitution of a methyl group at the 3-position in R<sup>3</sup>, which may further stabilize the hydrogen-bond interaction between the 4-methylpiperazinyl group and Asn701 and a favorable intramolecular π–π stacking interaction, led to compound <b>31</b>, the most potent compound in this series. This representative compound (<b>31</b>) has single-digit nanomolar FLT3 inhibitory and low-dose anti-AML activity. It shows great selectivity and significant binding affinity to FLT3 mutants in kinase profiling and growth inhibition activities against leukemia cell lines harboring FLT3-ITD mutants MV4–11 and Molm13 over other leukemia and solid tumor cell lines in profiling of in vitro tumor cell lines. We also clarified the cellular cytotoxic mechanism of representative pteridin-7(8<i>H</i>)-one derived FLT3 inhibitors, which is mediated through inhibition of phosphorylation of FLT3 and downstream signaling proteins and thereby induction of G<sub>0</sub>/G<sub>1</sub> stage cell cycle arrest and apoptosis in AML cells. In the in vivo studies, <b>31</b> showed a long half-life [3.1 h (iv) and 4.5 h (po)] and suppressed tumor growth in the MV4–11 xenograft model in dose-dependent manner via oral administration. This research provides a structurally distinct scaffold for development of selective FLT3 inhibitors in treatment of AML.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56314" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56314" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Computational Methods. Homology Modeling of an Active Conformation of FLT3</h3><div class="NLM_p last">The X-ray structure of FLT3 (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB">1RJB</a>) from the Protein Data Bank (PDB, <a href="http://www.pdb.org" class="extLink">http://www.pdb.org</a>) is in an inactive conformation, and our inhibitors cannot be docked into its ATP-binding site (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00374/suppl_file/jm6b00374_si_001.pdf" class="ext-link">Figure S10</a>). A homology model of FLT3 was constructed in an active conformation.<a onclick="showRef(event, 'ref22 ref35'); return false;" href="javascript:void(0);" class="ref ref22 ref35">(22, 35)</a> According to the results of BLAST search, the c-KIT kinase (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG">1PKG</a>) is the highest homology kinase structure in an active conformation. This dimer of active c-KIT kinase contains two identical chains, and one chain (chain A) was selected as the structure template for homology modeling. Subsequently multiple sequence alignment (the sequence identity and similarity are 54.8% and 70.2%) and 3D structure modeling of FLT3 (Glu588-946Gln, including the KID region, which lacks a template) in an active conformation were implemented in Discovery Studio (DS) 2.5<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> with default settings. An initial homology model of FLT3 was prepared in the Protein Preparation Wizard of Maestro<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> and subjected to energy minimization with the OPLS_2005 all-atom force field using Prime<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> in Schrödinger 2009.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Refinement of FLT3 Homology Model</h3><div class="NLM_p">In order to achieve a better fit between the pteridin-7(8<i>H</i>)-one scaffold and the FLT3 homology model, the initial FLT3 model was trained by flexible docking lead compound <b>1</b>. The 3D structure of compound <b>1</b> for further docking studies was prepared using LigPrep, version 2.3,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> with the Epik 2.0<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> option. Residues Leu616, Phe691, Tyr693, Leu818, Asp698, and Asn701 were defined as flexible. Induced fit docking in Maestro, version 9.0,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> was applied for flexible docking. The induced fit docking study revealed four possible binding poses of compound <b>1</b> at the active site. We selected the model shown in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>A in terms of the docking scores and with as many reasonable interactions as possible. Then, the receptor Grids generation of the docked FLT3 homology model followed the procedures recommended by Schrödinger. The geometric center of compound <b>1</b> in the docked FLT3 homology model was defined as the box center. Compound <b>1</b> was sequentially redocked into the ATP-binding site of the model using Glide, version 5.5,<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> in extra precision (XP) mode with default parameters.</div><div class="NLM_p">Then the validation of the FLT3 homology model was performed by MolProbity Ramachandran (<a href="http://kinemage.biochem.duke.edu" class="extLink">http://kinemage.biochem.duke.edu</a>) and Profiles-3D (DS 2.5) analysis. The Ramachandran plot (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00374/suppl_file/jm6b00374_si_001.pdf" class="ext-link">Figure S9</a>) indicated that 91.5% of all residues were in favored regions and 100.0% of all residues were in allowed regions. The Profiles-3D analysis evaluated this FLT3 homology model with the verification score of 115.31, which was close to the expected highest score (130.55). Collectively, the FLT3 homology model we built is structurally rational.</div><div class="NLM_p last">To further validate the reliability of the FLT3 homology model built by the above procedure, three known FLT3 type I inhibitors (CEP-701, PCK-412, and crenolanib) were docked into the receptor grid generated above, respectively. The XP Gscore for CEP-701, PCK-412, and crenolanib is −10.509, −9.370 and −9.093, respectively. The binding modes of these three inhibitors and the corresponding FLT3 IC<sub>50</sub> values<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18, 19)</a> are shown in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00374/suppl_file/jm6b00374_si_001.pdf" class="ext-link">Figure S11</a>. All inhibitors can fit the ATP-binding site of the FLT3 model well. Both CEP-701 and PCK-412 form the classical bidentate hydrogen bonds with gatekeeper + 1 (Glu692) and gatekeeper + 3 (Cys694) residues in the hinge region, which is identical with the reported binding mode for the same scaffold.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> The predicted binding mode of crenolanib is consistent with that reported by Smith et al.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> In addition, the more potent inhibitors CEP-701 and crenolanib both interact with Asp698, which is the key residue for potency improvements. All the results above validate that our FLT3 homology model in an active conformation is comparatively reliable.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Molecular Docking of Pteridin-7(8<i>H</i>)-one Compounds</h3><div class="NLM_p last">Compounds <b>1</b>–<b>35</b> were docked into the FLT3 homology model using the rigid docking method described above. The protonation states of the docked compounds were determined by Epik 2.0. The Gscores for all docked compounds are listed in the <a href="/doi/suppl/10.1021/acs.jmedchem.6b00374/suppl_file/jm6b00374_si_001.pdf" class="ext-link">Table S1</a>, and the linear relationship between Gscores and FLT3 pIC<sub>50</sub> (pIC<sub>50</sub> = −log<sub>10</sub>(IC<sub>50</sub>)) is shown in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00374/suppl_file/jm6b00374_si_001.pdf" class="ext-link">Figure S3</a>. The correlation (<i>R</i> value) between Gscores and FLT3 pIC<sub>50</sub> values for all docked compounds (including three known FLT3 inhibitors) is −0.74. This result also validates the reliability of our FLT3 homology model.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Reagents and General Methods</h3><div class="NLM_p last">The general synthesis of pteridin-7(8<i>H</i>)-one compounds is described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, and the detailed synthetic method was reported in our previous article.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> All compounds were purified by column chromatography using silica gel (200–300 mesh). The <sup>1</sup>H NMR spectra were recorded on a Bruker AM-400 spectrometer with chemical shift reported in ppm (in DMSO-<i>d</i><sub>6</sub>, Me<sub>4</sub>Si as internal standard). The mass spectra were measured at the Institute of Fine Chemistry of East China University of Science and Technology. Isolated yields of the final synthetic step were calculated. Melting points were determined using an X-6 micromelting point apparatus. All the final compounds were tested by high performance liquid chromatography, and the purity in every case was >95%. The reverse phase HPLC was conducted on a Hewlett-Packard 1100 system chromatograph, which was equipped with Zorbax RX-C18 or XDB-C18 (compounds <b>28</b> and <b>29</b>) column (250 mm × 4.6 mm). The mobile phase A was acetonitrile, and mobile phase B was 10 mM NH<sub>4</sub>OAc in water (pH 6.0). The gradient of 5–100% A was run at a flow rate of 1.0 mL/min over 20 min. MLN518 was obtained from Selleck Chemicals (Houston, TX, USA)</div></div><div id="sec5_1_4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 8-(3-Aminophenyl)-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pteridin-7(8<i>H</i>)-one (<b>22</b>)</h3><div class="NLM_p last">Orange solid (yield 70%), mp 262.5–262.9 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.01 (s, 1H), 8.81 (s, 1H), 7.99 (s, 1H), 7.35 (d, <i>J</i> = 7.2 Hz, 2H), 7.22 (t, <i>J</i> = 8.0 Hz, 1H), 6.75 (d, <i>J</i> = 7.2 Hz, 1H), 6.66 (br, 2H), 6.52 (br, 1H), 6.48 (d, <i>J</i> = 8.0 Hz, 1H), 5.35 (s, 2H), 3.02 (br, 4H), 2.46–2.44 (m, 4H), 2.23 (s, 3H). HPLC purity: 99.5%, retention time = 8.57 min. HRMS (ESI) (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>25</sub>N<sub>8</sub>O, 429.2151; found, 429.2151.</div></div><div id="sec5_1_4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 8-(4-Aminophenyl)-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pteridin-7(8<i>H</i>)-one (<b>23</b>)</h3><div class="NLM_p last">Orange solid (yield 76%), mp 235.6–236.4 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.98 (s, 1H), 8.79 (s, 1H), 7.99 (s, 1H), 7.33 (d, <i>J</i> = 6.4 Hz, 2H), 6.98 (d, <i>J</i> = 8.4 Hz, 2H), 6.74 (d, <i>J</i> = 8.4 Hz, 2H), 6.68 (br, 2H), 5.43 (s, 2H), 3.05–3.03 (m, 4H), 2.48–2.46 (m, 4H), 2.24 (s, 3H). HPLC purity: 95.4%, retention time = 8.53 min. HRMS (ESI) (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>25</sub>N<sub>8</sub>O, 429.2151; found, 429.2151.</div></div><div id="sec5_1_4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> <i>N</i>-(4-(2-((4-Methoxyphenyl)amino)-7-oxopteridin-8(7<i>H</i>)-yl)phenyl)acetamide (<b>24</b>)</h3><div class="NLM_p last">Yellow solid (yield 62%), mp >300 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.23 (s, 1H), 10.10 (s, 1H), 8.85 (s, 1H), 8.04 (s, 1H), 7.78 (d, <i>J</i> = 7.2 Hz, 2H), 7.34 (d, <i>J</i> = 7.6 Hz, 4H), 6.61 (s, 2H), 3.67 (s, 3H), 2.13 (s, 3H). HPLC purity: 97.5%, retention time = 10.54 min. HRMS (ESI) (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>19</sub>N<sub>6</sub>O<sub>3</sub>, 403.1519; found, 403.1500.</div></div><div id="sec5_1_4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> <i>N</i>-(4-(2-((4-Methoxyphenyl)amino)-7-oxopteridin-8(7<i>H</i>)-yl)phenyl)methanesulfonamide (<b>25</b>)</h3><div class="NLM_p last">Yellow solid (yield 47%), mp >300 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.11 (br, 1H), 8.84 (s, 1H), 8.03 (s, 1H), 7.40 (s, 4H), 7.31 (br, 2H), 6.66 (br, 2H), 3.69 (s, 3H), 3.12 (s, 3H). HPLC purity: 95.4%, retention time = 11.70 min. HRMS (ESI) (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>19</sub>N<sub>6</sub>O<sub>4</sub>S, 439.1189; found, 439.1187.</div></div><div id="sec5_1_4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> <i>N</i>-(4-(2-((4-(4-Methylpiperazin-1-yl)phenyl)amino)-7-oxopteridin-8(7<i>H</i>)-yl)phenyl)acetamide (<b>26</b>)</h3><div class="NLM_p last">Yellow solid (yield 58%), mp 288.0–288.7 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.44 (s, 1H), 10.05 (s, 1H), 8.82 (s, 1H), 8.02 (s, 1H), 7.80 (d, <i>J</i> = 8.0 Hz, 2H), 7.32 (d, <i>J</i> = 8.4 Hz, 2H), 7.25 (br, 2H), 6.64 (br, 2H), 3.24 (br, 4H), 3.05 (br, 4H), 2.64 (s, 3H), 2.15 (s, 3H). HPLC purity: 97.3%, retention time = 8.17 min. HRMS (ESI) (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>25</sub>H<sub>27</sub>N<sub>8</sub>O<sub>2</sub>, 471.2257; found, 471.2213.</div></div><div id="sec5_1_4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> <i>N</i>-(4-(2-((4-(4-Methylpiperazin-1-yl)phenyl)amino)-7-oxopteridin-8(7<i>H</i>)-yl)phenyl)methanesulfonamide (<b>27</b>)</h3><div class="NLM_p last">Yellow solid (yield 50%), mp >300 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.02 (s, 1H), 8.82 (s, 1H), 8.02 (s, 1H), 7.42–7.37 (m, 4H), 7.26 (br, 2H), 6.66 (br, 2H), 3.13 (s, 3H), 3.07 (br, 4H), 2.54 (br, 4H), 2.29(s, 3H). HPLC purity: 99.0%, retention time = 8.53 min. HRMS (ESI) (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>27</sub>N<sub>8</sub>O<sub>3</sub>S, 507.1927; found, 507.1926.</div></div><div id="sec5_1_4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 8-(4-(Aminomethyl)phenyl)-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pteridin-7(8<i>H</i>)-one (<b>28</b>)</h3><div class="NLM_p last">Yellow solid (yield 65%), mp 216.2–216.8 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.99 (s, 1H), 8.82 (s, 1H), 8.01 (s, 1H), 7.55 (d, <i>J</i> = 8.0 Hz, 2H), 7.32 (d, <i>J</i> = 8.4 Hz, 2H), 7.20 (s, 2H), 6.59 (s, 2H), 3.86 (s, 2H), 3.00–2.99 (m, 4H), 2.44–2.41 (m, 4H), 2.21 (s, 3H). HPLC purity: 97.4%, retention time = 6.92 min. HRMS (ESI) (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>27</sub>N<sub>8</sub>O, 443.2308; found, 443.2304.</div></div><div id="sec5_1_4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 2-((4-(4-Methylpiperazin-1-yl)phenyl)amino)-8-(4-(piperazin-1-yl)phenyl)pteridin-7(8<i>H</i>)-one (<b>29</b>)</h3><div class="NLM_p last">Yellow solid (yield 72%), mp 276.6–277.2 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.01 (s, 1H), 8.81 (s, 1H), 8.00 (s, 1H), 7.26 (d, <i>J</i> = 6.8 Hz, 2H), 7.20 (d, <i>J</i> = 8.8 Hz, 2H), 7.12 (d, <i>J</i> = 8.8 Hz, 2H), 6.58 (s, 2H), 3.19–3.17 (m, 4H), 3.02–3.00 (m, 4H), 2.90–2.88 (m, 4H), 2.45–2.43 (m, 4H), 2.22 (s, 3H). HPLC purity: 98.6%, retention time = 7.86 min. HRMS (ESI) (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>27</sub>H<sub>32</sub>N<sub>9</sub>O, 498.2730; found, 498.2728.</div></div><div id="sec5_1_4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 8-(4-Aminophenyl)-2-((4-methoxy-2-methylphenyl)amino)pteridin-7(8<i>H</i>)-one (<b>30</b>)</h3><div class="NLM_p last">Yellow solid (yield 82%), mp 149.1–149.3 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.13 (s, 1H), 8.72 (s, 1H), 7.95 (s, 1H), 7.21 (s, 1H), 6.94 (d, <i>J</i> = 8.0 Hz, 2H), 6.72 (s, 1H), 6.65 (d, <i>J</i> = 8.4 Hz, 2H), 6.60 (s, 1H), 5.33 (br, 2H), 3.72 (s, 3H), 2.13 (s, 3H). HPLC purity: 96.0%, retention time = 11.68 min. HRMS (ESI) (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>19</sub>N<sub>6</sub>O<sub>2</sub>, 375.1569; found, 375.1573.</div></div><div id="sec5_1_4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 8-(4-Aminophenyl)-2-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)pteridin-7(8<i>H</i>)-one (<b>31</b>)</h3><div class="NLM_p last">Yellow solid (yield 74%), mp 255.6–256.3 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.94 (br, 1H), 8.80 (s, 1H), 7.99 (s, 1H), 7.36 (br, 1H), 7.18 (d, <i>J</i> = 6.4 Hz, 1H), 6.97 (d, <i>J</i> = 8.4 Hz, 2H), 6.79 (d, <i>J</i> = 8.4 Hz, 1H), 6.71 (d, <i>J</i> = 8.4 Hz, 2H), 5.37 (s, 2H), 2.76–2.74 (m, 4H), 2.47 (br, 4H), 2.24 (s, 3H), 2.06 (s, 3H). HPLC purity: 99.2%, retention time = 9.44 min. HRMS (ESI) (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>27</sub>N<sub>8</sub>O, 443.2308; found, 443.2301.</div></div><div id="sec5_1_4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 8-(4-Aminophenyl)-2-((3-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pteridin-7(8<i>H</i>)-one (<b>32</b>)</h3><div class="NLM_p last">Orange solid (yield 63%), mp 147.4–147.9 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.94 (br, 1H), 8.81 (s, 1H), 7.99 (s, 1H), 7.09 (s, 2H), 6.97 (d, <i>J</i> = 8.4 Hz, 2H), 6.70 (d, <i>J</i> = 8.4 Hz, 2H), 6.60 (br, 1H), 5.41 (s, 2H), 3.56 (s, 3H), 2.87 (br, 4H), 2.43 (br, 4H), 2.21 (s, 3H). HPLC purity: 98.0%, retention time = 8.75 min. HRMS (ESI) (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>27</sub>N<sub>8</sub>O<sub>2</sub>, 459.2257; found, 459.2256.</div></div><div id="sec5_1_4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 8-(4-Aminophenyl)-2-((3-chloro-4-(4-methylpiperazin-1-yl)phenyl)amino)pteridin-7(8<i>H</i>)-one (<b>33</b>)</h3><div class="NLM_p last">Yellow solid (yield 62%), mp >300 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.13 (br, 1H), 8.85 (s, 1H), 8.03 (s, 1H), 7.60 (s, 1H), 7.37 (d, <i>J</i> = 7.6 Hz, 1H), 6.97 (d, <i>J</i> = 8.4 Hz, 2H), 6.89 (d, <i>J</i> = 7.6 Hz, 1H), 6.71 (d, <i>J</i> = 8.4 Hz, 2H), 5.38 (s, 2H), 2.89 (br, 4H), 2.47 (br, 4H), 2.34 (s, 3H). HPLC purity: 98.7%, retention time = 9.64 min. HRMS (ESI) (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>24</sub>ClN<sub>8</sub>O, 463.1762; found, 463.1710.</div></div><div id="sec5_1_4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 8-(4-Aminophenyl)-2-((3-chloro-4-methoxyphenyl)amino)pteridin-7(8<i>H</i>)-one (<b>34</b>)</h3><div class="NLM_p last">Yellow solid (yield 75%), mp >300 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.13 (s, 1H), 8.84 (s, 1H), 8.03 (s, 1H), 7.60 (s, 1H), 7.38 (s, 1H), 6.98 (d, <i>J</i> = 8.4 Hz, 2H), 6.87 (s, 1H), 6.72 (d, <i>J</i> = 8.4 Hz, 2H), 5.39 (br, 2H), 3.79 (s, 3H). HPLC purity: 97.0%, retention time = 11.55 min. HRMS (ESI) (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>16</sub>ClN<sub>6</sub>O<sub>2</sub>, 395.1023; found, 395.1027.</div></div><div id="sec5_1_4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 8-(4-Aminophenyl)-2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)pteridin-7(8<i>H</i>)-one (<b>35</b>)</h3><div class="NLM_p last">Yellow solid (yield 64%), mp 238.2–238.7 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.13 (br, 1H), 8.84 (s, 1H), 8.02 (s, 1H), 7.32 (d, <i>J</i> = 12.4 Hz, 1H), 7.19 (d, <i>J</i> = 7.2 Hz, 1H), 6.97 (d, <i>J</i> = 8.4 Hz, 2H), 6.77 (br, 1H), 6.72 (d, <i>J</i> = 8.4 Hz, 2H), 5.39 (s, 2H), 2.92–2.90 (m, 4H), 2.45 (br, 4H), 2.22 (s, 3H). HPLC purity: 96.9%, retention time = 9.12 min. HRMS (ESI) (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>24</sub>FN<sub>8</sub>O, 447.2057; found, 447.2057.</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> In Vitro Enzymatic Activity Assay</h3><div class="NLM_p last">The inhibitory activity of targeted compounds against FLT3 was determined using mobility shift assay by Shanghai ChemPartner Co., Ltd. Cytoplasmic FLT3 kinase contain juxtamembrane domain was provided by Carna (catalog no. 08-154). Peptide FAM-P2 was from GL Biochem (catalog no. 112394). Compounds were tested from 10 μM, 3-fold dilution, 7 points, in duplicate, and staurosporine was used as the reference compound. A detailed protocol description is provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.6b00374/suppl_file/jm6b00374_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Kinase Profiling Assay and Binding Constants (<i>K</i><sub>D</sub>) Assay</h3><div class="NLM_p last">The kinase profiling assay and binding constants assay were conducted using the KINOMEscan platform (<a href="http://www.discoverx.com" class="extLink">www.discoverx.com</a>). Kinase-tagged T7 phage or DNA were expressed in <i>E. coli</i> host or HEK-293 cells. Binding reactions were assembled by kinases, liganded affinity beads, and test compounds with shaking for 1 h at room temperature, then measured by qPCR. Kinome profile assays were shown as percent of control, and <i>K</i><sub>D</sub> values were determined by 11-point 3-fold serial dilution of each test compound in this method. The detailed protocol description is provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.6b00374/suppl_file/jm6b00374_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Cell Culture</h3><div class="NLM_p last">Unless otherwise specified, cell lines were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). K562 were obtained from the Shanghai Institute of Biochemistry and Cell Biology (Shanghai, China) and were maintained in strict accordance with the supplier’s instructions and established procedures.</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Cell Viability Assays</h3><div class="NLM_p last">Cell proliferation was evaluated using an MTT or a SRB assay. Cancer cells were seeded into 96-well plates and cultured overnight. The cells were then treated with increasing concentrations of compounds for a further 72 h. For suspension cells (MV4–11, K562, THP1, RS4;11, Molt4, HL60, DMS79, H146, H187, H209), 20 μL (5 mg/mL in 0.9% brine) of MTT (Sigma) was added to each well. The cells were then incubated for an additional 4 h, after which 100 μL of “triplex solution” (10% SDS–5% isobutanol–12 mM HCl) was added, and the cells were incubated overnight at 37 °C. The plates were read at 570 nm on the microplate spectrophotometer (Synergy2, BioTek). The inhibition rate on cell proliferation was calculated as % inhibition rate = (1 – <i>A</i><sub>570treated</sub>/<i>A</i><sub>570control</sub>) × 100. For adherent cell lines (WI-38, A549, H1299, H1975, RKO, HCT116, HT29, SW620, SH-SY5Y, MCF7), cells were fixed with 10% trichloroacetic acid and stained with sulforhodamine B (Sigma). Sulforhodamine B in the cells was dissolved in 10 mM Tris-HCl and was measured at 515 nm using microplate spectrophotometer. The inhibition rate on cell proliferation was calculated as follows: % inhibition rate = (1 – <i>A</i><sub>515treated</sub>/<i>A</i><sub>515control</sub>) × 100. The IC<sub>50</sub> values were obtained by the Logit method. Each experiment was repeated in triplicate.</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> Flow Cytometry Assays</h3><div class="NLM_p last">MV4–11 cells were seeded at a density of 1 × 10<sup>5</sup> cells/mL in six-well plates and exposed to different concentrations of compounds. After a 48 h treatment, cells were harvested and washed twice with cold PBS buffer. Cell cycle analysis follows the directions of the PI/RNase staining solution (Tianjin Sungene Biotech). The collected cells were fixed in 70% ethanol for 1 h. Afterward, cells were stained in propidium iodide (PI) solution at room temperature in the dark for 30 min. In the annexin-V apoptosis assay, cell samples were resuspended in binding buffer (apoptosis analysis kit from Tianjin Sungene Biotech) and incubated with annexin-V and propidium iodide solution protected from light. The samples in both assays were analyzed using a FACS Calibur Cytometer (Becton Dickinson, San Jose, CA, USA).</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Western Blot Assays</h3><div class="NLM_p last">The primary antibodies against FLT3, p-FLT3, AKT, p-AKT, STAT5, p-STAT5, and p44/42 MAPK were obtained from Cell Signaling Technology, and GAPDH antibody was from Kangchen (Shanghai, China). Cells were incubated with different concentrations of compounds. After a 2 h treatment, whole-cell lysates were collected and boiled for 10 min in 2× SDS sample buffer and subjected to SDS–PAGE. The proteins were transferred to nitrocellulose membranes (Millpore) and blocked in 5% nonfat dry milk in TBS for 1 h at room temperature and then incubated with primary antibodies, which were diluted according to product specification. The bands were visualized using HRP-conjugated secondary antibodies (Cell Signaling Technology) followed by enhanced ECL substrate (Millipore) in Tanon 5200 Multicapture System, and then quantified by ImageJ software (1.37v, National Institutes of Health, USA).</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> PK Analysis</h3><div class="NLM_p last">Male Sprague-Dawley rats (200–250 g) were used and randomly divided into two groups (<i>n</i> = 3 in each group). A catheter was surgically placed into the femoral vein for collection of blood samples. Rats were fasted overnight before dosing. Compound <b>31</b> was administered by intravenous injection or oral gavage at a dose of 1 mg/kg in saline mixture (DMSO/PEG400/saline = 5:40:55) or 10 mg/kg in 0.5% methlcellulose, respectively. Plasma of each time point (5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 24 h) were collected into heparin tubes, and compound concentrations were determined by LC–MS/MS. The LC system comprised a Waters (Waters Corporation, UAS) ultraperformance liquid chromatography (UPLC) instrument equipped with an ACQUITY UPLC binary solvent manager, ACQUITY UPLC autosampler mod., ACQUTIY UPLC sample organizer, and ACQUITY UPLC column heater HT. Mass spectrometric analysis was performed using an API 5500 (triple-quadrupole) instrument from Applied Biosystems/MDS Sciex with an ESI Ionsource. The data acquisition and control system were created using Analyst 1.6.2 software from Applied Biosystems/MDS Sciex.).</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> In Vivo Efficacy for MV4–11 Xenografts</h3><div class="NLM_p last">4- to 6-weeks-old BALB/c (nu/nu) mice were purchased from the Shanghai Laboratory Animal Research Center (Shanghai, China). All studies were carried out according to the Animal Care and Use Committee Guidelines of China. Approximately 1 × 10<sup>7</sup> cells were implanted with a mixture of Matrigel matrix (BD Biosciences) and PBS (1:1) in a total volume of 0.1 mL/mouse. Compounds were dissolved in saline mixture (DMSO/PEG400/saline = 1:30:69). Mice were randomized into vehicle and treated groups (<i>n</i> = 5 for each group) to ensure equal distribution with a group mean tumor size of 0.2 cm<sup>3</sup>. For efficacy studies, mice were dosed intraperitoneally with vehicle or with 25 and 50 mg/kg of <b>31</b> and orally with vehicle, 10, 25, 50 mg/kg of <b>31</b>, and 10 mg/kg of AC220 once daily for 14 days. The average tumor volume and mice weight were measured with vernier calipers every 2 days, and the volume was calculated with the formula <i>V</i> = (<i>L</i> × <i>W</i><sup>2</sup>)/2, where <i>L</i> = length and <i>W</i> = width. Inhibition (% TGI) was calculated at the end of dosing period using the formula: % TGI = {[1 – (<i>T<sub>t</sub></i>/<i>T</i><sub>0</sub>)/(<i>C<sub>t</sub></i>/<i>C</i><sub>0</sub>)]/(1 – <i>C</i><sub>0</sub>/<i>C<sub>t</sub></i>)} × 100 where <i>T<sub>t</sub></i> = median tumor volume of different treatment groups at time <i>t</i>, <i>T</i><sub>0</sub> = median tumor volume of different treatment groups at time 0, <i>C<sub>t</sub></i> = median tumor volume of the control group at time <i>t</i>, and <i>C</i><sub>0</sub> = median tumor volume of control group at time 0.</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> IHC Staining</h3><div class="NLM_p last">After treatment of the different groups, mice MV4–11 xenografts were harvested and fixed in formalin. Tumor samples were embedded in paraffin and prepared in sections (3 μm). Before incubation with the primary antibodies (Abcam Corporation) at room temperature, sections were deparaffinized and rehydrated, then developed in liquid 3,3′-diaminobenzidine (DAB) for 10 min for independent analysis. For the TUNEL assay, sections were processed according to the manufacturer’s instructions from Roche Corporation.</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Statistical Analysis</h3><div class="NLM_p last">Statistical analyses were performed with one way ANOVA followed by least significant difference post hoc analysis and <i>t</i> test when compared with only two groups.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i48"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00374">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17236" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17236" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b00374" class="ext-link">10.1021/acs.jmedchem.6b00374</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Selectivity profile data for <b>1</b> versus a panel of 26 kinase targets, table and figures presenting validations of FLT3 homology model and docking results, in vitro enzymatic selectivity against FLT3 over EGFR, Western blot results of <b>23</b> in MV4–11 cells, the cell arrest and apoptosis results of <b>23</b> in MV4–11 cells, in vivo effects of <b>31</b> against MV4–11 tumor xenografts via intraperitoneal administration, and details of kinase selectivity of <b>31</b> against a panel of 468 kinases (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00374/suppl_file/jm6b00374_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00374/suppl_file/jm6b00374_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00374/suppl_file/jm6b00374_si_001.pdf">jm6b00374_si_001.pdf (2.22 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00374/suppl_file/jm6b00374_si_002.csv">jm6b00374_si_002.csv (4.24 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b00374" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12426" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12426" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhuo Chen</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New
Drug Design, School of Pharmacy, East China
University of Science & Technology, Shanghai 200237, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#14777c717a6e7c617b5471776167603a7170613a777a"><span class="__cf_email__" data-cfemail="f2919a979c889a879db29791878186dc979687dc919c">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yufang Xu</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New
Drug Design, School of Pharmacy, East China
University of Science & Technology, Shanghai 200237, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#e099869895a08583959394ce858495ce838e"><span class="__cf_email__" data-cfemail="dfa6b9a7aa9fbabcaaacabf1babbaaf1bcb1">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Honglin Li</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New
Drug Design, School of Pharmacy, East China
University of Science & Technology, Shanghai 200237, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f69e9a9a9fb69395838582d8939283d89598"><span class="__cf_email__" data-cfemail="1d757171745d787e686e6933787968337e73">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Deheng Sun</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New
Drug Design, School of Pharmacy, East China
University of Science & Technology, Shanghai 200237, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yu Yang</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New
Drug Design, School of Pharmacy, East China
University of Science & Technology, Shanghai 200237, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiankun Lyu</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New
Drug Design, School of Pharmacy, East China
University of Science & Technology, Shanghai 200237, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Zhou</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New
Drug Design, School of Pharmacy, East China
University of Science & Technology, Shanghai 200237, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenlin Song</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New
Drug Design, School of Pharmacy, East China
University of Science & Technology, Shanghai 200237, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhenjiang Zhao</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New
Drug Design, School of Pharmacy, East China
University of Science & Technology, Shanghai 200237, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>D.S., Y.Y., and J.L. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d639e2897-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i50">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02560" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02560" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The research was supported in part by the Fundamental Research Funds for the Central Universities, the National Natural Science Foundation of China (Grants 21302054, 81222046, 21173076, and 81230076) (Z.C., H.L.), the Shanghai Committee of Science and Technology (Grants 14431902100 and 13ZR1453100) (Y.X., Z.C.), the National S&T Major Project of China (Grant 2013ZX09507004), the Twelfth Five-Year National Science & Technology Support Program (Grant 2012BAI29B06), and the 863 Hi-Tech Program of China (Grant 2012AA020308) (H.L.). H.L. is also sponsored by Specialized Research Fund for the Doctoral Program of Higher Education (Grant 20130074110004), the Innovation Program of Shanghai Municipal Education Commission (Grant 13SG32), and Fok Ying Tung Education Foundation (Grant 141035).</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i51" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i51"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i52" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i52"> Abbreviations Used</h2><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum concentration</p></td></tr><tr><td class="NLM_term">CL<sub><i>z</i></sub></td><td class="NLM_def"><p class="first last">clearance rate</p></td></tr><tr><td class="NLM_term">CML</td><td class="NLM_def"><p class="first last">chronic myelogenous leukemia</p></td></tr><tr><td class="NLM_term">DOF</td><td class="NLM_def"><p class="first last">degree of freedom</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">FLT3</td><td class="NLM_def"><p class="first last">FMS-like tyrosine kinase 3</p></td></tr><tr><td class="NLM_term">IHC</td><td class="NLM_def"><p class="first last">immunohistochemical</p></td></tr><tr><td class="NLM_term">ITD</td><td class="NLM_def"><p class="first last">internal tandem duplication</p></td></tr><tr><td class="NLM_term">KD</td><td class="NLM_def"><p class="first last">kinase domain</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">MTT</td><td class="NLM_def"><p class="first last">3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2<i>H</i>-tetrazolium bromide</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">Protein Data Bank</p></td></tr><tr><td class="NLM_term">p-FLT3/p-ERK/p-STAT5/p-AKT</td><td class="NLM_def"><p class="first last">phosphorylated FLT3/ERK/STAT5/AKT</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphatidylinositol 3-kinase</p></td></tr><tr><td class="NLM_term">R&D</td><td class="NLM_def"><p class="first last">research and development</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SRB</td><td class="NLM_def"><p class="first last">sulforhodamine B</p></td></tr><tr><td class="NLM_term">STAT5</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription 5</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>ss</sub></td><td class="NLM_def"><p class="first last">the steady-state volume of distribution</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i53">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86350" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86350" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 42 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Stirewalt, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radich, J. P.</span><span> </span><span class="NLM_article-title">The role of FLT3 in haematopoietic malignancies</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">650</span><span class="NLM_x">–</span> <span class="NLM_lpage">665</span><span class="refDoi"> DOI: 10.1038/nrc1169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1038%2Fnrc1169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=12951584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvVWlu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=650-665&author=D.+L.+Stirewaltauthor=J.+P.+Radich&title=The+role+of+FLT3+in+haematopoietic+malignancies&doi=10.1038%2Fnrc1169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The role of FLT3 in hematopoietic malignancies</span></div><div class="casAuthors">Stirewalt, Derek L.; Radich, Jerald P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">650-665</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Normal haematopoietic cells use complex systems to control proliferation, differentiation and cell death.  The control of proliferation is, in part, accomplished through the ligand-induced stimulation of receptor tyrosine kinases, which signal to downstream effectors through the RAS pathway.  Recently, mutations in the FMS-like tyrosine kinase 3 (FLT3) gene, which encodes a receptor tyrosine kinase, have been found to be the most common genetic lesion in acute myeloid leukemia (AML), occurring in ∼25% of cases.  Exploring the mechanism by which these FLT3 mutations cause uncontrolled proliferation might lead to a better understanding of how cells become cancerous and provide insights for the development of new drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRONPQkpemorVg90H21EOLACvtfcHk0lhwJnBBNoYfwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvVWlu7c%253D&md5=97183b7a6087fafe20bfc695f403825b</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc1169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1169%26sid%3Dliteratum%253Aachs%26aulast%3DStirewalt%26aufirst%3DD.%2BL.%26aulast%3DRadich%26aufirst%3DJ.%2BP.%26atitle%3DThe%2520role%2520of%2520FLT3%2520in%2520haematopoietic%2520malignancies%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26spage%3D650%26epage%3D665%26doi%3D10.1038%2Fnrc1169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Drexler, H.</span><span> </span><span class="NLM_article-title">Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">588</span><span class="NLM_x">–</span> <span class="NLM_lpage">599</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=8618433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A280%3ADyaK283gtV2qsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1996&pages=588-599&author=H.+Drexler&title=Expression+of+FLT3+receptor+and+response+to+FLT3+ligand+by+leukemic+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells</span></div><div class="casAuthors">Drexler H G</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">588-99</span>
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    </div><div class="casAbstract">The novel hematopoietic growth factor FLT3 ligand (FL) is the cognate ligand for the FLT3, tyrosine kinase receptor (R), also referred to as FLK-2 and STK-1.  The FLT3R belongs to a family of receptor tyrosine kinases involved in hematopoiesis that also includes KIT, the receptor for SCF (stem cell factor), and FMS. the receptor for M-CSF (macrophage colony- stimulating factor).  Restricted FLT3R expression was seen on human and murine hematopoietic progenitor cells.  In functional assays recombinant FL stimulated the proliferation and colony formation of human hematopoietic progenitor cells, i.e.  CD34+ cord and peripheral blood, bone marrow and fetal liver cells.  Synergy was reported for co-stimulation with G-CSF (granulocyte-CSF).  GM-CSF (granulocyte-macrophage CSF), M-CSF, interleukin-3 (IL-3), PIXY-321 (an IL-3/GM-CSF fusion protein) and SCF.  In the mouse, FL potently enhanced growth of various types of progenitor/precursor cells in synergy with G-CSF, GM-CSF, M-CSF, IL-3, IL-6, IL-7, IL-11, IL-12 and SCF.  The well-documented involvement of this ligand-receptor pair in physiological hematopoiesis brought forth the question whether FLT3R and FL might also have a role in the pathobiology of leukemia.  At the mRNA level FLT3R was expressed by most (80-100%) cases of AML (acute myeloid leukemia) throughout the different morphological subtypes (MO-M7), of ALL(acute lymphoblastic leukemia) of the immunological subtypes T-ALL and BCP-ALL (B cell precursor ALL including pre-pre B-ALL, cALL and pre B-ALL), of AMLL (acute mixed-lineage leukemia), and of CML (chronic myeloid leukemia) in lymphoid or mixed blast crisis.  Analysis of cell surface expression of FLT3R by flow cytometry confirmed these observations for AML (66% positivity when the data from all studies are combined), BCP-ALL (64%) and CML lymphoid blast crisis (86%) whereas less than 30% of T-ALL were FLT3R+.  The myeloid, monocytic and pre B cell type categories also contained the highest proportions of FLT3R+ leukemia cell lines .  In contrast to the selective expression of the receptor, FL expression was detected in 90-100% of the various cell types of leukemia cell lines from all hematopoietic cell lineages.  The potential of FL to induce proliferation of leukemia cells in vitro was also examined in primary and continuously cultured leukemia cells.  The data on FL-stimulated leukemia cell growth underline the extensive heterogeneity of primary AML and ALL samples in terms of cytokine-inducible DNA synthesis that has been seen with other effective cytokines.  While the majority of T-ALL (0-33% of the cases responded proliferatively; mean 11%) and BCP-ALL (0-30%; mean 20%) failed to proliferate in the presence of FL despite strong expression of surface FLT3R, FL caused a proliferative response in a significantly higher percentage of AML cases (22-90%; mean 53%).  In the panel of leukemia cell lines examined only myeloid and monocytic growth factor- dependent cell lines increased their proliferation upon incubation with FL, whereas all growth factor-independent cell lines were refractory to stimulation.  Combinations of FL with G-CSF, GM-CSF, M-CSF, IL-3, PIXY- 321 or SCF and FL with IL-3 or IL-7 had synergistic or additive mitogenic effects on primary AML and ALL cells, respectively.  The potent stimulation of the myelomonocytic cell lines was further augmented by addition of bFGF (basic fibroblast growth factor), GM-CSF, IL-3 or SCF.  The inhibitory effects of TGF-beta 1 (transforming growth factor-beta 1) on FL- supported proliferation were abrogated by bFGF.  Taken together, these results demonstrate the expression of functional FLT3R capable of mediating FL- dependent mitogenic signaling in a subset of AML and ALL cases further underline the heterogeneity of AML and ALL samples in their proliferative response to cytokine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT_MDUZMlgnZlm8bhe6roZYfW6udTcc2earnHggfmsB5Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK283gtV2qsA%253D%253D&md5=d9d427a65fa9b8b1b279c442d353f18f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDrexler%26aufirst%3DH.%26atitle%3DExpression%2520of%2520FLT3%2520receptor%2520and%2520response%2520to%2520FLT3%2520ligand%2520by%2520leukemic%2520cells%26jtitle%3DLeukemia%26date%3D1996%26volume%3D10%26spage%3D588%26epage%3D599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Takahashi, S.</span><span> </span><span class="NLM_article-title">Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications</span> <span class="citation_source-journal">J. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span><span class="refDoi"> DOI: 10.1186/1756-8722-4-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1186%2F1756-8722-4-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=21211043" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=1-10&author=S.+Takahashi&title=Downstream+molecular+pathways+of+FLT3+in+the+pathogenesis+of+acute+myeloid+leukemia%3A+biology+and+therapeutic+implications&doi=10.1186%2F1756-8722-4-13"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1186%2F1756-8722-4-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-8722-4-13%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DS.%26atitle%3DDownstream%2520molecular%2520pathways%2520of%2520FLT3%2520in%2520the%2520pathogenesis%2520of%2520acute%2520myeloid%2520leukemia%253A%2520biology%2520and%2520therapeutic%2520implications%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2011%26volume%3D4%26spage%3D1%26epage%3D10%26doi%3D10.1186%2F1756-8722-4-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Network, C. G. A. R.</span><span> </span><span class="NLM_article-title">Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">368</span><span class="NLM_x">, </span> <span class="NLM_fpage">2059</span><span class="refDoi"> DOI: 10.1056/NEJMoa1301689</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1056%2FNEJMoa1301689" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=23634996" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2013&pages=2059&author=C.+G.+A.+R.+Network&title=Genomic+and+epigenomic+landscapes+of+adult+de+novo+acute+myeloid+leukemia&doi=10.1056%2FNEJMoa1301689"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1301689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1301689%26sid%3Dliteratum%253Aachs%26aulast%3DNetwork%26aufirst%3DC.%2BG.%2BA.%2BR.%26atitle%3DGenomic%2520and%2520epigenomic%2520landscapes%2520of%2520adult%2520de%2520novo%2520acute%2520myeloid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D368%26spage%3D2059%26doi%3D10.1056%2FNEJMoa1301689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Quentmeier, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinhardt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaborski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drexler, H.</span><span> </span><span class="NLM_article-title">FLT3 mutations in acute myeloid leukemia cell lines</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">120</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span><span class="refDoi"> DOI: 10.1038/sj.leu.2402740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1038%2Fsj.leu.2402740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=12529668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjsFymtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2003&pages=120-124&author=H.+Quentmeierauthor=J.+Reinhardtauthor=M.+Zaborskiauthor=H.+Drexler&title=FLT3+mutations+in+acute+myeloid+leukemia+cell+lines&doi=10.1038%2Fsj.leu.2402740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 mutations in acute myeloid leukemia cell lines</span></div><div class="casAuthors">Quentmeier, H.; Reinhardt, J.; Zaborski, M.; Drexler, H. G.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">120-124</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Internal tandem duplications (ITD) and D835 point mutations of the receptor tyrosine kinase (RTK) FLT3 are found in a high proportion of cases with acute myeloid leukemia (AML).  These genetic aberrations may lead to the constitutive activation of the receptor, thus providing the mol. basis for a persisting growth stimulus.  We have screened 69 AML-derived cell lines for FLT3 mutations.  Four of these cell lines showed ITD of the FLT3 gene, none carried a D835 point mutation.  Two cell lines (MUTZ-11 and MV4-11) expressed exclusively the mutated allele, the other two cell lines (MOLM-13 and PL-21) displayed a mutated and the wild-type version of the gene.  Although mutationally activated FLT3 is supposed to substitute for the stimulatory signal of a growth factor, one of these cell lines (MUTZ-11) was strictly cytokine-dependent.  FLT3 transcripts were found in all four cell lines, but the constitutively phosphorylated receptor protein was clearly detectable only in cell line MV4-11, possibly explaining why MUTZ-11 cells were growth-factor dependent.  Thus, not all FLT3 ITD-pos. cells express high levels of the active receptor protein, a finding that might be of relevance for a possible future application of a kinase inhibitor as therapeutic agent.  It had been described that STAT-5 phosphorylation was part of the FLT3 signalling chain and that STAT-5 mols. were constitutively phosphorylated in FLT3 ITD-pos. cells.  Although we obsd. the constitutive phosphorylation of STAT-5 mols. in FLT3-mutant cells, FLT3 ligand (FL) did not induce STAT-5 phosphorylation in FLT3 wild-type cells.  These results suggest that the signalling mechanisms of the mutated FL receptor differ at least to some extent from those conferred by wild-type FLT3.  In conclusion, (1) not all cells with FLT3 ITD express significant amts. of the mutated receptor protein; (2) signals downstream from wild-type and mutant FLT3 receptors are not 100% identical; and (3) MV4-11 represents a model cell line for FLT3 ITD signalling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZpWGN8HPKnbVg90H21EOLACvtfcHk0liodxyuoJS84Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjsFymtg%253D%253D&md5=72b3ca3386a738407ab9ce9dc3e71ad1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2402740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2402740%26sid%3Dliteratum%253Aachs%26aulast%3DQuentmeier%26aufirst%3DH.%26aulast%3DReinhardt%26aufirst%3DJ.%26aulast%3DZaborski%26aufirst%3DM.%26aulast%3DDrexler%26aufirst%3DH.%26atitle%3DFLT3%2520mutations%2520in%2520acute%2520myeloid%2520leukemia%2520cell%2520lines%26jtitle%3DLeukemia%26date%3D2003%26volume%3D17%26spage%3D120%26epage%3D124%26doi%3D10.1038%2Fsj.leu.2402740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Leung, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Man, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwong, Y.</span><span> </span><span class="NLM_article-title">FLT3 inhibition: a moving and evolving target in acute myeloid leukemia</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">260</span><span class="NLM_x">–</span> <span class="NLM_lpage">268</span><span class="refDoi"> DOI: 10.1038/leu.2012.195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1038%2Fleu.2012.195" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=260-268&author=A.+Leungauthor=C.+Manauthor=Y.+Kwong&title=FLT3+inhibition%3A+a+moving+and+evolving+target+in+acute+myeloid+leukemia&doi=10.1038%2Fleu.2012.195"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fleu.2012.195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2012.195%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DA.%26aulast%3DMan%26aufirst%3DC.%26aulast%3DKwong%26aufirst%3DY.%26atitle%3DFLT3%2520inhibition%253A%2520a%2520moving%2520and%2520evolving%2520target%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2013%26volume%3D27%26spage%3D260%26epage%3D268%26doi%3D10.1038%2Fleu.2012.195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Choudhary, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwäble, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandts, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tickenbrock, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sargin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdel, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller-Tidow, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serve, H.</span><span> </span><span class="NLM_article-title">AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">265</span><span class="NLM_x">–</span> <span class="NLM_lpage">273</span><span class="refDoi"> DOI: 10.1182/blood-2004-07-2942</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1182%2Fblood-2004-07-2942" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=15769897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlvVWjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=265-273&author=C.+Choudharyauthor=J.+Schw%C3%A4bleauthor=C.+Brandtsauthor=L.+Tickenbrockauthor=B.+Sarginauthor=T.+Kindlerauthor=T.+Fischerauthor=W.+E.+Berdelauthor=C.+M%C3%BCller-Tidowauthor=H.+Serve&title=AML-associated+Flt3+kinase+domain+mutations+show+signal+transduction+differences+compared+with+Flt3+ITD+mutations&doi=10.1182%2Fblood-2004-07-2942"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations</span></div><div class="casAuthors">Choudhary, Chunaram; Schwaeble, Joachim; Brandts, Christian; Tickenbrock, Lara; Sargin, Buelent; Kindler, Thomas; Fischer, Thomas; Berdel, Wolfgang E.; Mueller-Tidow, Carsten; Serve, Hubert</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">265-273</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Activating mutations of Flt3 are found in approx. 1/3 of patients with acute myeloid leukemia (AML) and are an attractive drug target.  Two classes of Flt3 mutations occur: internal tandem duplications (ITDs) in the juxtamembrane and point mutations in the tyrosine kinase domain (TKD).  We and others have shown that Flt3-ITD induced aberrant signaling including strong activation of signal transducer and activator of transcription 5 (STAT5) and repression of CCAAT/estradiol-binding protein α (c/EBPα) and Pu.1.  Here, we compared the signaling properties of Flt3-ITD vs. Flt3-TKD in myeloid progenitor cells.  We demonstrate that Flt3-TKD mutations induced autonomous growth of 32D cells in suspension cultures.  However, in contrast to Flt3-ITD and similar to wild-type Flt3 (Flt3-WT), Flt3-TKD cannot support colony formation in semisolid media.  Also, in contrast to Flt3-ITD, neither Flt3-WT nor Flt3-TKD induced activation or induction of STAT5 target genes.  Flt3-TKD also failed to repress c/EBPα and Pu.1.  No significant differences were obsd. in receptor autophosphorylation and the phosphorylation of Erk-1 and -2, Akt, and Shc.  Importantly, TKD but not ITD mutations were a log power more sensitive toward the tyrosine kinase inhibitor protein kinase C 412 (PKC412) than Flt3-WT.  In conclusion, Flt3-ITD and Flt3-TKD mutations display differences in their signaling properties that could have important implications for their transforming capacity and for the design of mutation-specific therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK50hyr7RAoLVg90H21EOLACvtfcHk0liodxyuoJS84Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlvVWjtrw%253D&md5=a70850e3d6fe00e8316cc8d79c2d3016</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1182%2Fblood-2004-07-2942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2004-07-2942%26sid%3Dliteratum%253Aachs%26aulast%3DChoudhary%26aufirst%3DC.%26aulast%3DSchw%25C3%25A4ble%26aufirst%3DJ.%26aulast%3DBrandts%26aufirst%3DC.%26aulast%3DTickenbrock%26aufirst%3DL.%26aulast%3DSargin%26aufirst%3DB.%26aulast%3DKindler%26aufirst%3DT.%26aulast%3DFischer%26aufirst%3DT.%26aulast%3DBerdel%26aufirst%3DW.%2BE.%26aulast%3DM%25C3%25BCller-Tidow%26aufirst%3DC.%26aulast%3DServe%26aufirst%3DH.%26atitle%3DAML-associated%2520Flt3%2520kinase%2520domain%2520mutations%2520show%2520signal%2520transduction%2520differences%2520compared%2520with%2520Flt3%2520ITD%2520mutations%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D265%26epage%3D273%26doi%3D10.1182%2Fblood-2004-07-2942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Tse, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukherjee, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span> </span><span class="NLM_article-title">Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1766</span><span class="NLM_x">–</span> <span class="NLM_lpage">1776</span><span class="refDoi"> DOI: 10.1038/sj.leu.2401905</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1038%2Fsj.leu.2401905" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2000&pages=1766-1776&author=K.+F.+Tseauthor=G.+Mukherjeeauthor=D.+Small&title=Constitutive+activation+of+FLT3+stimulates+multiple+intracellular+signal+transducers+and+results+in+transformation&doi=10.1038%2Fsj.leu.2401905"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2401905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2401905%26sid%3Dliteratum%253Aachs%26aulast%3DTse%26aufirst%3DK.%2BF.%26aulast%3DMukherjee%26aufirst%3DG.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DConstitutive%2520activation%2520of%2520FLT3%2520stimulates%2520multiple%2520intracellular%2520signal%2520transducers%2520and%2520results%2520in%2520transformation%26jtitle%3DLeukemia%26date%3D2000%26volume%3D14%26spage%3D1766%26epage%3D1776%26doi%3D10.1038%2Fsj.leu.2401905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Hayakawa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Towatari, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyoi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanimoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoe, T.</span><span> </span><span class="NLM_article-title">Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">624</span><span class="NLM_x">–</span> <span class="NLM_lpage">631</span><span class="refDoi"> DOI: 10.1038/sj.onc.1203354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1038%2Fsj.onc.1203354" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=624-631&author=F.+Hayakawaauthor=M.+Towatariauthor=H.+Kiyoiauthor=M.+Tanimotoauthor=T.+Kitamuraauthor=H.+Saitoauthor=T.+Naoe&title=Tandem-duplicated+Flt3+constitutively+activates+STAT5+and+MAP+kinase+and+introduces+autonomous+cell+growth+in+IL-3-dependent+cell+lines&doi=10.1038%2Fsj.onc.1203354"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1203354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1203354%26sid%3Dliteratum%253Aachs%26aulast%3DHayakawa%26aufirst%3DF.%26aulast%3DTowatari%26aufirst%3DM.%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DTanimoto%26aufirst%3DM.%26aulast%3DKitamura%26aufirst%3DT.%26aulast%3DSaito%26aufirst%3DH.%26aulast%3DNaoe%26aufirst%3DT.%26atitle%3DTandem-duplicated%2520Flt3%2520constitutively%2520activates%2520STAT5%2520and%2520MAP%2520kinase%2520and%2520introduces%2520autonomous%2520cell%2520growth%2520in%2520IL-3-dependent%2520cell%2520lines%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D624%26epage%3D631%26doi%3D10.1038%2Fsj.onc.1203354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Smith, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, C.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salerno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damon, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perl, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Travers, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span> </span><span class="NLM_article-title">Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukemia</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">485</span><span class="NLM_x">, </span> <span class="NLM_fpage">260</span><span class="NLM_x">–</span> <span class="NLM_lpage">263</span><span class="refDoi"> DOI: 10.1038/nature11016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1038%2Fnature11016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=485&publication_year=2012&pages=260-263&author=C.+C.+Smithauthor=Q.+Wangauthor=C.-S.+Chinauthor=S.+Salernoauthor=L.+E.+Damonauthor=M.+J.+Levisauthor=A.+E.+Perlauthor=K.+J.+Traversauthor=S.+Wangauthor=J.+P.+Hunt&title=Validation+of+ITD+mutations+in+FLT3+as+a+therapeutic+target+in+human+acute+myeloid+leukemia&doi=10.1038%2Fnature11016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnature11016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11016%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DChin%26aufirst%3DC.-S.%26aulast%3DSalerno%26aufirst%3DS.%26aulast%3DDamon%26aufirst%3DL.%2BE.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DPerl%26aufirst%3DA.%2BE.%26aulast%3DTravers%26aufirst%3DK.%2BJ.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26atitle%3DValidation%2520of%2520ITD%2520mutations%2520in%2520FLT3%2520as%2520a%2520therapeutic%2520target%2520in%2520human%2520acute%2520myeloid%2520leukemia%26jtitle%3DNature%26date%3D2012%26volume%3D485%26spage%3D260%26epage%3D263%26doi%3D10.1038%2Fnature11016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Swords, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F.</span><span> </span><span class="NLM_article-title">Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">2176</span><span class="NLM_x">–</span> <span class="NLM_lpage">2185</span><span class="refDoi"> DOI: 10.1038/leu.2012.114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1038%2Fleu.2012.114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=22614177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSgu7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=2176-2185&author=R.+Swordsauthor=C.+Freemanauthor=F.+Giles&title=Targeting+the+FMS-like+tyrosine+kinase+3+in+acute+myeloid+leukemia&doi=10.1038%2Fleu.2012.114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia</span></div><div class="casAuthors">Swords, R.; Freeman, C.; Giles, F.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2176-2185</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Acute myeloid leukemia (AML) is a highly heterogenous disease with multiple signaling pathways contributing to its pathogenesis.  A key driver of AML is the FMS-like tyrosine kinase receptor-3 (FLT3).  Activating mutations in FLT3, primarily the FLT3-internal tandem duplication (FLT3-ITD), are assocd. with decreased progression-free and overall survival.  Identification of the importance of FLT3-ITD and the FLT3 pathway in the prognosis of patients with AML has stimulated efforts to develop therapeutic inhibitors of FLT3.  Although these inhibitors have shown promising antileukemic activity, they have had limited efficacy to date as single agents and may require use in combination with cytotoxic chemotherapies.  Here, we review clin. and preclin. results for the clin. mature FLT3 inhibitors currently in development.  We conclude that multitargeted FLT3 inhibitors may have more utility earlier in the course of disease, when in vitro evidence suggests that AML cells are less dependent on FLT3 signaling, perhaps because of upregulation of multiple other signaling pathways.  More potent agents may have greater utility in relapsed and heavily pretreated patients, in whom high levels of circulating FLT3 ligand may necessitate use of an agent with a very favorable pharmacokinetic/pharmacodynamic profile.  Novel combination regimens are also discussed.  Leukemia (2012) 26, 2176-2185; doi:10.1038/leu.2012.114; published online 22 May 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvNpqy5LWqA7Vg90H21EOLACvtfcHk0lgaeMRPzoTDhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSgu7zP&md5=774a2f787876a27b387cb3234f97cd1a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fleu.2012.114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2012.114%26sid%3Dliteratum%253Aachs%26aulast%3DSwords%26aufirst%3DR.%26aulast%3DFreeman%26aufirst%3DC.%26aulast%3DGiles%26aufirst%3DF.%26atitle%3DTargeting%2520the%2520FMS-like%2520tyrosine%2520kinase%25203%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26spage%3D2176%26epage%3D2185%26doi%3D10.1038%2Fleu.2012.114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Sudhindra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. C.</span><span> </span><span class="NLM_article-title">FLT3 Inhibitors in AML: Are We There Yet?</span> <span class="citation_source-journal">Curr. Hematol. Malig. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">174</span><span class="NLM_x">–</span> <span class="NLM_lpage">185</span><span class="refDoi"> DOI: 10.1007/s11899-014-0203-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1007%2Fs11899-014-0203-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=24682858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A280%3ADC%252BC2croslGksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=174-185&author=A.+Sudhindraauthor=C.+C.+Smith&title=FLT3+Inhibitors+in+AML%3A+Are+We+There+Yet%3F&doi=10.1007%2Fs11899-014-0203-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 inhibitors in AML: are we there yet?</span></div><div class="casAuthors">Sudhindra Akshay; Smith Catherine Choy</div><div class="citationInfo"><span class="NLM_cas:title">Current hematologic malignancy reports</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">174-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">FMS-like tyrosine kinase 3 (FLT3) is the most frequently mutated gene in AML.  Thirty percent of patients with acute myeloid leukemia (AML) harbor activating mutations in FLT3, either internal tandem duplication mutations in the juxtamembrane domain (FLT3-ITD) or point mutations in the tyrosine kinase domain (FLT3 TKD).  Small molecule FLT3 inhibitors have emerged as an attractive therapeutic option in patients with FLT3 mutations; however, the clinical activity of early inhibitors was limited by a lack of selectivity, potency and unfavorable pharmacokinetic properties.  Newer agents such as quizartinib have improved potency and selectivity associated with much higher bone marrow response rates; however, response duration is limited by the development of secondary resistance.  We will review here a number of FLT3 inhibitors that have been evaluated in clinical trials and discuss challenges facing the use of these agents in AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTea2f_u15zvsKL0FlyGHDofW6udTcc2eZJpkqXP5C1lLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2croslGksQ%253D%253D&md5=8db4cff077f6e60fdd0db2e6a641a093</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1007%2Fs11899-014-0203-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11899-014-0203-8%26sid%3Dliteratum%253Aachs%26aulast%3DSudhindra%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DC.%2BC.%26atitle%3DFLT3%2520Inhibitors%2520in%2520AML%253A%2520Are%2520We%2520There%2520Yet%253F%26jtitle%3DCurr.%2520Hematol.%2520Malig.%2520Rep.%26date%3D2014%26volume%3D9%26spage%3D174%26epage%3D185%26doi%3D10.1007%2Fs11899-014-0203-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiller, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiffer, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehninger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeAngelo, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntsman-Labed, A.</span><span> </span><span class="NLM_article-title">Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">2061</span><span class="NLM_x">–</span> <span class="NLM_lpage">2068</span><span class="refDoi"> DOI: 10.1038/leu.2012.115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1038%2Fleu.2012.115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=22627678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlWqsr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=2061-2068&author=R.+M.+Stoneauthor=T.+Fischerauthor=R.+Paquetteauthor=G.+Schillerauthor=C.+A.+Schifferauthor=G.+Ehningerauthor=J.+Cortesauthor=H.+M.+Kantarjianauthor=D.+J.+DeAngeloauthor=A.+Huntsman-Labed&title=Phase+IB+study+of+the+FLT3+kinase+inhibitor+midostaurin+with+chemotherapy+in+younger+newly+diagnosed+adult+patients+with+acute+myeloid+leukemia&doi=10.1038%2Fleu.2012.115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia</span></div><div class="casAuthors">Stone, R. M.; Fischer, T.; Paquette, R.; Schiller, G.; Schiffer, C. A.; Ehninger, G.; Cortes, J.; Kantarjian, H. M.; DeAngelo, D. J.; Huntsman-Labed, A.; Dutreix, C.; del Corral, A.; Giles, F.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2061-2068</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This phase 1b trial investigated several doses and schedules of midostaurin in combination with daunorubicin and cytarabine induction and high-dose cytarabine post-remission therapy in newly diagnosed patients with acute myeloid leukemia (AML).  The discontinuation rate on the 50-mg twice-daily dose schedule was lower than 100 mg twice daily, and no grade 3/4 nausea or vomiting was seen.  The complete remission rate for the midostaurin 50-mg twice-daily dose schedule was 80% (FMS-like tyrosine kinase 3 receptor (FLT3)-wild-type: 20 of 27 (74%), FLT3-mutant: 12 of 13 (92%)).  Overall survival (OS) probabilities of patients with FLT3-mutant AML at 1 and 2 years (0.85 and 0.62, resp.) were similar to the FLT3-wild-type population (0.78 and 0.52, resp.).  Midostaurin in combination with std. chemotherapy demonstrated high complete response and OS rates in newly diagnosed younger adults with AML, and was generally well tolerated at 50 mg twice daily for 14 days.  A phase III prospective trial is ongoing (CALGB 10603, NCT00651261).  Leukemia (2012) 26, 2061-2068; doi:10.1038/leu.2012.115; published online 25 May 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLoF6gfHbqorVg90H21EOLACvtfcHk0lgaeMRPzoTDhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlWqsr3L&md5=3084c40c113fbeaf8fea852a7a12b728</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fleu.2012.115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2012.115%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DFischer%26aufirst%3DT.%26aulast%3DPaquette%26aufirst%3DR.%26aulast%3DSchiller%26aufirst%3DG.%26aulast%3DSchiffer%26aufirst%3DC.%2BA.%26aulast%3DEhninger%26aufirst%3DG.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DHuntsman-Labed%26aufirst%3DA.%26atitle%3DPhase%2520IB%2520study%2520of%2520the%2520FLT3%2520kinase%2520inhibitor%2520midostaurin%2520with%2520chemotherapy%2520in%2520younger%2520newly%2520diagnosed%2520adult%2520patients%2520with%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26spage%3D2061%26epage%3D2068%26doi%3D10.1038%2Fleu.2012.115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Levis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravandi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perl, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coutre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erba, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuart, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccarani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cripe, L. D.</span><span> </span><span class="NLM_article-title">Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">3294</span><span class="NLM_x">–</span> <span class="NLM_lpage">3301</span><span class="refDoi"> DOI: 10.1182/blood-2010-08-301796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1182%2Fblood-2010-08-301796" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=21270442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslams7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=3294-3301&author=M.+Levisauthor=F.+Ravandiauthor=E.+S.+Wangauthor=M.+R.+Baerauthor=A.+Perlauthor=S.+Coutreauthor=H.+Erbaauthor=R.+K.+Stuartauthor=M.+Baccaraniauthor=L.+D.+Cripe&title=Results+from+a+randomized+trial+of+salvage+chemotherapy+followed+by+lestaurtinib+for+patients+with+FLT3+mutant+AML+in+first+relapse&doi=10.1182%2Fblood-2010-08-301796"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse</span></div><div class="casAuthors">Levis, Mark; Ravandi, Farhad; Wang, Eunice S.; Baer, Maria R.; Perl, Alexander; Coutre, Steven; Erba, Harry; Stuart, Robert K.; Baccarani, Michele; Cripe, Larry D.; Tallman, Martin S.; Meloni, Giovanna; Godley, Lucy A.; Langston, Amelia A.; Amadori, Sergio; Lewis, Ian D.; Nagler, Arnon; Stone, Richard; Yee, Karen; Advani, Anjali; Douer, Dan; Wiktor-Jedrzejczak, W.; Juliusson, Gunnar; Litzow, Mark R.; Petersdorf, Stephen; Sanz, Miguel; Kantarjian, Hagop M.; Sato, Takashi; Tremmel, Lothar; Bensen-Kennedy, Debra M.; Small, Donald; Smith, B. Douglas</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3294-3301</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">In a randomized trial of therapy for FMS-like tyrosine kinase-3 (FLT3) mutant acute myeloid leukemia in first relapse, 224 patients received chemotherapy alone or followed by 80 mg of the FLT3 inhibitor lestaurtinib twice daily.  Endpoints included complete remission or complete remission with incomplete platelet recovery (CR/CRp), overall survival, safety, and tolerability.  Correlative studies included pharmacokinetics and anal. of in vivo FLT3 inhibition.  There were 29 patients with CR/CRp in the lestaurtinib arm and 23 in the control arm (26% vs 21%; P = .35), and no difference in overall survival between the 2 arms.  There was evidence of toxicity in the lestaurtinib-treated patients, particularly those with plasma levels in excess of 20μM.  In the lestaurtinib arm, FLT3 inhibition was highly correlated with remission rate, but target inhibition on day 15 was achieved in only 58% of patients receiving lestaurtinib.  Given that such a small proportion of patients on this trial achieved sustained FLT3 inhibition in vivo, any conclusions regarding the efficacy of combining FLT3 inhibition with chemotherapy are limited.  Overall, lestaurtinib treatment after chemotherapy did not increase response rates or prolong survival of patients with FLT3 mutant acute myeloid leukemia in first relapse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNtYr30842srVg90H21EOLACvtfcHk0lh3xoHi8Uo1tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslams7o%253D&md5=7e3647298bb0ee66ac72786f103d8f3b</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-08-301796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-08-301796%26sid%3Dliteratum%253Aachs%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DE.%2BS.%26aulast%3DBaer%26aufirst%3DM.%2BR.%26aulast%3DPerl%26aufirst%3DA.%26aulast%3DCoutre%26aufirst%3DS.%26aulast%3DErba%26aufirst%3DH.%26aulast%3DStuart%26aufirst%3DR.%2BK.%26aulast%3DBaccarani%26aufirst%3DM.%26aulast%3DCripe%26aufirst%3DL.%2BD.%26atitle%3DResults%2520from%2520a%2520randomized%2520trial%2520of%2520salvage%2520chemotherapy%2520followed%2520by%2520lestaurtinib%2520for%2520patients%2520with%2520FLT3%2520mutant%2520AML%2520in%2520first%2520relapse%26jtitle%3DBlood%26date%3D2011%26volume%3D117%26spage%3D3294%26epage%3D3301%26doi%3D10.1182%2Fblood-2010-08-301796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">DeAngelo, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heaney, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klisovic, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caligiuri, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lecerf, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karol, M. D.</span><span> </span><span class="NLM_article-title">Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">3674</span><span class="NLM_x">–</span> <span class="NLM_lpage">3681</span><span class="refDoi"> DOI: 10.1182/blood-2006-02-005702</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1182%2Fblood-2006-02-005702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=16902153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Kgs7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2006&pages=3674-3681&author=D.+J.+DeAngeloauthor=R.+M.+Stoneauthor=M.+L.+Heaneyauthor=S.+D.+Nimerauthor=R.+L.+Paquetteauthor=R.+B.+Klisovicauthor=M.+A.+Caligiuriauthor=M.+R.+Cooperauthor=J.-M.+Lecerfauthor=M.+D.+Karol&title=Phase+1+clinical+results+with+tandutinib+%28MLN518%29%2C+a+novel+FLT3+antagonist%2C+in+patients+with+acute+myelogenous+leukemia+or+high-risk+myelodysplastic+syndrome%3A+safety%2C+pharmacokinetics%2C+and+pharmacodynamics&doi=10.1182%2Fblood-2006-02-005702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics</span></div><div class="casAuthors">DeAngelo, Daniel J.; Stone, Richard M.; Heaney, Mark L.; Nimer, Stephen D.; Paquette, Ronald L.; Klisovic, Rebecca B.; Caligiuri, Michael A.; Cooper, Michael R.; Lecerf, Jean-Michel; Karol, Michael D.; Sheng, Shihong; Holford, Nick; Curtin, Peter T.; Druker, Brian J.; Heinrich, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3674-3681</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Tandutinib (MLN518/CT53518) is a novel quinazoline-based inhibitor of the type III receptor tyrosine kinases: FMS-like tyrosine kinase 3 (FLT3), platelet-derived growth factor receptor (PDGFR), and KIT.  Because of the correlation between FLT3 internal tandem duplication (ITD) mutations and poor prognosis in acute myelogenous leukemia (AML), we conducted a phase 1 trial of tandutinib in 40 patients with either AML or high-risk myelodysplastic syndrome (MDS).  Tandutinib was given orally in doses ranging from 50 mg to 700 mg twice daily The principal dose-limiting toxicity (DLT) of tandutinib was reversible generalized muscular weakness, fatigue, or both, occurring at doses of 525 mg and 700 mg twice daily.  Tandutinib's pharmacokinetics were characterized by slow elimination, with achievement of steady-state plasma concns. requiring greater than 1 wk of dosing.  Western blotting showed that tandutinib inhibited phosphorylation of FLT3 in circulating leukemic blasts.  Eight patients had FLT3-ITD mutations; 5 of these were evaluable for assessment of tandutinib's antileukemic effect.  Two of the 5 patients, treated at 525 mg and 700 mg twice daily, showed evidence of antileukemic activity, with decreases in both peripheral and bone marrow blasts.  Tandutinib at the MTD (525 mg twice daily) should be evaluated more extensively in patients with AML with FLT3-ITD mutations to better define its antileukemic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraXRBv_Gv-TLVg90H21EOLACvtfcHk0lh3xoHi8Uo1tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Kgs7%252FM&md5=42c0b5a4c193955023198d6c6d12c463</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1182%2Fblood-2006-02-005702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2006-02-005702%26sid%3Dliteratum%253Aachs%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DHeaney%26aufirst%3DM.%2BL.%26aulast%3DNimer%26aufirst%3DS.%2BD.%26aulast%3DPaquette%26aufirst%3DR.%2BL.%26aulast%3DKlisovic%26aufirst%3DR.%2BB.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26aulast%3DCooper%26aufirst%3DM.%2BR.%26aulast%3DLecerf%26aufirst%3DJ.-M.%26aulast%3DKarol%26aufirst%3DM.%2BD.%26atitle%3DPhase%25201%2520clinical%2520results%2520with%2520tandutinib%2520%2528MLN518%2529%252C%2520a%2520novel%2520FLT3%2520antagonist%252C%2520in%2520patients%2520with%2520acute%2520myelogenous%2520leukemia%2520or%2520high-risk%2520myelodysplastic%2520syndrome%253A%2520safety%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%26jtitle%3DBlood%26date%3D2006%26volume%3D108%26spage%3D3674%26epage%3D3681%26doi%3D10.1182%2Fblood-2006-02-005702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Pratz, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roboz, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arowojolu, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiotsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shudo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span> </span><span class="NLM_article-title">A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">3938</span><span class="NLM_x">–</span> <span class="NLM_lpage">3946</span><span class="refDoi"> DOI: 10.1182/blood-2008-09-177030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1182%2Fblood-2008-09-177030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=19029442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsVWrsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=3938-3946&author=K.+W.+Pratzauthor=J.+Cortesauthor=G.+J.+Robozauthor=N.+Raoauthor=O.+Arowojoluauthor=A.+Stineauthor=Y.+Shiotsuauthor=A.+Shudoauthor=S.+Akinagaauthor=D.+Small&title=A+pharmacodynamic+study+of+the+FLT3+inhibitor+KW-2449+yields+insight+into+the+basis+for+clinical+response&doi=10.1182%2Fblood-2008-09-177030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response</span></div><div class="casAuthors">Pratz, Keith W.; Cortes, Jorge; Roboz, Gail J.; Rao, Niranjan; Arowojolu, Omotayo; Stine, Adam; Shiotsu, Yukimasa; Shudo, Aiko; Akinaga, Shiro; Small, Donald; Karp, Judith E.; Levis, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3938-3946</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Internal tandem duplication mutations of FLT3 (FLT3/ITD mutations) are common in acute myeloid leukemia (AML) and confer a poor prognosis.  This would suggest that FLT3 is an ideal therapeutic target, but FLT3 targeted therapy has produced only modest benefits in clin. trials.  Due to tech. obstacles, the assessment of target inhibition in patients treated with FLT3 inhibitors has been limited and generally only qual.  KW-2449 is a novel multitargeted kinase inhibitor that induces cytotoxicity in Molm14 cells (which harbor an FLT3/ITD mutation).  The cytotoxic effect occurs primarily at concns. sufficient to inhibit FLT3 autophosphorylation to less than 20% of its baseline.  We report here correlative data from a phase 1 trial of KW-2449, a trial in which typical transient redns. in the peripheral blast counts were obsd.  Using quant. measurement of FLT3 inhibition over time in these patients, we confirmed that FLT3 was inhibited, but only transiently to less than 20% of baseline.  These results suggest that the failure to fully inhibit FLT3 in sustained fashion may be an underlying reason for the minimal success of FLT3 inhibitors to date, and stress the importance of confirming in vivo target inhibition when taking a targeted agent into the clin. setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA9awndUDkxbVg90H21EOLACvtfcHk0lh3xoHi8Uo1tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsVWrsLg%253D&md5=436d5ee18d3b257a92546832e9eb9a6a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-09-177030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-09-177030%26sid%3Dliteratum%253Aachs%26aulast%3DPratz%26aufirst%3DK.%2BW.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DRoboz%26aufirst%3DG.%2BJ.%26aulast%3DRao%26aufirst%3DN.%26aulast%3DArowojolu%26aufirst%3DO.%26aulast%3DStine%26aufirst%3DA.%26aulast%3DShiotsu%26aufirst%3DY.%26aulast%3DShudo%26aufirst%3DA.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DA%2520pharmacodynamic%2520study%2520of%2520the%2520FLT3%2520inhibitor%2520KW-2449%2520yields%2520insight%2520into%2520the%2520basis%2520for%2520clinical%2520response%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D3938%26epage%3D3946%26doi%3D10.1182%2Fblood-2008-09-177030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Ravandi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alattar, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grunwald, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudek, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajkhowa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richie, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daver, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Manero, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faderl, S.</span><span> </span><span class="NLM_article-title">Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">4655</span><span class="NLM_x">–</span> <span class="NLM_lpage">4662</span><span class="refDoi"> DOI: 10.1182/blood-2013-01-480228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1182%2Fblood-2013-01-480228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=23613521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpsFWktbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2013&pages=4655-4662&author=F.+Ravandiauthor=M.+L.+Alattarauthor=M.+R.+Grunwaldauthor=M.+A.+Rudekauthor=T.+Rajkhowaauthor=M.+A.+Richieauthor=S.+Pierceauthor=N.+Daverauthor=G.+Garcia-Maneroauthor=S.+Faderl&title=Phase+2+study+of+azacytidine+plus+sorafenib+in+patients+with+acute+myeloid+leukemia+and+FLT-3+internal+tandem+duplication+mutation&doi=10.1182%2Fblood-2013-01-480228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation</span></div><div class="casAuthors">Ravandi, Farhad; Alattar, Mona Lisa; Grunwald, Michael R.; Rudek, Michelle A.; Rajkhowa, Trivikram; Richie, Mary Ann; Pierce, Sherry; Daver, Naval; Garcia-Manero, Guillermo; Faderl, Stefan; Nazha, Aziz; Konopleva, Marina; Borthakur, Gautam; Burger, Jan; Kadia, Tapan; Dellasala, Sara; Andreeff, Michael; Cortes, Jorge; Kantarjian, Hagop; Levis, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4655-4662</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Patients received 5-azacytidine (AZA) 75 mg/m2 i.v. daily for 7 days and sorafenib 400 mg orally twice daily continuously; cycles were repeated at ∼1-mo intervals.  Forty-three acute myeloid leukemia (AML) patients with a median age of 64 years (range, 24-87 years) were enrolled; 37 were evaluable for response.  FMS-like tyrosine kinase-3 (FLT3)-internal tandem duplication (ITD) mutation was detected in 40 (93%) patients, with a median allelic ratio of 0.32 (range, 0.009-0.93).  They had received a median of 2 prior treatment regimens (range, 0-7); 9 had failed prior therapy with a FLT3 kinase inhibitor.  The response rate was 46%, including 10 (27%) complete response with incomplete count recovery (CRi), 6 (16%) complete responses (CR), and 1 (3%) partial response.  The median time to achieve CR/CRi was 2 cycles (range, 1-4), and the median duration of CR/CRi was 2.3 mo (range, 1-14.3 mo).  Sixty-four percent of patients achieved adequate (defined as >85%) FLT3 inhibition during their first cycle of therapy.  The degree of FLT3 inhibition correlated with plasma sorafenib concns.  FLT3 ligand levels did not rise to levels seen in prior studies of patients receiving cytotoxic chemotherapy.  The combination of AZA and sorafenib is effective for patients with relapsed AML and FLT-3-ITD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx7FK4wFoKk7Vg90H21EOLACvtfcHk0liYjaolVCeQ0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpsFWktbo%253D&md5=cb763c746906ccd682cbe8faa5ec6f67</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-01-480228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-01-480228%26sid%3Dliteratum%253Aachs%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DAlattar%26aufirst%3DM.%2BL.%26aulast%3DGrunwald%26aufirst%3DM.%2BR.%26aulast%3DRudek%26aufirst%3DM.%2BA.%26aulast%3DRajkhowa%26aufirst%3DT.%26aulast%3DRichie%26aufirst%3DM.%2BA.%26aulast%3DPierce%26aufirst%3DS.%26aulast%3DDaver%26aufirst%3DN.%26aulast%3DGarcia-Manero%26aufirst%3DG.%26aulast%3DFaderl%26aufirst%3DS.%26atitle%3DPhase%25202%2520study%2520of%2520azacytidine%2520plus%2520sorafenib%2520in%2520patients%2520with%2520acute%2520myeloid%2520leukemia%2520and%2520FLT-3%2520internal%2520tandem%2520duplication%2520mutation%26jtitle%3DBlood%26date%3D2013%26volume%3D121%26spage%3D4655%26epage%3D4662%26doi%3D10.1182%2Fblood-2013-01-480228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunawardane, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cramer, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brigham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratz, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Q.</span><span> </span><span class="NLM_article-title">AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">2984</span><span class="NLM_x">–</span> <span class="NLM_lpage">2992</span><span class="refDoi"> DOI: 10.1182/blood-2009-05-222034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1182%2Fblood-2009-05-222034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=19654408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht12qurzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=2984-2992&author=P.+P.+Zarrinkarauthor=R.+N.+Gunawardaneauthor=M.+D.+Cramerauthor=M.+F.+Gardnerauthor=D.+Brighamauthor=B.+Belliauthor=M.+W.+Karamanauthor=K.+W.+Pratzauthor=G.+Pallaresauthor=Q.+Chao&title=AC220+is+a+uniquely+potent+and+selective+inhibitor+of+FLT3+for+the+treatment+of+acute+myeloid+leukemia+%28AML%29&doi=10.1182%2Fblood-2009-05-222034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)</span></div><div class="casAuthors">Zarrinkar, Patrick P.; Gunawardane, Ruwanthi N.; Cramer, Merryl D.; Gardner, Michael F.; Brigham, Daniel; Belli, Barbara; Karaman, Mazen W.; Pratz, Keith W.; Pallares, Gabriel; Chao, Qi; Sprankle, Kelly G.; Patel, Hitesh K.; Levis, Mark; Armstrong, Robert C.; James, Joyce; Bhagwat, Shripad S.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2984-2992</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Activating mutations in the receptor tyrosine kinase FLT3 are present in up to approx. 30% of acute myeloid leukemia (AML) patients, implicating FLT3 as a driver of the disease and therefore as a target for therapy.  We report the characterization of AC220, a second-generation FLT3 inhibitor, and a comparison of AC220 with the first-generation FLT3 inhibitors CEP-701, MLN-518, PKC-412, sorafenib, and sunitinib.  AC220 exhibits low nanomolar potency in biochem. and cellular assays and exceptional kinase selectivity, and in animal models is efficacious at doses as low as 1 mg/kg given orally once daily.  The data reveal that the combination of excellent potency, selectivity, and pharmacokinetic properties is unique to AC220, which therefore is the first drug candidate with a profile that matches the characteristics desirable for a clin. FLT3 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_RzDr7kzxsLVg90H21EOLACvtfcHk0liYjaolVCeQ0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht12qurzN&md5=4f8368a7b2eab9d1234ef36e01f5f260</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-05-222034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-05-222034%26sid%3Dliteratum%253Aachs%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DCramer%26aufirst%3DM.%2BD.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DBelli%26aufirst%3DB.%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DPratz%26aufirst%3DK.%2BW.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DChao%26aufirst%3DQ.%26atitle%3DAC220%2520is%2520a%2520uniquely%2520potent%2520and%2520selective%2520inhibitor%2520of%2520FLT3%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D2984%26epage%3D2992%26doi%3D10.1182%2Fblood-2009-05-222034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Galanis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajkhowa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramachandran, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M.</span><span> </span><span class="NLM_article-title">Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">94</span><span class="NLM_x">–</span> <span class="NLM_lpage">100</span><span class="refDoi"> DOI: 10.1182/blood-2013-10-529313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1182%2Fblood-2013-10-529313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=24227820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVCksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2014&pages=94-100&author=A.+Galanisauthor=H.+Maauthor=T.+Rajkhowaauthor=A.+Ramachandranauthor=D.+Smallauthor=J.+Cortesauthor=M.+Levis&title=Crenolanib+is+a+potent+inhibitor+of+FLT3+with+activity+against+resistance-conferring+point+mutants&doi=10.1182%2Fblood-2013-10-529313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants</span></div><div class="casAuthors">Galanis, Allison; Ma, Hayley; Rajkhowa, Trivikram; Ramachandran, Abhijit; Small, Donald; Cortes, Jorge; Levis, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-100</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Mutations of the type III receptor tyrosine kinase FLT3 occur in approx. 30% of acute myeloid leukemia patients and lead to constitutive activation.  This has made FLT3-activating mutations an attractive drug target because they are probable driver mutations of this disease.  As more potent FLT3 inhibitors are developed, a predictable development of resistance-conferring point mutations, commonly at residue D835, has been obsd.  Crenolanib is a highly selective and potent FLT3 tyrosine kinase inhibitor (TKI) with activity against the internal tandem duplication (FLT3/ITD) mutants and the FLT3/D835 point mutants.  We tested crenolanib against a panel of D835 mutant cell lines and primary patient blasts and obsd. superior cytotoxic effects when compared with other available FLT3 TKIs such as quizartinib and sorafenib.  Another potential advantage of crenolanib is its reduced inhibition of c-Kit compared with quizartinib.  In progenitor cell assays, crenolanib was less disruptive of erythroid colony growth, which may result in relatively less myelosuppression than quizartinib.  Finally, correlative data from an ongoing clin. trial demonstrate that acute myeloid leukemia patients can achieve sufficient levels of crenolanib to inhibit both FLT3/ITD and resistance-conferring FLT3/D835 mutants in vivo.  Crenolanib is thus an important next-generation FLT3 TKI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmTJQsMqjR3rVg90H21EOLACvtfcHk0liYjaolVCeQ0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVCksA%253D%253D&md5=c622e44844e5038fe3567735ea3fee7e</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-10-529313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-10-529313%26sid%3Dliteratum%253Aachs%26aulast%3DGalanis%26aufirst%3DA.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DRajkhowa%26aufirst%3DT.%26aulast%3DRamachandran%26aufirst%3DA.%26aulast%3DSmall%26aufirst%3DD.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DLevis%26aufirst%3DM.%26atitle%3DCrenolanib%2520is%2520a%2520potent%2520inhibitor%2520of%2520FLT3%2520with%2520activity%2520against%2520resistance-conferring%2520point%2520mutants%26jtitle%3DBlood%26date%3D2014%26volume%3D123%26spage%3D94%26epage%3D100%26doi%3D10.1182%2Fblood-2013-10-529313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Zimmerman, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buaboonnam, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orwick, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janke, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramachandran, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inaba, H.</span><span> </span><span class="NLM_article-title">Crenolanib is active against models of drug-resistant FLT3-ITD– positive acute myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">3607</span><span class="NLM_x">–</span> <span class="NLM_lpage">3615</span><span class="refDoi"> DOI: 10.1182/blood-2013-07-513044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1182%2Fblood-2013-07-513044" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=3607-3615&author=E.+I.+Zimmermanauthor=D.+C.+Turnerauthor=J.+Buaboonnamauthor=S.+Huauthor=S.+Orwickauthor=M.+S.+Robertsauthor=L.+J.+Jankeauthor=A.+Ramachandranauthor=C.+F.+Stewartauthor=H.+Inaba&title=Crenolanib+is+active+against+models+of+drug-resistant+FLT3-ITD%E2%80%93+positive+acute+myeloid+leukemia&doi=10.1182%2Fblood-2013-07-513044"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-07-513044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-07-513044%26sid%3Dliteratum%253Aachs%26aulast%3DZimmerman%26aufirst%3DE.%2BI.%26aulast%3DTurner%26aufirst%3DD.%2BC.%26aulast%3DBuaboonnam%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DS.%26aulast%3DOrwick%26aufirst%3DS.%26aulast%3DRoberts%26aufirst%3DM.%2BS.%26aulast%3DJanke%26aufirst%3DL.%2BJ.%26aulast%3DRamachandran%26aufirst%3DA.%26aulast%3DStewart%26aufirst%3DC.%2BF.%26aulast%3DInaba%26aufirst%3DH.%26atitle%3DCrenolanib%2520is%2520active%2520against%2520models%2520of%2520drug-resistant%2520FLT3-ITD%25E2%2580%2593%2520positive%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26spage%3D3607%26epage%3D3615%26doi%3D10.1182%2Fblood-2013-07-513044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Grunwald, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M. J.</span><span> </span><span class="NLM_article-title">FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance</span> <span class="citation_source-journal">Int. J. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">683</span><span class="NLM_x">–</span> <span class="NLM_lpage">694</span><span class="refDoi"> DOI: 10.1007/s12185-013-1334-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1007%2Fs12185-013-1334-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=23613268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BC3sXps1ynt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2013&pages=683-694&author=M.+R.+Grunwaldauthor=M.+J.+Levis&title=FLT3+inhibitors+for+acute+myeloid+leukemia%3A+a+review+of+their+efficacy+and+mechanisms+of+resistance&doi=10.1007%2Fs12185-013-1334-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance</span></div><div class="casAuthors">Grunwald, Michael R.; Levis, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Hematology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">683-694</span>CODEN:
                <span class="NLM_cas:coden">IJHEEY</span>;
        ISSN:<span class="NLM_cas:issn">0925-5710</span>.
    
            (<span class="NLM_cas:orgname">Springer Japan</span>)
        </div><div class="casAbstract">A review.  Since the Food and Drug Administration approval of imatinib for treatment of chronic myeloid leukemia in 2001, tyrosine kinase inhibitors (TKIs) have become a mainstay in the care of many malignancies.  In acute myeloid leukemia (AML), activating mutations in the FMS-like tyrosine kinase 3 (FLT3) gene result in survival and proliferation of leukemic blasts and are assocd. with adverse prognosis.  Therefore, the FLT3 receptor is an appealing target for inhibition.  Multiple small mol. TKIs are currently in development for FLT3-mutated AML, and agents are beginning to show promising efficacy.  In other malignancies, the development of resistance to TKIs during the course of therapy has proven to be a challenge, and thus far, in clin. trials of FLT3 TKIs, resistance to inhibition represents a significant barrier to successful FLT3 inhibition.  Understanding the mechanisms of resistance and overcoming these obstacles to target inhibition will be central to the success of these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLGvQhRtVOcLVg90H21EOLACvtfcHk0ljqIyWBJEnZAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXps1ynt7Y%253D&md5=f760866dbcd953c09143e0290fbffe3c</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1007%2Fs12185-013-1334-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12185-013-1334-8%26sid%3Dliteratum%253Aachs%26aulast%3DGrunwald%26aufirst%3DM.%2BR.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26atitle%3DFLT3%2520inhibitors%2520for%2520acute%2520myeloid%2520leukemia%253A%2520a%2520review%2520of%2520their%2520efficacy%2520and%2520mechanisms%2520of%2520resistance%26jtitle%3DInt.%2520J.%2520Hematol.%26date%3D2013%26volume%3D97%26spage%3D683%26epage%3D694%26doi%3D10.1007%2Fs12185-013-1334-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Smith, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasater, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCreery, M. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damon, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perl, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeschke, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugita, M.</span><span> </span><span class="NLM_article-title">Crenolanib is a selective type I pan-FLT3 inhibitor</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">5319</span><span class="NLM_x">–</span> <span class="NLM_lpage">5324</span><span class="refDoi"> DOI: 10.1073/pnas.1320661111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1073%2Fpnas.1320661111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=24623852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkt1Snsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=5319-5324&author=C.+C.+Smithauthor=E.+A.+Lasaterauthor=K.+C.+Linauthor=Q.+Wangauthor=M.+Q.+McCreeryauthor=W.+K.+Stewartauthor=L.+E.+Damonauthor=A.+E.+Perlauthor=G.+R.+Jeschkeauthor=M.+Sugita&title=Crenolanib+is+a+selective+type+I+pan-FLT3+inhibitor&doi=10.1073%2Fpnas.1320661111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Crenolanib is a selective type I pan-FLT3 inhibitor</span></div><div class="casAuthors">Smith, Catherine Choy; Lasater, Elisabeth A.; Lin, Kimberly C.; Wang, Qi; McCreery, Melissa Quino; Stewart, Whitney K.; Damon, Lauren E.; Perl, Alexander E.; Jeschke, Grace R.; Sugita, Mayumi; Carroll, Martin; Kogan, Scott C.; Kuriyan, John; Shah, Neil P.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5319-5324</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Tyrosine kinase inhibitors (TKIs) represent transformative therapies for several malignancies.  Two crit. features necessary for maximizing TKI tolerability and response duration are kinase selectivity and invulnerability to resistance-conferring kinase domain (KD) mutations in the intended target.  No prior TKI has demonstrated both of these properties.  Aiming to maximize selectivity, medicinal chemists have largely sought to create TKIs that bind to an inactive (type II) kinase conformation.  The investigational type I TKI crenolanib is a potent inhibitor of Fms tyrosine kinase-3 (FLT3) internal tandem duplication, a validated therapeutic target in human acute myeloid leukemia (AML), as well as all secondary KD mutants previously shown to confer resistance to the first highly active FLT3 TKI quizartinib.  Moreover, crenolanib is highly selective for FLT3 relative to the closely related protein tyrosine kinase KIT, demonstrating that simultaneous FLT3/KIT inhibition, a prominent feature of other clin. active FLT3 TKIs, is not required for AML cell cytotoxicity in vitro and may contribute to undesirable toxicity in patients.  A satn. mutagenesis screen of FLT3-internal tandem duplication failed to recover any resistant colonies in the presence of a crenolanib concn. well below what has been safely achieved in humans, suggesting that crenolanib has the potential to suppress KD mutation-mediated clin. resistance.  Crenolanib represents the first TKI to exhibit both kinase selectivity and invulnerability to resistance-conferring KD mutations, which is unexpected of a type I inhibitor.  Crenolanib has significant promise for achieving deep and durable responses in FLT3-mutant AML, and may have a profound impact upon future medicinal chem. efforts in oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwxReAanOwB7Vg90H21EOLACvtfcHk0ljqIyWBJEnZAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkt1Snsbw%253D&md5=955f1f242a1690247ae239050e2a8a8f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1320661111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1320661111%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DLasater%26aufirst%3DE.%2BA.%26aulast%3DLin%26aufirst%3DK.%2BC.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DMcCreery%26aufirst%3DM.%2BQ.%26aulast%3DStewart%26aufirst%3DW.%2BK.%26aulast%3DDamon%26aufirst%3DL.%2BE.%26aulast%3DPerl%26aufirst%3DA.%2BE.%26aulast%3DJeschke%26aufirst%3DG.%2BR.%26aulast%3DSugita%26aufirst%3DM.%26atitle%3DCrenolanib%2520is%2520a%2520selective%2520type%2520I%2520pan-FLT3%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D5319%26epage%3D5324%26doi%3D10.1073%2Fpnas.1320661111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ku, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span> </span><span class="NLM_article-title">Discovery of Pteridin-7 (8 H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) Kinase T790M/L858R mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">7821</span><span class="NLM_x">–</span> <span class="NLM_lpage">7837</span><span class="refDoi"> DOI: 10.1021/jm401045n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401045n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7821-7837&author=W.+Zhouauthor=X.+Liuauthor=Z.+Tuauthor=L.+Zhangauthor=X.+Kuauthor=F.+Baiauthor=Z.+Zhaoauthor=Y.+Xuauthor=K.+Dingauthor=H.+Li&title=Discovery+of+Pteridin-7+%288+H%29-one-based+irreversible+inhibitors+targeting+the+epidermal+growth+factor+receptor+%28EGFR%29+Kinase+T790M%2FL858R+mutant&doi=10.1021%2Fjm401045n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm401045n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401045n%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DKu%26aufirst%3DX.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520Pteridin-7%2520%25288%2520H%2529-one-based%2520irreversible%2520inhibitors%2520targeting%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520Kinase%2520T790M%252FL858R%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7821%26epage%3D7837%26doi%3D10.1021%2Fjm401045n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span><span class="refDoi"> DOI: 10.1038/nature08622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.-H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Padera&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M&doi=10.1038%2Fnature08622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0lhLCwkCQw4UzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074%26doi%3D10.1038%2Fnature08622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Song, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ge, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, X.</span><span> </span><span class="NLM_article-title">Challenges and Perspectives on the Development of Small-molecule EGFR Inhibitors against T790M-mediated Resistance in Non-small-cell Lung Cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00840</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00840" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Z.+Songauthor=Y.+Geauthor=C.+Wangauthor=S.+Huangauthor=X.+Shuauthor=K.+Liuauthor=Y.+Zhouauthor=X.+Ma&title=Challenges+and+Perspectives+on+the+Development+of+Small-molecule+EGFR+Inhibitors+against+T790M-mediated+Resistance+in+Non-small-cell+Lung+Cancer&doi=10.1021%2Facs.jmedchem.5b00840"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00840%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DGe%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DShu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DX.%26atitle%3DChallenges%2520and%2520Perspectives%2520on%2520the%2520Development%2520of%2520Small-molecule%2520EGFR%2520Inhibitors%2520against%2520T790M-mediated%2520Resistance%2520in%2520Non-small-cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26doi%3D10.1021%2Facs.jmedchem.5b00840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Walter, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjin, R. T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span> </span><span class="NLM_article-title">Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1404</span><span class="NLM_x">–</span> <span class="NLM_lpage">1415</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1158%2F2159-8290.CD-13-0314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=24065731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1404-1415&author=A.+O.+Walterauthor=R.+T.+T.+Sjinauthor=H.+J.+Haringsmaauthor=K.+Ohashiauthor=J.+Sunauthor=K.+Leeauthor=A.+Dubrovskiyauthor=M.+Labenskiauthor=Z.+Zhuauthor=Z.+Wang&title=Discovery+of+a+mutant-selective+covalent+inhibitor+of+EGFR+that+overcomes+T790M-mediated+resistance+in+NSCLC&doi=10.1158%2F2159-8290.CD-13-0314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span></div><div class="casAuthors">Walter, Annette O.; Sjin, Robert Tjin Tham; Haringsma, Henry J.; Ohashi, Kadoaki; Sun, Jing; Lee, Kwangho; Dubrovskiy, Aleksandr; Labenski, Matthew; Zhu, Zhendong; Wang, Zhigang; Sheets, Michael; St. Martin, Thia; Karp, Russell; van Kalken, Dan; Chaturvedi, Prasoon; Niu, Deqiang; Nacht, Mariana; Petter, Russell C.; Westlin, William; Lin, Kevin; Jaw-Tsai, Sarah; Raponi, Mitch; Van Dyke, Terry; Etter, Jeff; Weaver, Zoe; Pao, William; Singh, Juswinder; Simmons, Andrew D.; Harding, Thomas C.; Allen, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1404-1415</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors.  However, clin. efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation.  CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor.  Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models.  Minimal activity of CO-1686 against the WT EGFR receptor was obsd.  In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of addnl. mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial-mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors.  These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR0CDWQZ5wn7Vg90H21EOLACvtfcHk0lhLCwkCQw4UzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN&md5=3d111f4bf958f2fda6890fbc0e1d99f5</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0314%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DSjin%26aufirst%3DR.%2BT.%2BT.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520a%2520mutant-selective%2520covalent%2520inhibitor%2520of%2520EGFR%2520that%2520overcomes%2520T790M-mediated%2520resistance%2520in%2520NSCLC%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D1404%26epage%3D1415%26doi%3D10.1158%2F2159-8290.CD-13-0314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Cross, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nebhan, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitzler, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, M. R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span> </span><span class="NLM_article-title">AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&author=D.+A.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+V.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellor&title=AZD9291%2C+an+irreversible+EGFR+TKI%2C+overcomes+T790M-mediated+resistance+to+EGFR+inhibitors+in+lung+cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0lhtxAkrjErJIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26atitle%3DAZD9291%252C%2520an%2520irreversible%2520EGFR%2520TKI%252C%2520overcomes%2520T790M-mediated%2520resistance%2520to%2520EGFR%2520inhibitors%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bold, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roesel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guagnano, V.</span><span> </span><span class="NLM_article-title">Aromatic interactions with phenylalanine 691 and cysteine 828: a concept for FMS-like tyrosine kinase-3 inhibition. Application to the discovery of a new class of potential antileukemia agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">4451</span><span class="NLM_x">–</span> <span class="NLM_lpage">4454</span><span class="refDoi"> DOI: 10.1021/jm060368s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060368s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4451-4454&author=P.+Furetauthor=G.+Boldauthor=T.+Meyerauthor=J.+Roeselauthor=V.+Guagnano&title=Aromatic+interactions+with+phenylalanine+691+and+cysteine+828%3A+a+concept+for+FMS-like+tyrosine+kinase-3+inhibition.+Application+to+the+discovery+of+a+new+class+of+potential+antileukemia+agents&doi=10.1021%2Fjm060368s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm060368s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060368s%26sid%3Dliteratum%253Aachs%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DBold%26aufirst%3DG.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DRoesel%26aufirst%3DJ.%26aulast%3DGuagnano%26aufirst%3DV.%26atitle%3DAromatic%2520interactions%2520with%2520phenylalanine%2520691%2520and%2520cysteine%2520828%253A%2520a%2520concept%2520for%2520FMS-like%2520tyrosine%2520kinase-3%2520inhibition.%2520Application%2520to%2520the%2520discovery%2520of%2520a%2520new%2520class%2520of%2520potential%2520antileukemia%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4451%26epage%3D4454%26doi%3D10.1021%2Fjm060368s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Williams, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leahy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span> </span><span class="NLM_article-title">Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">48</span><span class="NLM_x">–</span> <span class="NLM_lpage">55</span><span class="refDoi"> DOI: 10.1038/leu.2012.191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1038%2Fleu.2012.191" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=48-55&author=A.+B.+Williamsauthor=B.+Nguyenauthor=L.+Liauthor=P.+Brownauthor=M.+Levisauthor=D.+Leahyauthor=D.+Small&title=Mutations+of+FLT3%2FITD+confer+resistance+to+multiple+tyrosine+kinase+inhibitors&doi=10.1038%2Fleu.2012.191"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fleu.2012.191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2012.191%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DA.%2BB.%26aulast%3DNguyen%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DBrown%26aufirst%3DP.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DLeahy%26aufirst%3DD.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DMutations%2520of%2520FLT3%252FITD%2520confer%2520resistance%2520to%2520multiple%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DLeukemia%26date%3D2013%26volume%3D27%26spage%3D48%26epage%3D55%26doi%3D10.1038%2Fleu.2012.191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Albers, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leischner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verbeek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Illert, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peschel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Bubnoff, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duyster, J.</span><span> </span><span class="NLM_article-title">The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD<sup>+</sup> AML but retains in vitro sensitivity to PKC412 and Sunitinib</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1416</span><span class="NLM_x">–</span> <span class="NLM_lpage">1418</span><span class="refDoi"> DOI: 10.1038/leu.2013.14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1038%2Fleu.2013.14" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=1416-1418&author=C.+Albersauthor=H.+Leischnerauthor=M.+Verbeekauthor=C.+Yuauthor=A.+L.+Illertauthor=C.+Peschelauthor=N.+von+Bubnoffauthor=J.+Duyster&title=The+secondary+FLT3-ITD+F691L+mutation+induces+resistance+to+AC220+in+FLT3-ITD%2B+AML+but+retains+in+vitro+sensitivity+to+PKC412+and+Sunitinib&doi=10.1038%2Fleu.2013.14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fleu.2013.14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2013.14%26sid%3Dliteratum%253Aachs%26aulast%3DAlbers%26aufirst%3DC.%26aulast%3DLeischner%26aufirst%3DH.%26aulast%3DVerbeek%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DIllert%26aufirst%3DA.%2BL.%26aulast%3DPeschel%26aufirst%3DC.%26aulast%3Dvon%2BBubnoff%26aufirst%3DN.%26aulast%3DDuyster%26aufirst%3DJ.%26atitle%3DThe%2520secondary%2520FLT3-ITD%2520F691L%2520mutation%2520induces%2520resistance%2520to%2520AC220%2520in%2520FLT3-ITD%252B%2520AML%2520but%2520retains%2520in%2520vitro%2520sensitivity%2520to%2520PKC412%2520and%2520Sunitinib%26jtitle%3DLeukemia%26date%3D2013%26volume%3D27%26spage%3D1416%26epage%3D1418%26doi%3D10.1038%2Fleu.2013.14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Barry, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cools, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roesel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span> </span><span class="NLM_article-title">Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">4476</span><span class="NLM_x">–</span> <span class="NLM_lpage">4479</span><span class="refDoi"> DOI: 10.1182/blood-2007-07-101238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1182%2Fblood-2007-07-101238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=17827387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BD1cXot1Wr" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=4476-4479&author=E.+V.+Barryauthor=J.+J.+Clarkauthor=J.+Coolsauthor=J.+Roeselauthor=D.+G.+Gilliland&title=Uniform+sensitivity+of+FLT3+activation+loop+mutants+to+the+tyrosine+kinase+inhibitor+midostaurin&doi=10.1182%2Fblood-2007-07-101238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin</span></div><div class="casAuthors">Barry, Elly V.; Clark, Jennifer J.; Cools, Jan; Roesel, Johannes; Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4476-4479</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Small mol. inhibitors that target fms-like tyrosine kinase 3 (FLT3)-activating mutations have potential in the treatment of leukemias.  However, certain mutations can simultaneously activate the tyrosine kinase, and confer resistance to small mol. inhibitors.  We therefore tested the sensitivity of 8 FLT3 activation loop mutants to midostaurin.  Each mutant conferred IL-3 factor-independent proliferation to Ba/F3 cells, and each resulted in the constitutive activation of FLT3 and its targets, signal transducer and activator of transcription 5 (STAT5) and extracellular stimuli-responsive kinase (ERK).  For each mutant tested, midostaurin inhibited cell growth and phosphorylation of FLT3, STAT5, and ERK.  In contrast, midostaruin did not inhibit Ba/F3 cells stably transduced with FLT3-internal tandem duplications contg. a G697R mutation that confers resistance to midostaurin, demonstrating that midostaurin inhibition of FLT3 activation loop mutants was not due to off-target effects.  We conclude that midostaurin is a potent inhibitor of a spectrum of FLT3 activation loop mutations, and that acute myeloid leukemia patients with such mutations are potential candidates for clin. trials involving midostaurin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdwABqNKHecLVg90H21EOLACvtfcHk0lhtxAkrjErJIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXot1Wr&md5=a4093ba0c60d4c239226a25eba2a266c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-07-101238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-07-101238%26sid%3Dliteratum%253Aachs%26aulast%3DBarry%26aufirst%3DE.%2BV.%26aulast%3DClark%26aufirst%3DJ.%2BJ.%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DRoesel%26aufirst%3DJ.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DUniform%2520sensitivity%2520of%2520FLT3%2520activation%2520loop%2520mutants%2520to%2520the%2520tyrosine%2520kinase%2520inhibitor%2520midostaurin%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D4476%26epage%3D4479%26doi%3D10.1182%2Fblood-2007-07-101238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Gilliland, D. G.</span><span> </span><span class="NLM_article-title">FLT3-activating mutations in acute promyelocytic leukemia: a rationale for risk-adapted therapy with FLT3 inhibitors</span> <span class="citation_source-journal">Best Practice & Research Clinical Haematology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">409</span><span class="NLM_x">–</span> <span class="NLM_lpage">417</span><span class="refDoi"> DOI: 10.1016/S1521-6926(03)00063-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1016%2FS1521-6926%2803%2900063-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2003&pages=409-417&author=D.+G.+Gilliland&title=FLT3-activating+mutations+in+acute+promyelocytic+leukemia%3A+a+rationale+for+risk-adapted+therapy+with+FLT3+inhibitors&doi=10.1016%2FS1521-6926%2803%2900063-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2FS1521-6926%2803%2900063-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1521-6926%252803%252900063-X%26sid%3Dliteratum%253Aachs%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DFLT3-activating%2520mutations%2520in%2520acute%2520promyelocytic%2520leukemia%253A%2520a%2520rationale%2520for%2520risk-adapted%2520therapy%2520with%2520FLT3%2520inhibitors%26jtitle%3DBest%2520Practice%2520%2526%2520Research%2520Clinical%2520Haematology%26date%3D2003%26volume%3D16%26spage%3D409%26epage%3D417%26doi%3D10.1016%2FS1521-6926%2803%2900063-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Moore, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faisal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Castro, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bavetsias, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atrash, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Haven Brandon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avery, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mair, D.</span><span> </span><span class="NLM_article-title">Selective FLT3 inhibition of FLT3-ITD<sup>+</sup> acute myeloid leukemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1462</span><span class="NLM_x">–</span> <span class="NLM_lpage">1470</span><span class="refDoi"> DOI: 10.1038/leu.2012.52</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1038%2Fleu.2012.52" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=1462-1470&author=A.+S.+Mooreauthor=A.+Faisalauthor=D.+G.+de+Castroauthor=V.+Bavetsiasauthor=C.+Sunauthor=B.+Atrashauthor=M.+Valentiauthor=A.+de+Haven+Brandonauthor=S.+Averyauthor=D.+Mair&title=Selective+FLT3+inhibition+of+FLT3-ITD%2B+acute+myeloid+leukemia+resulting+in+secondary+D835Y+mutation%3A+a+model+for+emerging+clinical+resistance+patterns&doi=10.1038%2Fleu.2012.52"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fleu.2012.52&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2012.52%26sid%3Dliteratum%253Aachs%26aulast%3DMoore%26aufirst%3DA.%2BS.%26aulast%3DFaisal%26aufirst%3DA.%26aulast%3Dde%2BCastro%26aufirst%3DD.%2BG.%26aulast%3DBavetsias%26aufirst%3DV.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DAtrash%26aufirst%3DB.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3Dde%2BHaven%2BBrandon%26aufirst%3DA.%26aulast%3DAvery%26aufirst%3DS.%26aulast%3DMair%26aufirst%3DD.%26atitle%3DSelective%2520FLT3%2520inhibition%2520of%2520FLT3-ITD%252B%2520acute%2520myeloid%2520leukemia%2520resulting%2520in%2520secondary%2520D835Y%2520mutation%253A%2520a%2520model%2520for%2520emerging%2520clinical%2520resistance%2520patterns%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26spage%3D1462%26epage%3D1470%26doi%3D10.1038%2Fleu.2012.52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Yamamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyoi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyawaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yagasaki, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimazaki, C.</span><span> </span><span class="NLM_article-title">Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">2434</span><span class="NLM_x">–</span> <span class="NLM_lpage">2439</span><span class="refDoi"> DOI: 10.1182/blood.V97.8.2434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1182%2Fblood.V97.8.2434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=11290608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivFOgtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2001&pages=2434-2439&author=Y.+Yamamotoauthor=H.+Kiyoiauthor=Y.+Nakanoauthor=R.+Suzukiauthor=Y.+Koderaauthor=S.+Miyawakiauthor=N.+Asouauthor=K.+Kuriyamaauthor=F.+Yagasakiauthor=C.+Shimazaki&title=Activating+mutation+of+D835+within+the+activation+loop+of+FLT3+in+human+hematologic+malignancies&doi=10.1182%2Fblood.V97.8.2434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies</span></div><div class="casAuthors">Yamamoto, Yukiya; Kiyoi, Hitoshi; Nakano, Yasuyuki; Suzuki, Ritsuro; Kodera, Yoshihisa; Miyawaki, Shuichi; Asou, Norio; Kuriyama, Kazutaka; Yagasaki, Fumiharu; Shimazaki, Chihiro; Akiyama, Hideki; Saito, Kenji; Nishimura, Miki; Motoji, Toshiko; Shinagawa, Katsuji; Takeshita, Akihiro; Saito, Hidehiko; Ueda, Ryuzo; Ohno, Ryuzo; Naoe, Tomoki</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2434-2439</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Mutations of receptor tyrosine kinases are implicated in the constitutive activation and development of human malignancy.  An internal tandem duplication (ITD) of the juxtamembrane (JM) domain-coding sequence of the FLT3 gene (FLT3/ITD) is found in 20% of patients with acute myeloid leukemia (AML) and is strongly assocd. with leukocytosis and a poor prognosis.  On the other hand, mutations of the c-KIT gene, which have been found in mast cell leukemia and AML, are clustered in 2 distinct regions, the JM domain and D816 within the activation loop.  This study was designed to analyze the mutation of D835 of FLT3, which corresponds to D816 of c-KIT, in a large series of human hematol. malignancies.  Several kinds of missense mutations were found in 30 of the 429 (7.0%) AML cases, 1 of the 29 (3.4%) myelodysplastic syndrome (MDS) cases, and 1 of the 36 (2.8%) acute lymphocytic leukemia patients.  The D835Y mutation was most frequently found (22 of the 32 D835 mutations), followed by the D835V (5), and D835H (1), D835E (1), and D835N (1) mutations.  Of note is that D835 mutations occurred independently of FLT3/ITD.  An anal. in the 201 patients newly diagnosed with AML (excluding M3) revealed that, in contrast to the FLT3/ITD mutation, D835 mutations were not significantly related to the leukocytosis, but tended to worsen disease-free survival.  All D835-mutant FLT3 were constitutively tyrosine-phosphorylated and transformed 32D cells, suggesting these mutations were constitutively active.  These results demonstrate that the FLT3 gene is the target most frequently mutated to become constitutively active in AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrydJnPT47K17Vg90H21EOLACvtfcHk0liO3P7_OpQp5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivFOgtbk%253D&md5=646e1b1a04c570f4094e7d83723d47fb</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1182%2Fblood.V97.8.2434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V97.8.2434%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DNakano%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DKodera%26aufirst%3DY.%26aulast%3DMiyawaki%26aufirst%3DS.%26aulast%3DAsou%26aufirst%3DN.%26aulast%3DKuriyama%26aufirst%3DK.%26aulast%3DYagasaki%26aufirst%3DF.%26aulast%3DShimazaki%26aufirst%3DC.%26atitle%3DActivating%2520mutation%2520of%2520D835%2520within%2520the%2520activation%2520loop%2520of%2520FLT3%2520in%2520human%2520hematologic%2520malignancies%26jtitle%3DBlood%26date%3D2001%26volume%3D97%26spage%3D2434%26epage%3D2439%26doi%3D10.1182%2Fblood.V97.8.2434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eksterowicz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribble, M. W.,  Jr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alba, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, R.</span><span> </span><span class="NLM_article-title">Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">3430</span><span class="NLM_x">–</span> <span class="NLM_lpage">3449</span><span class="refDoi"> DOI: 10.1021/jm500118j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500118j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktl2itLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3430-3449&author=Z.+Liauthor=X.+Wangauthor=J.+Eksterowiczauthor=M.+W.+Gribbleauthor=G.+Q.+Albaauthor=M.+Ayresauthor=T.+J.+Carlsonauthor=A.+Chenauthor=X.+Chenauthor=R.+Cho&title=Discovery+of+AMG+925%2C+a+FLT3+and+CDK4+Dual+Kinase+Inhibitor+with+Preferential+Affinity+for+the+Activated+State+of+FLT3&doi=10.1021%2Fjm500118j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3</span></div><div class="casAuthors">Li, Zhihong; Wang, Xianghong; Eksterowicz, John; Gribble, Michael W.; Alba, Grace Q.; Ayres, Merrill; Carlson, Timothy J.; Chen, Ada; Chen, Xiaoqi; Cho, Robert; Connors, Richard V.; DeGraffenreid, Michael; Deignan, Jeffrey T.; Duquette, Jason; Fan, Pingchen; Fisher, Benjamin; Fu, Jiasheng; Huard, Justin N.; Kaizerman, Jacob; Keegan, Kathleen S.; Li, Cong; Li, Kexue; Li, Yunxiao; Liang, Lingming; Liu, Wen; Lively, Sarah E.; Lo, Mei-Chu; Ma, Ji; McMinn, Dustin L.; Mihalic, Jeffrey T.; Modi, Kriti; Ngo, Rachel; Pattabiraman, Kanaka; Piper, Derek E.; Queva, Christophe; Ragains, Mark L.; Suchomel, Julia; Thibault, Steve; Walker, Nigel; Wang, Xiaodong; Wang, Zhulun; Wanska, Malgorzata; Wehn, Paul M.; Weidner, Margaret F.; Zhang, Alex J.; Zhao, Xiaoning; Kamb, Alexander; Wickramasinghe, Dineli; Dai, Kang; McGee, Lawrence R.; Medina, Julio C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3430-3449</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors describe the structural optimization of a lead compd. that exhibits dual inhibitory activities against FLT3 and CDK4.  A series of pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidine derivs. was synthesized, and SAR anal., using cell-based assays, led to the discovery of AMG 925 (I), a potent and orally bioavailable dual inhibitor of CDK4 and FLT3, including many FLT3 mutants reported to date.  Compd. I inhibits the proliferation of a panel of human tumor cell lines including Colo205 (Rb+) and U937 (FLT3WT) and induced cell death in MOLM13 (FLT3ITD) and even in MOLM13 (FLT3ITD, D835Y), which exhibits resistance to a no. of FLT3 inhibitors currently under clin. development.  At well-tolerated doses, compd. I leads to significant growth inhibition of MOLM13 xenografts in nude mice, and the activity correlates with inhibition of STAT5 and Rb phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcJdjH0aU8KrVg90H21EOLACvtfcHk0liO3P7_OpQp5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktl2itLg%253D&md5=4047a6ea068dbde57896da520fbdf0d3</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm500118j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500118j%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DGribble%26aufirst%3DM.%2BW.%26aulast%3DAlba%26aufirst%3DG.%2BQ.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DCarlson%26aufirst%3DT.%2BJ.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DCho%26aufirst%3DR.%26atitle%3DDiscovery%2520of%2520AMG%2520925%252C%2520a%2520FLT3%2520and%2520CDK4%2520Dual%2520Kinase%2520Inhibitor%2520with%2520Preferential%2520Affinity%2520for%2520the%2520Activated%2520State%2520of%2520FLT3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3430%26epage%3D3449%26doi%3D10.1021%2Fjm500118j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span>Discovery Studio, version <span class="NLM_edition">2.5</span>; <span class="NLM_publisher-name">Accelrys, Inc.</span>: <span class="NLM_publisher-loc">San Diego, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Discovery+Studio%2C+version+2.5%3B+Accelrys%2C+Inc.%3A+San+Diego%2C+CA%2C+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DDiscovery%2520Studio%26pub%3DAccelrys%252C%2520Inc%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span>Maestro, version <span class="NLM_edition">9.0</span>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York, NY</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Maestro%2C+version+9.0%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+NY%2C+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DMaestro%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span>Prime, version <span class="NLM_edition">2.1</span>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York, NY</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Prime%2C+version+2.1%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+NY%2C+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DPrime%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span>LigPrep, version <span class="NLM_edition">2.3</span>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York, NY</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=LigPrep%2C+version+2.3%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+NY%2C+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DLigPrep%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span>Epik, version <span class="NLM_edition">2.0</span>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York, NY</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Epik%2C+version+2.0%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+NY%2C+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DEpik%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span>Glide, version <span class="NLM_edition">5.5</span>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York, NY</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Glide%2C+version+5.5%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+NY%2C+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DGlide%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbertz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pippin, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvino, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallamo, J. P.</span><span> </span><span class="NLM_article-title">Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5149</span><span class="NLM_x">–</span> <span class="NLM_lpage">5171</span><span class="refDoi"> DOI: 10.1021/jm800475y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800475y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVWmurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5149-5171&author=A.+K.+Ghoseauthor=T.+Herbertzauthor=D.+A.+Pippinauthor=J.+M.+Salvinoauthor=J.+P.+Mallamo&title=Knowledge+based+prediction+of+ligand+binding+modes+and+rational+inhibitor+design+for+kinase+drug+discovery&doi=10.1021%2Fjm800475y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Knowledge Based Prediction of Ligand Binding Modes and Rational Inhibitor Design for Kinase Drug Discovery</span></div><div class="casAuthors">Ghose, Arup K.; Herbertz, Torsten; Pippin, Douglas A.; Salvino, Joseph M.; Mallamo, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5149-5171</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review describing the use of Protein Data Bank (PDB) entries specifically for kinase inhibitor drug discovery.  Topics discussed include: the current state of structure-aided ligand design, kinase structure queries and extn. from the PDB, alignment of protein structures, structural classification of ligands, anal. of ligands and binding modes, and ligand design strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDINDYVE15cbVg90H21EOLACvtfcHk0ljlpUCnTd47WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVWmurnM&md5=a1afc4d6c7f6fa4dd6aa9da8d78f1ee3</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm800475y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800475y%26sid%3Dliteratum%253Aachs%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DHerbertz%26aufirst%3DT.%26aulast%3DPippin%26aufirst%3DD.%2BA.%26aulast%3DSalvino%26aufirst%3DJ.%2BM.%26aulast%3DMallamo%26aufirst%3DJ.%2BP.%26atitle%3DKnowledge%2520based%2520prediction%2520of%2520ligand%2520binding%2520modes%2520and%2520rational%2520inhibitor%2520design%2520for%2520kinase%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5149%26epage%3D5171%26doi%3D10.1021%2Fjm800475y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 16 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Junwei Wang, Xiang Pan, Yi Song, Jian Liu, Fei Ma, Ping Wang, Yan Liu, Lin Zhao, Di Kang, <span class="NLM_string-name hlFld-ContribAuthor">Lihong Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Potent and Selective FLT3 Inhibitor (Z)-N-(5-((5-Fluoro-2-oxoindolin-3-ylidene)methyl)-4-methyl-1H-pyrrol-3-yl)-3-(pyrrolidin-1-yl)propanamide with Improved Drug-like Properties and Superior Efficacy in FLT3-ITD-Positive Acute Myeloid Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (8)
                                     , 4870-4890. <a href="https://doi.org/10.1021/acs.jmedchem.0c02247" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02247</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02247%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BPotent%252Band%252BSelective%252BFLT3%252BInhibitor%252B%252528Z%252529-N-%2525285-%252528%2525285-Fluoro-2-oxoindolin-3-ylidene%252529methyl%252529-4-methyl-1H-pyrrol-3-yl%252529-3-%252528pyrrolidin-1-yl%252529propanamide%252Bwith%252BImproved%252BDrug-like%252BProperties%252Band%252BSuperior%252BEfficacy%252Bin%252BFLT3-ITD-Positive%252BAcute%252BMyeloid%252BLeukemia%26aulast%3DWang%26aufirst%3DJunwei%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D28122020%26date%3D02042021%26volume%3D64%26issue%3D8%26spage%3D4870%26epage%3D4890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yue Zhong, Run-Ze Qiu, Shan-Liang Sun, Chao Zhao, Tian-Yuan Fan, Min Chen, Nian-Guang Li, <span class="NLM_string-name hlFld-ContribAuthor">Zhi-Hao Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (21)
                                     , 12403-12428. <a href="https://doi.org/10.1021/acs.jmedchem.0c00696" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00696</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00696&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00696%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BFms-like%252BTyrosine%252BKinase%252B3%252BInhibitors%25253A%252BAn%252BAttractive%252Band%252BEfficient%252BMethod%252Bfor%252Bthe%252BTreatment%252Bof%252BAcute%252BMyeloid%252BLeukemia%26aulast%3DZhong%26aufirst%3DYue%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26042020%26date%3D21072020%26date%3D13072020%26volume%3D63%26issue%3D21%26spage%3D12403%26epage%3D12428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xue Yuan, Yong Chen, Wanhua Zhang, Jun He, Lei Lei, Minghai Tang, Jiang Liu, Muzhou Li, Caixia Dou, Tao Yang, Linyu Yang, Shengyong Yang, Yuquan Wei, Aihua Peng, Ting Niu, Mingli Xiang, Haoyu Ye, <span class="NLM_string-name hlFld-ContribAuthor">Lijuan Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Pyrrolo[2,3-d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (8)
                                     , 4158-4173. <a href="https://doi.org/10.1021/acs.jmedchem.9b00223" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00223</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00223%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BPyrrolo%25255B2%25252C3-d%25255Dpyrimidine-Based%252BDerivatives%252Bas%252BPotent%252Band%252BOrally%252BEffective%252BFms-like%252BTyrosine%252BReceptor%252BKinase%252B3%252B%252528FLT3%252529%252BInhibitors%252Bfor%252BTreating%252BAcute%252BMyelogenous%252BLeukemia%26aulast%3DYuan%26aufirst%3DXue%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D02022019%26date%3D15042019%26date%3D02042019%26volume%3D62%26issue%3D8%26spage%3D4158%26epage%3D4173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaofei Liang, Beilei Wang, Cheng Chen, Aoli Wang, Chen Hu, Fengming Zou, Kailin Yu, Qingwang Liu, Feng Li, Zhenquan Hu, Tingting Lu, Junjie Wang, Li Wang, Ellen L. Weisberg, Lili Li, Ruixiang Xia, Wenchao Wang, Tao Ren, Jian Ge, Jing Liu, <span class="NLM_string-name hlFld-ContribAuthor">Qingsong Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (2)
                                     , 875-892. <a href="https://doi.org/10.1021/acs.jmedchem.8b01594" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01594</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01594%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BN-%2525284-%2525286-Acetamidopyrimidin-4-yloxy%252529phenyl%252529-2-%2525282-%252528trifluoromethyl%252529phenyl%252529acetamide%252B%252528CHMFL-FLT3-335%252529%252Bas%252Ba%252BPotent%252BFMS-like%252BTyrosine%252BKinase%252B3%252BInternal%252BTandem%252BDuplication%252B%252528FLT3-ITD%252529%252BMutant%252BSelective%252BInhibitor%252Bfor%252BAcute%252BMyeloid%252BLeukemia%26aulast%3DLiang%26aufirst%3DXiaofei%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D13102018%26date%3D08012019%26date%3D19122018%26volume%3D62%26issue%3D2%26spage%3D875%26epage%3D892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michele T.  Buetti-Weekly</span>, <span class="hlFld-ContribAuthor ">Pamela  Clifford</span>, <span class="hlFld-ContribAuthor ">Brian P.  Jones</span>, and <span class="hlFld-ContribAuthor ">Jade D.  Nelson</span>  . </span><span class="cited-content_cbyCitation_article-title">Development of a Safe and Scalable Process for the Preparation of Allyl Glyoxalate. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2018,</strong> <em>22 </em>
                                    (1)
                                     , 82-90. <a href="https://doi.org/10.1021/acs.oprd.7b00345" title="DOI URL">https://doi.org/10.1021/acs.oprd.7b00345</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.7b00345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.7b00345%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DDevelopment%252Bof%252Ba%252BSafe%252Band%252BScalable%252BProcess%252Bfor%252Bthe%252BPreparation%252Bof%252BAllyl%252BGlyoxalate%26aulast%3DBuetti-Weekly%26aufirst%3DMichele%2BT.%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D27102017%26date%3D15122017%26date%3D19012018%26date%3D06122017%26volume%3D22%26issue%3D1%26spage%3D82%26epage%3D90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaochu  Ma</span>, <span class="hlFld-ContribAuthor ">Jie  Zhou</span>, <span class="hlFld-ContribAuthor ">Changhao  Wang</span>, <span class="hlFld-ContribAuthor ">Brandon  Carter-Cooper</span>, <span class="hlFld-ContribAuthor ">Fan  Yang</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Larocque</span>, <span class="hlFld-ContribAuthor ">Jonathan  Fine</span>, <span class="hlFld-ContribAuthor ">Genichiro  Tsuji</span>, <span class="hlFld-ContribAuthor ">Gaurav  Chopra</span>, <span class="hlFld-ContribAuthor ">Rena G.  Lapidus</span>, and <span class="hlFld-ContribAuthor ">Herman O.  Sintim</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification of New FLT3 Inhibitors That Potently Inhibit AML Cell Lines via an Azo Click-It/Staple-It Approach. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>8 </em>
                                    (5)
                                     , 492-497. <a href="https://doi.org/10.1021/acsmedchemlett.6b00468" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.6b00468</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.6b00468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.6b00468%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DIdentification%252Bof%252BNew%252BFLT3%252BInhibitors%252BThat%252BPotently%252BInhibit%252BAML%252BCell%252BLines%252Bvia%252Ban%252BAzo%252BClick-It%25252FStaple-It%252BApproach%26aulast%3DMa%26aufirst%3DXiaochu%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D18112016%26date%3D14042017%26date%3D21042017%26date%3D11052017%26date%3D14042017%26volume%3D8%26issue%3D5%26spage%3D492%26epage%3D497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sharon  Rossiter</span>, <span class="hlFld-ContribAuthor ">Mehrnoosh  Ostovar</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclic 6-6 Systems: Pteridines. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-818655-8.00040-8" title="DOI URL">https://doi.org/10.1016/B978-0-12-818655-8.00040-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-818655-8.00040-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-818655-8.00040-8%26sid%3Dliteratum%253Aachs%26atitle%3DBicyclic%252B6-6%252BSystems%25253A%252BPteridines%26aulast%3DRossiter%26aufirst%3DSharon%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2021%26volume%3Dvol.%252010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yingxiu  Li</span>, <span class="hlFld-ContribAuthor ">Peng  Wang</span>, <span class="hlFld-ContribAuthor ">Cong  Chen</span>, <span class="hlFld-ContribAuthor ">Tianyu  Ye</span>, <span class="hlFld-ContribAuthor ">Yufei  Han</span>, <span class="hlFld-ContribAuthor ">Yunlei  Hou</span>, <span class="hlFld-ContribAuthor ">Yajing  Liu</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>, <span class="hlFld-ContribAuthor ">Mingze  Qin</span>, <span class="hlFld-ContribAuthor ">Yanfang  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and rational design of 2-aminopyrimidine-based derivatives targeting Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>104 </em>, 104361. <a href="https://doi.org/10.1016/j.bioorg.2020.104361" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104361</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104361%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDiscovery%252Band%252Brational%252Bdesign%252Bof%252B2-aminopyrimidine-based%252Bderivatives%252Btargeting%252BJanus%252Bkinase%252B2%252B%252528JAK2%252529%252Band%252BFMS-like%252Btyrosine%252Bkinase%252B3%252B%252528FLT3%252529%26aulast%3DLi%26aufirst%3DYingxiu%26date%3D2020%26volume%3D104%26spage%3D104361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tingyi  Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Review of Evaluation Methods of Tumor Pharmacodynamics. </span><span class="cited-content_cbyCitation_journal-name">IOP Conference Series: Earth and Environmental Science</span><span> <strong>2020,</strong> <em>512 </em>, 012104. <a href="https://doi.org/10.1088/1755-1315/512/1/012104" title="DOI URL">https://doi.org/10.1088/1755-1315/512/1/012104</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1088/1755-1315/512/1/012104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1088%2F1755-1315%2F512%2F1%2F012104%26sid%3Dliteratum%253Aachs%26jtitle%3DIOP%2520Conference%2520Series%253A%2520Earth%2520and%2520Environmental%2520Science%26atitle%3DReview%252Bof%252BEvaluation%252BMethods%252Bof%252BTumor%252BPharmacodynamics%26aulast%3DShi%26aufirst%3DTingyi%26date%3D2020%26date%3D2020%26volume%3D512%26spage%3D012104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lexian  Tong</span>, <span class="hlFld-ContribAuthor ">Xuemei  Li</span>, <span class="hlFld-ContribAuthor ">Yongzhou  Hu</span>, <span class="hlFld-ContribAuthor ">Tao  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in FLT3 inhibitors for acute myeloid leukemia. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2020,</strong> <em>12 </em>
                                    (10)
                                     , 961-981. <a href="https://doi.org/10.4155/fmc-2019-0365" title="DOI URL">https://doi.org/10.4155/fmc-2019-0365</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2019-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2019-0365%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bin%252BFLT3%252Binhibitors%252Bfor%252Bacute%252Bmyeloid%252Bleukemia%26aulast%3DTong%26aufirst%3DLexian%26date%3D2020%26volume%3D12%26issue%3D10%26spage%3D961%26epage%3D981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cheolhee  Kim</span>, <span class="hlFld-ContribAuthor ">Eunae  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Rational Drug Design Approach of Receptor Tyrosine Kinase Type III Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2020,</strong> <em>26 </em>
                                    (42)
                                     , 7623-7640. <a href="https://doi.org/10.2174/0929867325666180622143548" title="DOI URL">https://doi.org/10.2174/0929867325666180622143548</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/0929867325666180622143548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F0929867325666180622143548%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DRational%252BDrug%252BDesign%252BApproach%252Bof%252BReceptor%252BTyrosine%252BKinase%252BType%252BIII%252BInhibitors%26aulast%3DKim%26aufirst%3DCheolhee%26date%3D2020%26volume%3D26%26issue%3D42%26spage%3D7623%26epage%3D7640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daseul  Im</span>, <span class="hlFld-ContribAuthor ">Hyungwoo  Moon</span>, <span class="hlFld-ContribAuthor ">Jinwoong  Kim</span>, <span class="hlFld-ContribAuthor ">Youri  Oh</span>, <span class="hlFld-ContribAuthor ">Miyoung  Jang</span>, <span class="hlFld-ContribAuthor ">Jung-Mi  Hah</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 5-methyl-
              N
              -(2-arylquinazolin-7-yl)isoxazole-4-carboxamide analogues as highly selective FLT3 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2020,</strong> <em>35 </em>
                                    (1)
                                     , 1110-1115. <a href="https://doi.org/10.1080/14756366.2020.1758689" title="DOI URL">https://doi.org/10.1080/14756366.2020.1758689</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2020.1758689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2020.1758689%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B5-methyl-%252BN%252B-%2525282-arylquinazolin-7-yl%252529isoxazole-4-carboxamide%252Banalogues%252Bas%252Bhighly%252Bselective%252BFLT3%252Binhibitors%26aulast%3DIm%26aufirst%3DDaseul%26date%3D2020%26date%3D2020%26volume%3D35%26issue%3D1%26spage%3D1110%26epage%3D1115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Violeta  Carmona‐Martínez</span>, <span class="hlFld-ContribAuthor ">Antonio J.  Ruiz‐Alcaraz</span>, <span class="hlFld-ContribAuthor ">María  Vera</span>, <span class="hlFld-ContribAuthor ">Antonio  Guirado</span>, <span class="hlFld-ContribAuthor ">María  Martínez‐Esparza</span>, <span class="hlFld-ContribAuthor ">Pilar  García‐Peñarrubia</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic potential of pteridine derivatives: A comprehensive review. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2019,</strong> <em>39 </em>
                                    (2)
                                     , 461-516. <a href="https://doi.org/10.1002/med.21529" title="DOI URL">https://doi.org/10.1002/med.21529</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21529%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DTherapeutic%252Bpotential%252Bof%252Bpteridine%252Bderivatives%25253A%252BA%252Bcomprehensive%252Breview%26aulast%3DCarmona%25E2%2580%2590Mart%25C3%25ADnez%26aufirst%3DVioleta%26date%3D2019%26date%3D2018%26volume%3D39%26issue%3D2%26spage%3D461%26epage%3D516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Antonio J.  Ruiz-Alcaraz</span>, <span class="hlFld-ContribAuthor ">Violeta  Carmona-Martínez</span>, <span class="hlFld-ContribAuthor ">Antonio  Guirado</span>, <span class="hlFld-ContribAuthor ">Jesús  Gálvez</span>, <span class="hlFld-ContribAuthor ">María  Martínez-Esparza</span>, <span class="hlFld-ContribAuthor ">Pilar  García-Peñarrubia</span>. </span><span class="cited-content_cbyCitation_article-title">Anti-leukemia activity of 4-amino-2-aryl-6,9-dichlorobenzo[g]pteridines. </span><span class="cited-content_cbyCitation_journal-name">Naunyn-Schmiedeberg's Archives of Pharmacology</span><span> <strong>2019,</strong> <em>392 </em>
                                    (2)
                                     , 219-227. <a href="https://doi.org/10.1007/s00210-018-1587-0" title="DOI URL">https://doi.org/10.1007/s00210-018-1587-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00210-018-1587-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00210-018-1587-0%26sid%3Dliteratum%253Aachs%26jtitle%3DNaunyn-Schmiedeberg%2527s%2520Archives%2520of%2520Pharmacology%26atitle%3DAnti-leukemia%252Bactivity%252Bof%252B4-amino-2-aryl-6%25252C9-dichlorobenzo%25255Bg%25255Dpteridines%26aulast%3DRuiz-Alcaraz%26aufirst%3DAntonio%2BJ.%26date%3D2019%26date%3D2018%26volume%3D392%26issue%3D2%26spage%3D219%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jaideep B.  Bharate</span>, <span class="hlFld-ContribAuthor ">Nicholas  McConnell</span>, <span class="hlFld-ContribAuthor ">Gunaganti  Naresh</span>, <span class="hlFld-ContribAuthor ">Lingtian  Zhang</span>, <span class="hlFld-ContribAuthor ">Naga Rajiv  Lakkaniga</span>, <span class="hlFld-ContribAuthor ">Lucky  Ding</span>, <span class="hlFld-ContribAuthor ">Neil P.  Shah</span>, <span class="hlFld-ContribAuthor ">Brendan  Frett</span>, <span class="hlFld-ContribAuthor ">Hong-yu  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KIT. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2018,</strong> <em>8 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-018-21839-3" title="DOI URL">https://doi.org/10.1038/s41598-018-21839-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-018-21839-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-018-21839-3%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DRational%252BDesign%25252C%252BSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BPyrimidine-4%25252C6-diamine%252Bderivatives%252Bas%252BType-II%252Binhibitors%252Bof%252BFLT3%252BSelective%252BAgainst%252Bc-KIT%26aulast%3DBharate%26aufirst%3DJaideep%2BB.%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hong-Yi  Zhao</span>, <span class="hlFld-ContribAuthor ">Hui-Yan  Wang</span>, <span class="hlFld-ContribAuthor ">Shuai  Mao</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">Hao  Zhang</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2-(pyridin-2-yl)aniline as a directing group for the sp
              2
              C–H bond amination mediated by cupric acetate. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2017,</strong> <em>15 </em>
                                    (31)
                                     , 6622-6631. <a href="https://doi.org/10.1039/C7OB01353A" title="DOI URL">https://doi.org/10.1039/C7OB01353A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7OB01353A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7OB01353A%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2-%252528pyridin-2-yl%252529aniline%252Bas%252Ba%252Bdirecting%252Bgroup%252Bfor%252Bthe%252Bsp%252B2%252BC%2525E2%252580%252593H%252Bbond%252Bamination%252Bmediated%252Bby%252Bcupric%252Bacetate%26aulast%3DZhao%26aufirst%3DHong-Yi%26date%3D2017%26date%3D2017%26volume%3D15%26issue%3D31%26spage%3D6622%26epage%3D6631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/medium/jm-2016-00374p_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/large/jm-2016-00374p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00374&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/medium/jm-2016-00374p_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/large/jm-2016-00374p_0009.jpeg" id="rightTab-GRAPHIC-d639e364-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Pteridin-7(8<i>H</i>)-one Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/large/jm-2016-00374p_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00374&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagent and conditions: (a) ArNH<sub>2</sub>, DIPEA, 1,4-dioxane, rt; (b) ArNH<sub>2</sub>, DIPEA, 1,4-dioxane, rt; (c) Pd/C, H<sub>2</sub>, EtOH; (d) EtOOC–CHO, HOAc, EtOH, reflux; (e) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt; (f) acyl chloride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt or CH<sub>3</sub>SO<sub>2</sub>Cl, 1-methyl-2-pyrrolidinone, CH<sub>3</sub>CN, 0 °C to rt.</p></p></figure><figure data-id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/medium/jm-2016-00374p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/large/jm-2016-00374p_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Compound <b>1</b> at the active site of the FLT3 homology model (template PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG">1PKG</a>) with the P-loop hidden for clarity. The green-colored compound <b>1</b> is presented as a ball and stick model. The contacting residues in the active site are depicted as stick, and the backbone of hinge region is shown as stick. The EGFR crystal structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>) is aligned to the homology model of FLT3, and residues in EGFR are highlighted in pink stick presentation. (B) SAR overview. (C) FLT3 inhibition IC<sub>50</sub> curves of compounds <b>1</b> and <b>31</b>. (D) Compound <b>31</b> docked into the active site of the FLT3 homology model with the P-loop hidden for clarity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/large/jm-2016-00374p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00374&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/medium/jm-2016-00374p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/large/jm-2016-00374p_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Western blot analysis. (A) Compound <b>31</b> inhibits FLT3 autophosphorylation and the phosphorylation of downstream signaling effectors STAT5, ERK, and AKT in 2 h. (B) Immunoblots quantification of p-FLT3, p-STAT5, p-AKT, and p-ERK, respectively. All bands were quantified and normalized by GAPDH. The data are expressed as the mean ± SEM from at least three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/large/jm-2016-00374p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00374&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/medium/jm-2016-00374p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/large/jm-2016-00374p_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. After a 48 h treatment, compound <b>31</b> induces dose-dependent cell cycle G<sub>0</sub>/G<sub>1</sub> phase arrest (A) and apoptosis (B) in MV4–11 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/large/jm-2016-00374p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00374&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/medium/jm-2016-00374p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/large/jm-2016-00374p_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Profiling of compound <b>31</b> at a 1 μM concentration versus a panel of 468 kinase targets. The blue circles label the FLT3 and its related mutants. The red circles label the off-targets. FLT3, five main FLT3-related mutants, and seven main off-targets (inhibition with percent control values of ≤1%) are labeled in bold font style.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/large/jm-2016-00374p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00374&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/medium/jm-2016-00374p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/large/jm-2016-00374p_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. In vivo effects of compound <b>31</b> against MV4–11 tumor xenografts via oral administration. (A) Compound <b>31</b> and AC220 were administered orally at concentrations ranging from 10 to 50 mg kg<sup>–1</sup> d<sup>–1</sup>. <i>N</i> = 5 for each group. Data are shown as the mean ± SEM. (B) Body weight change in mouse xenograft model for each daily dosing group. (C) After 1 and 3 days of compound <b>31</b> once daily oral treatment, Ki67 and TUNEL were detected in MV4–11 tumors (three per group).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00374/20160708/images/large/jm-2016-00374p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00374&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i53">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68438" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68438" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 42 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Stirewalt, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radich, J. P.</span><span> </span><span class="NLM_article-title">The role of FLT3 in haematopoietic malignancies</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">650</span><span class="NLM_x">–</span> <span class="NLM_lpage">665</span><span class="refDoi"> DOI: 10.1038/nrc1169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1038%2Fnrc1169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=12951584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvVWlu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=650-665&author=D.+L.+Stirewaltauthor=J.+P.+Radich&title=The+role+of+FLT3+in+haematopoietic+malignancies&doi=10.1038%2Fnrc1169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The role of FLT3 in hematopoietic malignancies</span></div><div class="casAuthors">Stirewalt, Derek L.; Radich, Jerald P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">650-665</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Normal haematopoietic cells use complex systems to control proliferation, differentiation and cell death.  The control of proliferation is, in part, accomplished through the ligand-induced stimulation of receptor tyrosine kinases, which signal to downstream effectors through the RAS pathway.  Recently, mutations in the FMS-like tyrosine kinase 3 (FLT3) gene, which encodes a receptor tyrosine kinase, have been found to be the most common genetic lesion in acute myeloid leukemia (AML), occurring in ∼25% of cases.  Exploring the mechanism by which these FLT3 mutations cause uncontrolled proliferation might lead to a better understanding of how cells become cancerous and provide insights for the development of new drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRONPQkpemorVg90H21EOLACvtfcHk0lisemPdKy7YFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvVWlu7c%253D&md5=97183b7a6087fafe20bfc695f403825b</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc1169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1169%26sid%3Dliteratum%253Aachs%26aulast%3DStirewalt%26aufirst%3DD.%2BL.%26aulast%3DRadich%26aufirst%3DJ.%2BP.%26atitle%3DThe%2520role%2520of%2520FLT3%2520in%2520haematopoietic%2520malignancies%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26spage%3D650%26epage%3D665%26doi%3D10.1038%2Fnrc1169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Drexler, H.</span><span> </span><span class="NLM_article-title">Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">588</span><span class="NLM_x">–</span> <span class="NLM_lpage">599</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=8618433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A280%3ADyaK283gtV2qsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1996&pages=588-599&author=H.+Drexler&title=Expression+of+FLT3+receptor+and+response+to+FLT3+ligand+by+leukemic+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells</span></div><div class="casAuthors">Drexler H G</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">588-99</span>
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    </div><div class="casAbstract">The novel hematopoietic growth factor FLT3 ligand (FL) is the cognate ligand for the FLT3, tyrosine kinase receptor (R), also referred to as FLK-2 and STK-1.  The FLT3R belongs to a family of receptor tyrosine kinases involved in hematopoiesis that also includes KIT, the receptor for SCF (stem cell factor), and FMS. the receptor for M-CSF (macrophage colony- stimulating factor).  Restricted FLT3R expression was seen on human and murine hematopoietic progenitor cells.  In functional assays recombinant FL stimulated the proliferation and colony formation of human hematopoietic progenitor cells, i.e.  CD34+ cord and peripheral blood, bone marrow and fetal liver cells.  Synergy was reported for co-stimulation with G-CSF (granulocyte-CSF).  GM-CSF (granulocyte-macrophage CSF), M-CSF, interleukin-3 (IL-3), PIXY-321 (an IL-3/GM-CSF fusion protein) and SCF.  In the mouse, FL potently enhanced growth of various types of progenitor/precursor cells in synergy with G-CSF, GM-CSF, M-CSF, IL-3, IL-6, IL-7, IL-11, IL-12 and SCF.  The well-documented involvement of this ligand-receptor pair in physiological hematopoiesis brought forth the question whether FLT3R and FL might also have a role in the pathobiology of leukemia.  At the mRNA level FLT3R was expressed by most (80-100%) cases of AML (acute myeloid leukemia) throughout the different morphological subtypes (MO-M7), of ALL(acute lymphoblastic leukemia) of the immunological subtypes T-ALL and BCP-ALL (B cell precursor ALL including pre-pre B-ALL, cALL and pre B-ALL), of AMLL (acute mixed-lineage leukemia), and of CML (chronic myeloid leukemia) in lymphoid or mixed blast crisis.  Analysis of cell surface expression of FLT3R by flow cytometry confirmed these observations for AML (66% positivity when the data from all studies are combined), BCP-ALL (64%) and CML lymphoid blast crisis (86%) whereas less than 30% of T-ALL were FLT3R+.  The myeloid, monocytic and pre B cell type categories also contained the highest proportions of FLT3R+ leukemia cell lines .  In contrast to the selective expression of the receptor, FL expression was detected in 90-100% of the various cell types of leukemia cell lines from all hematopoietic cell lineages.  The potential of FL to induce proliferation of leukemia cells in vitro was also examined in primary and continuously cultured leukemia cells.  The data on FL-stimulated leukemia cell growth underline the extensive heterogeneity of primary AML and ALL samples in terms of cytokine-inducible DNA synthesis that has been seen with other effective cytokines.  While the majority of T-ALL (0-33% of the cases responded proliferatively; mean 11%) and BCP-ALL (0-30%; mean 20%) failed to proliferate in the presence of FL despite strong expression of surface FLT3R, FL caused a proliferative response in a significantly higher percentage of AML cases (22-90%; mean 53%).  In the panel of leukemia cell lines examined only myeloid and monocytic growth factor- dependent cell lines increased their proliferation upon incubation with FL, whereas all growth factor-independent cell lines were refractory to stimulation.  Combinations of FL with G-CSF, GM-CSF, M-CSF, IL-3, PIXY- 321 or SCF and FL with IL-3 or IL-7 had synergistic or additive mitogenic effects on primary AML and ALL cells, respectively.  The potent stimulation of the myelomonocytic cell lines was further augmented by addition of bFGF (basic fibroblast growth factor), GM-CSF, IL-3 or SCF.  The inhibitory effects of TGF-beta 1 (transforming growth factor-beta 1) on FL- supported proliferation were abrogated by bFGF.  Taken together, these results demonstrate the expression of functional FLT3R capable of mediating FL- dependent mitogenic signaling in a subset of AML and ALL cases further underline the heterogeneity of AML and ALL samples in their proliferative response to cytokine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT_MDUZMlgnZlm8bhe6roZYfW6udTcc2ea3EhUcOIASx7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK283gtV2qsA%253D%253D&md5=d9d427a65fa9b8b1b279c442d353f18f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDrexler%26aufirst%3DH.%26atitle%3DExpression%2520of%2520FLT3%2520receptor%2520and%2520response%2520to%2520FLT3%2520ligand%2520by%2520leukemic%2520cells%26jtitle%3DLeukemia%26date%3D1996%26volume%3D10%26spage%3D588%26epage%3D599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Takahashi, S.</span><span> </span><span class="NLM_article-title">Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications</span> <span class="citation_source-journal">J. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span><span class="refDoi"> DOI: 10.1186/1756-8722-4-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1186%2F1756-8722-4-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=21211043" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=1-10&author=S.+Takahashi&title=Downstream+molecular+pathways+of+FLT3+in+the+pathogenesis+of+acute+myeloid+leukemia%3A+biology+and+therapeutic+implications&doi=10.1186%2F1756-8722-4-13"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1186%2F1756-8722-4-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-8722-4-13%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DS.%26atitle%3DDownstream%2520molecular%2520pathways%2520of%2520FLT3%2520in%2520the%2520pathogenesis%2520of%2520acute%2520myeloid%2520leukemia%253A%2520biology%2520and%2520therapeutic%2520implications%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2011%26volume%3D4%26spage%3D1%26epage%3D10%26doi%3D10.1186%2F1756-8722-4-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Network, C. G. A. R.</span><span> </span><span class="NLM_article-title">Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">368</span><span class="NLM_x">, </span> <span class="NLM_fpage">2059</span><span class="refDoi"> DOI: 10.1056/NEJMoa1301689</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1056%2FNEJMoa1301689" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=23634996" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2013&pages=2059&author=C.+G.+A.+R.+Network&title=Genomic+and+epigenomic+landscapes+of+adult+de+novo+acute+myeloid+leukemia&doi=10.1056%2FNEJMoa1301689"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1301689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1301689%26sid%3Dliteratum%253Aachs%26aulast%3DNetwork%26aufirst%3DC.%2BG.%2BA.%2BR.%26atitle%3DGenomic%2520and%2520epigenomic%2520landscapes%2520of%2520adult%2520de%2520novo%2520acute%2520myeloid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D368%26spage%3D2059%26doi%3D10.1056%2FNEJMoa1301689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Quentmeier, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinhardt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaborski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drexler, H.</span><span> </span><span class="NLM_article-title">FLT3 mutations in acute myeloid leukemia cell lines</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">120</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span><span class="refDoi"> DOI: 10.1038/sj.leu.2402740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1038%2Fsj.leu.2402740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=12529668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjsFymtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2003&pages=120-124&author=H.+Quentmeierauthor=J.+Reinhardtauthor=M.+Zaborskiauthor=H.+Drexler&title=FLT3+mutations+in+acute+myeloid+leukemia+cell+lines&doi=10.1038%2Fsj.leu.2402740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 mutations in acute myeloid leukemia cell lines</span></div><div class="casAuthors">Quentmeier, H.; Reinhardt, J.; Zaborski, M.; Drexler, H. G.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">120-124</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Internal tandem duplications (ITD) and D835 point mutations of the receptor tyrosine kinase (RTK) FLT3 are found in a high proportion of cases with acute myeloid leukemia (AML).  These genetic aberrations may lead to the constitutive activation of the receptor, thus providing the mol. basis for a persisting growth stimulus.  We have screened 69 AML-derived cell lines for FLT3 mutations.  Four of these cell lines showed ITD of the FLT3 gene, none carried a D835 point mutation.  Two cell lines (MUTZ-11 and MV4-11) expressed exclusively the mutated allele, the other two cell lines (MOLM-13 and PL-21) displayed a mutated and the wild-type version of the gene.  Although mutationally activated FLT3 is supposed to substitute for the stimulatory signal of a growth factor, one of these cell lines (MUTZ-11) was strictly cytokine-dependent.  FLT3 transcripts were found in all four cell lines, but the constitutively phosphorylated receptor protein was clearly detectable only in cell line MV4-11, possibly explaining why MUTZ-11 cells were growth-factor dependent.  Thus, not all FLT3 ITD-pos. cells express high levels of the active receptor protein, a finding that might be of relevance for a possible future application of a kinase inhibitor as therapeutic agent.  It had been described that STAT-5 phosphorylation was part of the FLT3 signalling chain and that STAT-5 mols. were constitutively phosphorylated in FLT3 ITD-pos. cells.  Although we obsd. the constitutive phosphorylation of STAT-5 mols. in FLT3-mutant cells, FLT3 ligand (FL) did not induce STAT-5 phosphorylation in FLT3 wild-type cells.  These results suggest that the signalling mechanisms of the mutated FL receptor differ at least to some extent from those conferred by wild-type FLT3.  In conclusion, (1) not all cells with FLT3 ITD express significant amts. of the mutated receptor protein; (2) signals downstream from wild-type and mutant FLT3 receptors are not 100% identical; and (3) MV4-11 represents a model cell line for FLT3 ITD signalling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZpWGN8HPKnbVg90H21EOLACvtfcHk0ljLiZuuHWt3rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjsFymtg%253D%253D&md5=72b3ca3386a738407ab9ce9dc3e71ad1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2402740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2402740%26sid%3Dliteratum%253Aachs%26aulast%3DQuentmeier%26aufirst%3DH.%26aulast%3DReinhardt%26aufirst%3DJ.%26aulast%3DZaborski%26aufirst%3DM.%26aulast%3DDrexler%26aufirst%3DH.%26atitle%3DFLT3%2520mutations%2520in%2520acute%2520myeloid%2520leukemia%2520cell%2520lines%26jtitle%3DLeukemia%26date%3D2003%26volume%3D17%26spage%3D120%26epage%3D124%26doi%3D10.1038%2Fsj.leu.2402740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Leung, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Man, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwong, Y.</span><span> </span><span class="NLM_article-title">FLT3 inhibition: a moving and evolving target in acute myeloid leukemia</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">260</span><span class="NLM_x">–</span> <span class="NLM_lpage">268</span><span class="refDoi"> DOI: 10.1038/leu.2012.195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1038%2Fleu.2012.195" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=260-268&author=A.+Leungauthor=C.+Manauthor=Y.+Kwong&title=FLT3+inhibition%3A+a+moving+and+evolving+target+in+acute+myeloid+leukemia&doi=10.1038%2Fleu.2012.195"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fleu.2012.195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2012.195%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DA.%26aulast%3DMan%26aufirst%3DC.%26aulast%3DKwong%26aufirst%3DY.%26atitle%3DFLT3%2520inhibition%253A%2520a%2520moving%2520and%2520evolving%2520target%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2013%26volume%3D27%26spage%3D260%26epage%3D268%26doi%3D10.1038%2Fleu.2012.195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Choudhary, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwäble, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandts, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tickenbrock, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sargin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdel, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller-Tidow, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serve, H.</span><span> </span><span class="NLM_article-title">AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">265</span><span class="NLM_x">–</span> <span class="NLM_lpage">273</span><span class="refDoi"> DOI: 10.1182/blood-2004-07-2942</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1182%2Fblood-2004-07-2942" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=15769897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlvVWjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=265-273&author=C.+Choudharyauthor=J.+Schw%C3%A4bleauthor=C.+Brandtsauthor=L.+Tickenbrockauthor=B.+Sarginauthor=T.+Kindlerauthor=T.+Fischerauthor=W.+E.+Berdelauthor=C.+M%C3%BCller-Tidowauthor=H.+Serve&title=AML-associated+Flt3+kinase+domain+mutations+show+signal+transduction+differences+compared+with+Flt3+ITD+mutations&doi=10.1182%2Fblood-2004-07-2942"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations</span></div><div class="casAuthors">Choudhary, Chunaram; Schwaeble, Joachim; Brandts, Christian; Tickenbrock, Lara; Sargin, Buelent; Kindler, Thomas; Fischer, Thomas; Berdel, Wolfgang E.; Mueller-Tidow, Carsten; Serve, Hubert</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">265-273</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Activating mutations of Flt3 are found in approx. 1/3 of patients with acute myeloid leukemia (AML) and are an attractive drug target.  Two classes of Flt3 mutations occur: internal tandem duplications (ITDs) in the juxtamembrane and point mutations in the tyrosine kinase domain (TKD).  We and others have shown that Flt3-ITD induced aberrant signaling including strong activation of signal transducer and activator of transcription 5 (STAT5) and repression of CCAAT/estradiol-binding protein α (c/EBPα) and Pu.1.  Here, we compared the signaling properties of Flt3-ITD vs. Flt3-TKD in myeloid progenitor cells.  We demonstrate that Flt3-TKD mutations induced autonomous growth of 32D cells in suspension cultures.  However, in contrast to Flt3-ITD and similar to wild-type Flt3 (Flt3-WT), Flt3-TKD cannot support colony formation in semisolid media.  Also, in contrast to Flt3-ITD, neither Flt3-WT nor Flt3-TKD induced activation or induction of STAT5 target genes.  Flt3-TKD also failed to repress c/EBPα and Pu.1.  No significant differences were obsd. in receptor autophosphorylation and the phosphorylation of Erk-1 and -2, Akt, and Shc.  Importantly, TKD but not ITD mutations were a log power more sensitive toward the tyrosine kinase inhibitor protein kinase C 412 (PKC412) than Flt3-WT.  In conclusion, Flt3-ITD and Flt3-TKD mutations display differences in their signaling properties that could have important implications for their transforming capacity and for the design of mutation-specific therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK50hyr7RAoLVg90H21EOLACvtfcHk0ljaehaLtAiHAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlvVWjtrw%253D&md5=a70850e3d6fe00e8316cc8d79c2d3016</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1182%2Fblood-2004-07-2942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2004-07-2942%26sid%3Dliteratum%253Aachs%26aulast%3DChoudhary%26aufirst%3DC.%26aulast%3DSchw%25C3%25A4ble%26aufirst%3DJ.%26aulast%3DBrandts%26aufirst%3DC.%26aulast%3DTickenbrock%26aufirst%3DL.%26aulast%3DSargin%26aufirst%3DB.%26aulast%3DKindler%26aufirst%3DT.%26aulast%3DFischer%26aufirst%3DT.%26aulast%3DBerdel%26aufirst%3DW.%2BE.%26aulast%3DM%25C3%25BCller-Tidow%26aufirst%3DC.%26aulast%3DServe%26aufirst%3DH.%26atitle%3DAML-associated%2520Flt3%2520kinase%2520domain%2520mutations%2520show%2520signal%2520transduction%2520differences%2520compared%2520with%2520Flt3%2520ITD%2520mutations%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D265%26epage%3D273%26doi%3D10.1182%2Fblood-2004-07-2942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Tse, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukherjee, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span> </span><span class="NLM_article-title">Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1766</span><span class="NLM_x">–</span> <span class="NLM_lpage">1776</span><span class="refDoi"> DOI: 10.1038/sj.leu.2401905</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1038%2Fsj.leu.2401905" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2000&pages=1766-1776&author=K.+F.+Tseauthor=G.+Mukherjeeauthor=D.+Small&title=Constitutive+activation+of+FLT3+stimulates+multiple+intracellular+signal+transducers+and+results+in+transformation&doi=10.1038%2Fsj.leu.2401905"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2401905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2401905%26sid%3Dliteratum%253Aachs%26aulast%3DTse%26aufirst%3DK.%2BF.%26aulast%3DMukherjee%26aufirst%3DG.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DConstitutive%2520activation%2520of%2520FLT3%2520stimulates%2520multiple%2520intracellular%2520signal%2520transducers%2520and%2520results%2520in%2520transformation%26jtitle%3DLeukemia%26date%3D2000%26volume%3D14%26spage%3D1766%26epage%3D1776%26doi%3D10.1038%2Fsj.leu.2401905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Hayakawa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Towatari, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyoi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanimoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoe, T.</span><span> </span><span class="NLM_article-title">Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">624</span><span class="NLM_x">–</span> <span class="NLM_lpage">631</span><span class="refDoi"> DOI: 10.1038/sj.onc.1203354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1038%2Fsj.onc.1203354" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=624-631&author=F.+Hayakawaauthor=M.+Towatariauthor=H.+Kiyoiauthor=M.+Tanimotoauthor=T.+Kitamuraauthor=H.+Saitoauthor=T.+Naoe&title=Tandem-duplicated+Flt3+constitutively+activates+STAT5+and+MAP+kinase+and+introduces+autonomous+cell+growth+in+IL-3-dependent+cell+lines&doi=10.1038%2Fsj.onc.1203354"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1203354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1203354%26sid%3Dliteratum%253Aachs%26aulast%3DHayakawa%26aufirst%3DF.%26aulast%3DTowatari%26aufirst%3DM.%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DTanimoto%26aufirst%3DM.%26aulast%3DKitamura%26aufirst%3DT.%26aulast%3DSaito%26aufirst%3DH.%26aulast%3DNaoe%26aufirst%3DT.%26atitle%3DTandem-duplicated%2520Flt3%2520constitutively%2520activates%2520STAT5%2520and%2520MAP%2520kinase%2520and%2520introduces%2520autonomous%2520cell%2520growth%2520in%2520IL-3-dependent%2520cell%2520lines%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D624%26epage%3D631%26doi%3D10.1038%2Fsj.onc.1203354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Smith, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, C.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salerno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damon, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perl, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Travers, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span> </span><span class="NLM_article-title">Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukemia</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">485</span><span class="NLM_x">, </span> <span class="NLM_fpage">260</span><span class="NLM_x">–</span> <span class="NLM_lpage">263</span><span class="refDoi"> DOI: 10.1038/nature11016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1038%2Fnature11016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=485&publication_year=2012&pages=260-263&author=C.+C.+Smithauthor=Q.+Wangauthor=C.-S.+Chinauthor=S.+Salernoauthor=L.+E.+Damonauthor=M.+J.+Levisauthor=A.+E.+Perlauthor=K.+J.+Traversauthor=S.+Wangauthor=J.+P.+Hunt&title=Validation+of+ITD+mutations+in+FLT3+as+a+therapeutic+target+in+human+acute+myeloid+leukemia&doi=10.1038%2Fnature11016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnature11016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11016%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DChin%26aufirst%3DC.-S.%26aulast%3DSalerno%26aufirst%3DS.%26aulast%3DDamon%26aufirst%3DL.%2BE.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DPerl%26aufirst%3DA.%2BE.%26aulast%3DTravers%26aufirst%3DK.%2BJ.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26atitle%3DValidation%2520of%2520ITD%2520mutations%2520in%2520FLT3%2520as%2520a%2520therapeutic%2520target%2520in%2520human%2520acute%2520myeloid%2520leukemia%26jtitle%3DNature%26date%3D2012%26volume%3D485%26spage%3D260%26epage%3D263%26doi%3D10.1038%2Fnature11016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Swords, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F.</span><span> </span><span class="NLM_article-title">Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">2176</span><span class="NLM_x">–</span> <span class="NLM_lpage">2185</span><span class="refDoi"> DOI: 10.1038/leu.2012.114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1038%2Fleu.2012.114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=22614177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSgu7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=2176-2185&author=R.+Swordsauthor=C.+Freemanauthor=F.+Giles&title=Targeting+the+FMS-like+tyrosine+kinase+3+in+acute+myeloid+leukemia&doi=10.1038%2Fleu.2012.114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia</span></div><div class="casAuthors">Swords, R.; Freeman, C.; Giles, F.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2176-2185</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Acute myeloid leukemia (AML) is a highly heterogenous disease with multiple signaling pathways contributing to its pathogenesis.  A key driver of AML is the FMS-like tyrosine kinase receptor-3 (FLT3).  Activating mutations in FLT3, primarily the FLT3-internal tandem duplication (FLT3-ITD), are assocd. with decreased progression-free and overall survival.  Identification of the importance of FLT3-ITD and the FLT3 pathway in the prognosis of patients with AML has stimulated efforts to develop therapeutic inhibitors of FLT3.  Although these inhibitors have shown promising antileukemic activity, they have had limited efficacy to date as single agents and may require use in combination with cytotoxic chemotherapies.  Here, we review clin. and preclin. results for the clin. mature FLT3 inhibitors currently in development.  We conclude that multitargeted FLT3 inhibitors may have more utility earlier in the course of disease, when in vitro evidence suggests that AML cells are less dependent on FLT3 signaling, perhaps because of upregulation of multiple other signaling pathways.  More potent agents may have greater utility in relapsed and heavily pretreated patients, in whom high levels of circulating FLT3 ligand may necessitate use of an agent with a very favorable pharmacokinetic/pharmacodynamic profile.  Novel combination regimens are also discussed.  Leukemia (2012) 26, 2176-2185; doi:10.1038/leu.2012.114; published online 22 May 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvNpqy5LWqA7Vg90H21EOLACvtfcHk0ljaehaLtAiHAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSgu7zP&md5=774a2f787876a27b387cb3234f97cd1a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fleu.2012.114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2012.114%26sid%3Dliteratum%253Aachs%26aulast%3DSwords%26aufirst%3DR.%26aulast%3DFreeman%26aufirst%3DC.%26aulast%3DGiles%26aufirst%3DF.%26atitle%3DTargeting%2520the%2520FMS-like%2520tyrosine%2520kinase%25203%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26spage%3D2176%26epage%3D2185%26doi%3D10.1038%2Fleu.2012.114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Sudhindra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. C.</span><span> </span><span class="NLM_article-title">FLT3 Inhibitors in AML: Are We There Yet?</span> <span class="citation_source-journal">Curr. Hematol. Malig. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">174</span><span class="NLM_x">–</span> <span class="NLM_lpage">185</span><span class="refDoi"> DOI: 10.1007/s11899-014-0203-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1007%2Fs11899-014-0203-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=24682858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A280%3ADC%252BC2croslGksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=174-185&author=A.+Sudhindraauthor=C.+C.+Smith&title=FLT3+Inhibitors+in+AML%3A+Are+We+There+Yet%3F&doi=10.1007%2Fs11899-014-0203-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 inhibitors in AML: are we there yet?</span></div><div class="casAuthors">Sudhindra Akshay; Smith Catherine Choy</div><div class="citationInfo"><span class="NLM_cas:title">Current hematologic malignancy reports</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">174-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">FMS-like tyrosine kinase 3 (FLT3) is the most frequently mutated gene in AML.  Thirty percent of patients with acute myeloid leukemia (AML) harbor activating mutations in FLT3, either internal tandem duplication mutations in the juxtamembrane domain (FLT3-ITD) or point mutations in the tyrosine kinase domain (FLT3 TKD).  Small molecule FLT3 inhibitors have emerged as an attractive therapeutic option in patients with FLT3 mutations; however, the clinical activity of early inhibitors was limited by a lack of selectivity, potency and unfavorable pharmacokinetic properties.  Newer agents such as quizartinib have improved potency and selectivity associated with much higher bone marrow response rates; however, response duration is limited by the development of secondary resistance.  We will review here a number of FLT3 inhibitors that have been evaluated in clinical trials and discuss challenges facing the use of these agents in AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTea2f_u15zvsKL0FlyGHDofW6udTcc2eatdQS3kd6dtLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2croslGksQ%253D%253D&md5=8db4cff077f6e60fdd0db2e6a641a093</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1007%2Fs11899-014-0203-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11899-014-0203-8%26sid%3Dliteratum%253Aachs%26aulast%3DSudhindra%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DC.%2BC.%26atitle%3DFLT3%2520Inhibitors%2520in%2520AML%253A%2520Are%2520We%2520There%2520Yet%253F%26jtitle%3DCurr.%2520Hematol.%2520Malig.%2520Rep.%26date%3D2014%26volume%3D9%26spage%3D174%26epage%3D185%26doi%3D10.1007%2Fs11899-014-0203-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiller, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiffer, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehninger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeAngelo, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntsman-Labed, A.</span><span> </span><span class="NLM_article-title">Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">2061</span><span class="NLM_x">–</span> <span class="NLM_lpage">2068</span><span class="refDoi"> DOI: 10.1038/leu.2012.115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1038%2Fleu.2012.115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=22627678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlWqsr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=2061-2068&author=R.+M.+Stoneauthor=T.+Fischerauthor=R.+Paquetteauthor=G.+Schillerauthor=C.+A.+Schifferauthor=G.+Ehningerauthor=J.+Cortesauthor=H.+M.+Kantarjianauthor=D.+J.+DeAngeloauthor=A.+Huntsman-Labed&title=Phase+IB+study+of+the+FLT3+kinase+inhibitor+midostaurin+with+chemotherapy+in+younger+newly+diagnosed+adult+patients+with+acute+myeloid+leukemia&doi=10.1038%2Fleu.2012.115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia</span></div><div class="casAuthors">Stone, R. M.; Fischer, T.; Paquette, R.; Schiller, G.; Schiffer, C. A.; Ehninger, G.; Cortes, J.; Kantarjian, H. M.; DeAngelo, D. J.; Huntsman-Labed, A.; Dutreix, C.; del Corral, A.; Giles, F.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2061-2068</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This phase 1b trial investigated several doses and schedules of midostaurin in combination with daunorubicin and cytarabine induction and high-dose cytarabine post-remission therapy in newly diagnosed patients with acute myeloid leukemia (AML).  The discontinuation rate on the 50-mg twice-daily dose schedule was lower than 100 mg twice daily, and no grade 3/4 nausea or vomiting was seen.  The complete remission rate for the midostaurin 50-mg twice-daily dose schedule was 80% (FMS-like tyrosine kinase 3 receptor (FLT3)-wild-type: 20 of 27 (74%), FLT3-mutant: 12 of 13 (92%)).  Overall survival (OS) probabilities of patients with FLT3-mutant AML at 1 and 2 years (0.85 and 0.62, resp.) were similar to the FLT3-wild-type population (0.78 and 0.52, resp.).  Midostaurin in combination with std. chemotherapy demonstrated high complete response and OS rates in newly diagnosed younger adults with AML, and was generally well tolerated at 50 mg twice daily for 14 days.  A phase III prospective trial is ongoing (CALGB 10603, NCT00651261).  Leukemia (2012) 26, 2061-2068; doi:10.1038/leu.2012.115; published online 25 May 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLoF6gfHbqorVg90H21EOLACvtfcHk0lhdYXIXM5RzjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlWqsr3L&md5=3084c40c113fbeaf8fea852a7a12b728</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fleu.2012.115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2012.115%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DFischer%26aufirst%3DT.%26aulast%3DPaquette%26aufirst%3DR.%26aulast%3DSchiller%26aufirst%3DG.%26aulast%3DSchiffer%26aufirst%3DC.%2BA.%26aulast%3DEhninger%26aufirst%3DG.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DHuntsman-Labed%26aufirst%3DA.%26atitle%3DPhase%2520IB%2520study%2520of%2520the%2520FLT3%2520kinase%2520inhibitor%2520midostaurin%2520with%2520chemotherapy%2520in%2520younger%2520newly%2520diagnosed%2520adult%2520patients%2520with%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26spage%3D2061%26epage%3D2068%26doi%3D10.1038%2Fleu.2012.115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Levis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravandi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perl, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coutre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erba, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuart, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccarani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cripe, L. D.</span><span> </span><span class="NLM_article-title">Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">3294</span><span class="NLM_x">–</span> <span class="NLM_lpage">3301</span><span class="refDoi"> DOI: 10.1182/blood-2010-08-301796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1182%2Fblood-2010-08-301796" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=21270442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslams7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=3294-3301&author=M.+Levisauthor=F.+Ravandiauthor=E.+S.+Wangauthor=M.+R.+Baerauthor=A.+Perlauthor=S.+Coutreauthor=H.+Erbaauthor=R.+K.+Stuartauthor=M.+Baccaraniauthor=L.+D.+Cripe&title=Results+from+a+randomized+trial+of+salvage+chemotherapy+followed+by+lestaurtinib+for+patients+with+FLT3+mutant+AML+in+first+relapse&doi=10.1182%2Fblood-2010-08-301796"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse</span></div><div class="casAuthors">Levis, Mark; Ravandi, Farhad; Wang, Eunice S.; Baer, Maria R.; Perl, Alexander; Coutre, Steven; Erba, Harry; Stuart, Robert K.; Baccarani, Michele; Cripe, Larry D.; Tallman, Martin S.; Meloni, Giovanna; Godley, Lucy A.; Langston, Amelia A.; Amadori, Sergio; Lewis, Ian D.; Nagler, Arnon; Stone, Richard; Yee, Karen; Advani, Anjali; Douer, Dan; Wiktor-Jedrzejczak, W.; Juliusson, Gunnar; Litzow, Mark R.; Petersdorf, Stephen; Sanz, Miguel; Kantarjian, Hagop M.; Sato, Takashi; Tremmel, Lothar; Bensen-Kennedy, Debra M.; Small, Donald; Smith, B. Douglas</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3294-3301</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">In a randomized trial of therapy for FMS-like tyrosine kinase-3 (FLT3) mutant acute myeloid leukemia in first relapse, 224 patients received chemotherapy alone or followed by 80 mg of the FLT3 inhibitor lestaurtinib twice daily.  Endpoints included complete remission or complete remission with incomplete platelet recovery (CR/CRp), overall survival, safety, and tolerability.  Correlative studies included pharmacokinetics and anal. of in vivo FLT3 inhibition.  There were 29 patients with CR/CRp in the lestaurtinib arm and 23 in the control arm (26% vs 21%; P = .35), and no difference in overall survival between the 2 arms.  There was evidence of toxicity in the lestaurtinib-treated patients, particularly those with plasma levels in excess of 20μM.  In the lestaurtinib arm, FLT3 inhibition was highly correlated with remission rate, but target inhibition on day 15 was achieved in only 58% of patients receiving lestaurtinib.  Given that such a small proportion of patients on this trial achieved sustained FLT3 inhibition in vivo, any conclusions regarding the efficacy of combining FLT3 inhibition with chemotherapy are limited.  Overall, lestaurtinib treatment after chemotherapy did not increase response rates or prolong survival of patients with FLT3 mutant acute myeloid leukemia in first relapse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNtYr30842srVg90H21EOLACvtfcHk0lhdYXIXM5RzjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslams7o%253D&md5=7e3647298bb0ee66ac72786f103d8f3b</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-08-301796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-08-301796%26sid%3Dliteratum%253Aachs%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DE.%2BS.%26aulast%3DBaer%26aufirst%3DM.%2BR.%26aulast%3DPerl%26aufirst%3DA.%26aulast%3DCoutre%26aufirst%3DS.%26aulast%3DErba%26aufirst%3DH.%26aulast%3DStuart%26aufirst%3DR.%2BK.%26aulast%3DBaccarani%26aufirst%3DM.%26aulast%3DCripe%26aufirst%3DL.%2BD.%26atitle%3DResults%2520from%2520a%2520randomized%2520trial%2520of%2520salvage%2520chemotherapy%2520followed%2520by%2520lestaurtinib%2520for%2520patients%2520with%2520FLT3%2520mutant%2520AML%2520in%2520first%2520relapse%26jtitle%3DBlood%26date%3D2011%26volume%3D117%26spage%3D3294%26epage%3D3301%26doi%3D10.1182%2Fblood-2010-08-301796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">DeAngelo, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heaney, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klisovic, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caligiuri, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lecerf, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karol, M. D.</span><span> </span><span class="NLM_article-title">Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">3674</span><span class="NLM_x">–</span> <span class="NLM_lpage">3681</span><span class="refDoi"> DOI: 10.1182/blood-2006-02-005702</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1182%2Fblood-2006-02-005702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=16902153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Kgs7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2006&pages=3674-3681&author=D.+J.+DeAngeloauthor=R.+M.+Stoneauthor=M.+L.+Heaneyauthor=S.+D.+Nimerauthor=R.+L.+Paquetteauthor=R.+B.+Klisovicauthor=M.+A.+Caligiuriauthor=M.+R.+Cooperauthor=J.-M.+Lecerfauthor=M.+D.+Karol&title=Phase+1+clinical+results+with+tandutinib+%28MLN518%29%2C+a+novel+FLT3+antagonist%2C+in+patients+with+acute+myelogenous+leukemia+or+high-risk+myelodysplastic+syndrome%3A+safety%2C+pharmacokinetics%2C+and+pharmacodynamics&doi=10.1182%2Fblood-2006-02-005702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics</span></div><div class="casAuthors">DeAngelo, Daniel J.; Stone, Richard M.; Heaney, Mark L.; Nimer, Stephen D.; Paquette, Ronald L.; Klisovic, Rebecca B.; Caligiuri, Michael A.; Cooper, Michael R.; Lecerf, Jean-Michel; Karol, Michael D.; Sheng, Shihong; Holford, Nick; Curtin, Peter T.; Druker, Brian J.; Heinrich, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3674-3681</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Tandutinib (MLN518/CT53518) is a novel quinazoline-based inhibitor of the type III receptor tyrosine kinases: FMS-like tyrosine kinase 3 (FLT3), platelet-derived growth factor receptor (PDGFR), and KIT.  Because of the correlation between FLT3 internal tandem duplication (ITD) mutations and poor prognosis in acute myelogenous leukemia (AML), we conducted a phase 1 trial of tandutinib in 40 patients with either AML or high-risk myelodysplastic syndrome (MDS).  Tandutinib was given orally in doses ranging from 50 mg to 700 mg twice daily The principal dose-limiting toxicity (DLT) of tandutinib was reversible generalized muscular weakness, fatigue, or both, occurring at doses of 525 mg and 700 mg twice daily.  Tandutinib's pharmacokinetics were characterized by slow elimination, with achievement of steady-state plasma concns. requiring greater than 1 wk of dosing.  Western blotting showed that tandutinib inhibited phosphorylation of FLT3 in circulating leukemic blasts.  Eight patients had FLT3-ITD mutations; 5 of these were evaluable for assessment of tandutinib's antileukemic effect.  Two of the 5 patients, treated at 525 mg and 700 mg twice daily, showed evidence of antileukemic activity, with decreases in both peripheral and bone marrow blasts.  Tandutinib at the MTD (525 mg twice daily) should be evaluated more extensively in patients with AML with FLT3-ITD mutations to better define its antileukemic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraXRBv_Gv-TLVg90H21EOLACvtfcHk0lgOopSzEtRa-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Kgs7%252FM&md5=42c0b5a4c193955023198d6c6d12c463</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1182%2Fblood-2006-02-005702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2006-02-005702%26sid%3Dliteratum%253Aachs%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DHeaney%26aufirst%3DM.%2BL.%26aulast%3DNimer%26aufirst%3DS.%2BD.%26aulast%3DPaquette%26aufirst%3DR.%2BL.%26aulast%3DKlisovic%26aufirst%3DR.%2BB.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26aulast%3DCooper%26aufirst%3DM.%2BR.%26aulast%3DLecerf%26aufirst%3DJ.-M.%26aulast%3DKarol%26aufirst%3DM.%2BD.%26atitle%3DPhase%25201%2520clinical%2520results%2520with%2520tandutinib%2520%2528MLN518%2529%252C%2520a%2520novel%2520FLT3%2520antagonist%252C%2520in%2520patients%2520with%2520acute%2520myelogenous%2520leukemia%2520or%2520high-risk%2520myelodysplastic%2520syndrome%253A%2520safety%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%26jtitle%3DBlood%26date%3D2006%26volume%3D108%26spage%3D3674%26epage%3D3681%26doi%3D10.1182%2Fblood-2006-02-005702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Pratz, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roboz, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arowojolu, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiotsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shudo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span> </span><span class="NLM_article-title">A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">3938</span><span class="NLM_x">–</span> <span class="NLM_lpage">3946</span><span class="refDoi"> DOI: 10.1182/blood-2008-09-177030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1182%2Fblood-2008-09-177030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=19029442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsVWrsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=3938-3946&author=K.+W.+Pratzauthor=J.+Cortesauthor=G.+J.+Robozauthor=N.+Raoauthor=O.+Arowojoluauthor=A.+Stineauthor=Y.+Shiotsuauthor=A.+Shudoauthor=S.+Akinagaauthor=D.+Small&title=A+pharmacodynamic+study+of+the+FLT3+inhibitor+KW-2449+yields+insight+into+the+basis+for+clinical+response&doi=10.1182%2Fblood-2008-09-177030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response</span></div><div class="casAuthors">Pratz, Keith W.; Cortes, Jorge; Roboz, Gail J.; Rao, Niranjan; Arowojolu, Omotayo; Stine, Adam; Shiotsu, Yukimasa; Shudo, Aiko; Akinaga, Shiro; Small, Donald; Karp, Judith E.; Levis, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3938-3946</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Internal tandem duplication mutations of FLT3 (FLT3/ITD mutations) are common in acute myeloid leukemia (AML) and confer a poor prognosis.  This would suggest that FLT3 is an ideal therapeutic target, but FLT3 targeted therapy has produced only modest benefits in clin. trials.  Due to tech. obstacles, the assessment of target inhibition in patients treated with FLT3 inhibitors has been limited and generally only qual.  KW-2449 is a novel multitargeted kinase inhibitor that induces cytotoxicity in Molm14 cells (which harbor an FLT3/ITD mutation).  The cytotoxic effect occurs primarily at concns. sufficient to inhibit FLT3 autophosphorylation to less than 20% of its baseline.  We report here correlative data from a phase 1 trial of KW-2449, a trial in which typical transient redns. in the peripheral blast counts were obsd.  Using quant. measurement of FLT3 inhibition over time in these patients, we confirmed that FLT3 was inhibited, but only transiently to less than 20% of baseline.  These results suggest that the failure to fully inhibit FLT3 in sustained fashion may be an underlying reason for the minimal success of FLT3 inhibitors to date, and stress the importance of confirming in vivo target inhibition when taking a targeted agent into the clin. setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA9awndUDkxbVg90H21EOLACvtfcHk0lgOopSzEtRa-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsVWrsLg%253D&md5=436d5ee18d3b257a92546832e9eb9a6a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-09-177030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-09-177030%26sid%3Dliteratum%253Aachs%26aulast%3DPratz%26aufirst%3DK.%2BW.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DRoboz%26aufirst%3DG.%2BJ.%26aulast%3DRao%26aufirst%3DN.%26aulast%3DArowojolu%26aufirst%3DO.%26aulast%3DStine%26aufirst%3DA.%26aulast%3DShiotsu%26aufirst%3DY.%26aulast%3DShudo%26aufirst%3DA.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DA%2520pharmacodynamic%2520study%2520of%2520the%2520FLT3%2520inhibitor%2520KW-2449%2520yields%2520insight%2520into%2520the%2520basis%2520for%2520clinical%2520response%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D3938%26epage%3D3946%26doi%3D10.1182%2Fblood-2008-09-177030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Ravandi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alattar, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grunwald, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudek, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajkhowa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richie, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daver, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Manero, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faderl, S.</span><span> </span><span class="NLM_article-title">Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">4655</span><span class="NLM_x">–</span> <span class="NLM_lpage">4662</span><span class="refDoi"> DOI: 10.1182/blood-2013-01-480228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1182%2Fblood-2013-01-480228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=23613521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpsFWktbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2013&pages=4655-4662&author=F.+Ravandiauthor=M.+L.+Alattarauthor=M.+R.+Grunwaldauthor=M.+A.+Rudekauthor=T.+Rajkhowaauthor=M.+A.+Richieauthor=S.+Pierceauthor=N.+Daverauthor=G.+Garcia-Maneroauthor=S.+Faderl&title=Phase+2+study+of+azacytidine+plus+sorafenib+in+patients+with+acute+myeloid+leukemia+and+FLT-3+internal+tandem+duplication+mutation&doi=10.1182%2Fblood-2013-01-480228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation</span></div><div class="casAuthors">Ravandi, Farhad; Alattar, Mona Lisa; Grunwald, Michael R.; Rudek, Michelle A.; Rajkhowa, Trivikram; Richie, Mary Ann; Pierce, Sherry; Daver, Naval; Garcia-Manero, Guillermo; Faderl, Stefan; Nazha, Aziz; Konopleva, Marina; Borthakur, Gautam; Burger, Jan; Kadia, Tapan; Dellasala, Sara; Andreeff, Michael; Cortes, Jorge; Kantarjian, Hagop; Levis, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4655-4662</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Patients received 5-azacytidine (AZA) 75 mg/m2 i.v. daily for 7 days and sorafenib 400 mg orally twice daily continuously; cycles were repeated at ∼1-mo intervals.  Forty-three acute myeloid leukemia (AML) patients with a median age of 64 years (range, 24-87 years) were enrolled; 37 were evaluable for response.  FMS-like tyrosine kinase-3 (FLT3)-internal tandem duplication (ITD) mutation was detected in 40 (93%) patients, with a median allelic ratio of 0.32 (range, 0.009-0.93).  They had received a median of 2 prior treatment regimens (range, 0-7); 9 had failed prior therapy with a FLT3 kinase inhibitor.  The response rate was 46%, including 10 (27%) complete response with incomplete count recovery (CRi), 6 (16%) complete responses (CR), and 1 (3%) partial response.  The median time to achieve CR/CRi was 2 cycles (range, 1-4), and the median duration of CR/CRi was 2.3 mo (range, 1-14.3 mo).  Sixty-four percent of patients achieved adequate (defined as >85%) FLT3 inhibition during their first cycle of therapy.  The degree of FLT3 inhibition correlated with plasma sorafenib concns.  FLT3 ligand levels did not rise to levels seen in prior studies of patients receiving cytotoxic chemotherapy.  The combination of AZA and sorafenib is effective for patients with relapsed AML and FLT-3-ITD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx7FK4wFoKk7Vg90H21EOLACvtfcHk0lgOopSzEtRa-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpsFWktbo%253D&md5=cb763c746906ccd682cbe8faa5ec6f67</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-01-480228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-01-480228%26sid%3Dliteratum%253Aachs%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DAlattar%26aufirst%3DM.%2BL.%26aulast%3DGrunwald%26aufirst%3DM.%2BR.%26aulast%3DRudek%26aufirst%3DM.%2BA.%26aulast%3DRajkhowa%26aufirst%3DT.%26aulast%3DRichie%26aufirst%3DM.%2BA.%26aulast%3DPierce%26aufirst%3DS.%26aulast%3DDaver%26aufirst%3DN.%26aulast%3DGarcia-Manero%26aufirst%3DG.%26aulast%3DFaderl%26aufirst%3DS.%26atitle%3DPhase%25202%2520study%2520of%2520azacytidine%2520plus%2520sorafenib%2520in%2520patients%2520with%2520acute%2520myeloid%2520leukemia%2520and%2520FLT-3%2520internal%2520tandem%2520duplication%2520mutation%26jtitle%3DBlood%26date%3D2013%26volume%3D121%26spage%3D4655%26epage%3D4662%26doi%3D10.1182%2Fblood-2013-01-480228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunawardane, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cramer, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brigham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratz, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Q.</span><span> </span><span class="NLM_article-title">AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">2984</span><span class="NLM_x">–</span> <span class="NLM_lpage">2992</span><span class="refDoi"> DOI: 10.1182/blood-2009-05-222034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1182%2Fblood-2009-05-222034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=19654408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht12qurzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=2984-2992&author=P.+P.+Zarrinkarauthor=R.+N.+Gunawardaneauthor=M.+D.+Cramerauthor=M.+F.+Gardnerauthor=D.+Brighamauthor=B.+Belliauthor=M.+W.+Karamanauthor=K.+W.+Pratzauthor=G.+Pallaresauthor=Q.+Chao&title=AC220+is+a+uniquely+potent+and+selective+inhibitor+of+FLT3+for+the+treatment+of+acute+myeloid+leukemia+%28AML%29&doi=10.1182%2Fblood-2009-05-222034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)</span></div><div class="casAuthors">Zarrinkar, Patrick P.; Gunawardane, Ruwanthi N.; Cramer, Merryl D.; Gardner, Michael F.; Brigham, Daniel; Belli, Barbara; Karaman, Mazen W.; Pratz, Keith W.; Pallares, Gabriel; Chao, Qi; Sprankle, Kelly G.; Patel, Hitesh K.; Levis, Mark; Armstrong, Robert C.; James, Joyce; Bhagwat, Shripad S.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2984-2992</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Activating mutations in the receptor tyrosine kinase FLT3 are present in up to approx. 30% of acute myeloid leukemia (AML) patients, implicating FLT3 as a driver of the disease and therefore as a target for therapy.  We report the characterization of AC220, a second-generation FLT3 inhibitor, and a comparison of AC220 with the first-generation FLT3 inhibitors CEP-701, MLN-518, PKC-412, sorafenib, and sunitinib.  AC220 exhibits low nanomolar potency in biochem. and cellular assays and exceptional kinase selectivity, and in animal models is efficacious at doses as low as 1 mg/kg given orally once daily.  The data reveal that the combination of excellent potency, selectivity, and pharmacokinetic properties is unique to AC220, which therefore is the first drug candidate with a profile that matches the characteristics desirable for a clin. FLT3 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_RzDr7kzxsLVg90H21EOLACvtfcHk0lh-FbLGEBy38g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht12qurzN&md5=4f8368a7b2eab9d1234ef36e01f5f260</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-05-222034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-05-222034%26sid%3Dliteratum%253Aachs%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DCramer%26aufirst%3DM.%2BD.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DBelli%26aufirst%3DB.%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DPratz%26aufirst%3DK.%2BW.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DChao%26aufirst%3DQ.%26atitle%3DAC220%2520is%2520a%2520uniquely%2520potent%2520and%2520selective%2520inhibitor%2520of%2520FLT3%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D2984%26epage%3D2992%26doi%3D10.1182%2Fblood-2009-05-222034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Galanis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajkhowa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramachandran, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M.</span><span> </span><span class="NLM_article-title">Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">94</span><span class="NLM_x">–</span> <span class="NLM_lpage">100</span><span class="refDoi"> DOI: 10.1182/blood-2013-10-529313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1182%2Fblood-2013-10-529313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=24227820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVCksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2014&pages=94-100&author=A.+Galanisauthor=H.+Maauthor=T.+Rajkhowaauthor=A.+Ramachandranauthor=D.+Smallauthor=J.+Cortesauthor=M.+Levis&title=Crenolanib+is+a+potent+inhibitor+of+FLT3+with+activity+against+resistance-conferring+point+mutants&doi=10.1182%2Fblood-2013-10-529313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants</span></div><div class="casAuthors">Galanis, Allison; Ma, Hayley; Rajkhowa, Trivikram; Ramachandran, Abhijit; Small, Donald; Cortes, Jorge; Levis, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-100</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Mutations of the type III receptor tyrosine kinase FLT3 occur in approx. 30% of acute myeloid leukemia patients and lead to constitutive activation.  This has made FLT3-activating mutations an attractive drug target because they are probable driver mutations of this disease.  As more potent FLT3 inhibitors are developed, a predictable development of resistance-conferring point mutations, commonly at residue D835, has been obsd.  Crenolanib is a highly selective and potent FLT3 tyrosine kinase inhibitor (TKI) with activity against the internal tandem duplication (FLT3/ITD) mutants and the FLT3/D835 point mutants.  We tested crenolanib against a panel of D835 mutant cell lines and primary patient blasts and obsd. superior cytotoxic effects when compared with other available FLT3 TKIs such as quizartinib and sorafenib.  Another potential advantage of crenolanib is its reduced inhibition of c-Kit compared with quizartinib.  In progenitor cell assays, crenolanib was less disruptive of erythroid colony growth, which may result in relatively less myelosuppression than quizartinib.  Finally, correlative data from an ongoing clin. trial demonstrate that acute myeloid leukemia patients can achieve sufficient levels of crenolanib to inhibit both FLT3/ITD and resistance-conferring FLT3/D835 mutants in vivo.  Crenolanib is thus an important next-generation FLT3 TKI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmTJQsMqjR3rVg90H21EOLACvtfcHk0lh-FbLGEBy38g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVCksA%253D%253D&md5=c622e44844e5038fe3567735ea3fee7e</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-10-529313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-10-529313%26sid%3Dliteratum%253Aachs%26aulast%3DGalanis%26aufirst%3DA.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DRajkhowa%26aufirst%3DT.%26aulast%3DRamachandran%26aufirst%3DA.%26aulast%3DSmall%26aufirst%3DD.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DLevis%26aufirst%3DM.%26atitle%3DCrenolanib%2520is%2520a%2520potent%2520inhibitor%2520of%2520FLT3%2520with%2520activity%2520against%2520resistance-conferring%2520point%2520mutants%26jtitle%3DBlood%26date%3D2014%26volume%3D123%26spage%3D94%26epage%3D100%26doi%3D10.1182%2Fblood-2013-10-529313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Zimmerman, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buaboonnam, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orwick, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janke, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramachandran, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inaba, H.</span><span> </span><span class="NLM_article-title">Crenolanib is active against models of drug-resistant FLT3-ITD– positive acute myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">3607</span><span class="NLM_x">–</span> <span class="NLM_lpage">3615</span><span class="refDoi"> DOI: 10.1182/blood-2013-07-513044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1182%2Fblood-2013-07-513044" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=3607-3615&author=E.+I.+Zimmermanauthor=D.+C.+Turnerauthor=J.+Buaboonnamauthor=S.+Huauthor=S.+Orwickauthor=M.+S.+Robertsauthor=L.+J.+Jankeauthor=A.+Ramachandranauthor=C.+F.+Stewartauthor=H.+Inaba&title=Crenolanib+is+active+against+models+of+drug-resistant+FLT3-ITD%E2%80%93+positive+acute+myeloid+leukemia&doi=10.1182%2Fblood-2013-07-513044"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-07-513044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-07-513044%26sid%3Dliteratum%253Aachs%26aulast%3DZimmerman%26aufirst%3DE.%2BI.%26aulast%3DTurner%26aufirst%3DD.%2BC.%26aulast%3DBuaboonnam%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DS.%26aulast%3DOrwick%26aufirst%3DS.%26aulast%3DRoberts%26aufirst%3DM.%2BS.%26aulast%3DJanke%26aufirst%3DL.%2BJ.%26aulast%3DRamachandran%26aufirst%3DA.%26aulast%3DStewart%26aufirst%3DC.%2BF.%26aulast%3DInaba%26aufirst%3DH.%26atitle%3DCrenolanib%2520is%2520active%2520against%2520models%2520of%2520drug-resistant%2520FLT3-ITD%25E2%2580%2593%2520positive%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26spage%3D3607%26epage%3D3615%26doi%3D10.1182%2Fblood-2013-07-513044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Grunwald, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M. J.</span><span> </span><span class="NLM_article-title">FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance</span> <span class="citation_source-journal">Int. J. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">683</span><span class="NLM_x">–</span> <span class="NLM_lpage">694</span><span class="refDoi"> DOI: 10.1007/s12185-013-1334-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1007%2Fs12185-013-1334-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=23613268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BC3sXps1ynt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2013&pages=683-694&author=M.+R.+Grunwaldauthor=M.+J.+Levis&title=FLT3+inhibitors+for+acute+myeloid+leukemia%3A+a+review+of+their+efficacy+and+mechanisms+of+resistance&doi=10.1007%2Fs12185-013-1334-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance</span></div><div class="casAuthors">Grunwald, Michael R.; Levis, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Hematology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">683-694</span>CODEN:
                <span class="NLM_cas:coden">IJHEEY</span>;
        ISSN:<span class="NLM_cas:issn">0925-5710</span>.
    
            (<span class="NLM_cas:orgname">Springer Japan</span>)
        </div><div class="casAbstract">A review.  Since the Food and Drug Administration approval of imatinib for treatment of chronic myeloid leukemia in 2001, tyrosine kinase inhibitors (TKIs) have become a mainstay in the care of many malignancies.  In acute myeloid leukemia (AML), activating mutations in the FMS-like tyrosine kinase 3 (FLT3) gene result in survival and proliferation of leukemic blasts and are assocd. with adverse prognosis.  Therefore, the FLT3 receptor is an appealing target for inhibition.  Multiple small mol. TKIs are currently in development for FLT3-mutated AML, and agents are beginning to show promising efficacy.  In other malignancies, the development of resistance to TKIs during the course of therapy has proven to be a challenge, and thus far, in clin. trials of FLT3 TKIs, resistance to inhibition represents a significant barrier to successful FLT3 inhibition.  Understanding the mechanisms of resistance and overcoming these obstacles to target inhibition will be central to the success of these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLGvQhRtVOcLVg90H21EOLACvtfcHk0lheBVWNG7v6jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXps1ynt7Y%253D&md5=f760866dbcd953c09143e0290fbffe3c</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1007%2Fs12185-013-1334-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12185-013-1334-8%26sid%3Dliteratum%253Aachs%26aulast%3DGrunwald%26aufirst%3DM.%2BR.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26atitle%3DFLT3%2520inhibitors%2520for%2520acute%2520myeloid%2520leukemia%253A%2520a%2520review%2520of%2520their%2520efficacy%2520and%2520mechanisms%2520of%2520resistance%26jtitle%3DInt.%2520J.%2520Hematol.%26date%3D2013%26volume%3D97%26spage%3D683%26epage%3D694%26doi%3D10.1007%2Fs12185-013-1334-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Smith, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasater, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCreery, M. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damon, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perl, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeschke, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugita, M.</span><span> </span><span class="NLM_article-title">Crenolanib is a selective type I pan-FLT3 inhibitor</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">5319</span><span class="NLM_x">–</span> <span class="NLM_lpage">5324</span><span class="refDoi"> DOI: 10.1073/pnas.1320661111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1073%2Fpnas.1320661111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=24623852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkt1Snsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=5319-5324&author=C.+C.+Smithauthor=E.+A.+Lasaterauthor=K.+C.+Linauthor=Q.+Wangauthor=M.+Q.+McCreeryauthor=W.+K.+Stewartauthor=L.+E.+Damonauthor=A.+E.+Perlauthor=G.+R.+Jeschkeauthor=M.+Sugita&title=Crenolanib+is+a+selective+type+I+pan-FLT3+inhibitor&doi=10.1073%2Fpnas.1320661111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Crenolanib is a selective type I pan-FLT3 inhibitor</span></div><div class="casAuthors">Smith, Catherine Choy; Lasater, Elisabeth A.; Lin, Kimberly C.; Wang, Qi; McCreery, Melissa Quino; Stewart, Whitney K.; Damon, Lauren E.; Perl, Alexander E.; Jeschke, Grace R.; Sugita, Mayumi; Carroll, Martin; Kogan, Scott C.; Kuriyan, John; Shah, Neil P.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5319-5324</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Tyrosine kinase inhibitors (TKIs) represent transformative therapies for several malignancies.  Two crit. features necessary for maximizing TKI tolerability and response duration are kinase selectivity and invulnerability to resistance-conferring kinase domain (KD) mutations in the intended target.  No prior TKI has demonstrated both of these properties.  Aiming to maximize selectivity, medicinal chemists have largely sought to create TKIs that bind to an inactive (type II) kinase conformation.  The investigational type I TKI crenolanib is a potent inhibitor of Fms tyrosine kinase-3 (FLT3) internal tandem duplication, a validated therapeutic target in human acute myeloid leukemia (AML), as well as all secondary KD mutants previously shown to confer resistance to the first highly active FLT3 TKI quizartinib.  Moreover, crenolanib is highly selective for FLT3 relative to the closely related protein tyrosine kinase KIT, demonstrating that simultaneous FLT3/KIT inhibition, a prominent feature of other clin. active FLT3 TKIs, is not required for AML cell cytotoxicity in vitro and may contribute to undesirable toxicity in patients.  A satn. mutagenesis screen of FLT3-internal tandem duplication failed to recover any resistant colonies in the presence of a crenolanib concn. well below what has been safely achieved in humans, suggesting that crenolanib has the potential to suppress KD mutation-mediated clin. resistance.  Crenolanib represents the first TKI to exhibit both kinase selectivity and invulnerability to resistance-conferring KD mutations, which is unexpected of a type I inhibitor.  Crenolanib has significant promise for achieving deep and durable responses in FLT3-mutant AML, and may have a profound impact upon future medicinal chem. efforts in oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwxReAanOwB7Vg90H21EOLACvtfcHk0lheBVWNG7v6jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkt1Snsbw%253D&md5=955f1f242a1690247ae239050e2a8a8f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1320661111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1320661111%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DLasater%26aufirst%3DE.%2BA.%26aulast%3DLin%26aufirst%3DK.%2BC.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DMcCreery%26aufirst%3DM.%2BQ.%26aulast%3DStewart%26aufirst%3DW.%2BK.%26aulast%3DDamon%26aufirst%3DL.%2BE.%26aulast%3DPerl%26aufirst%3DA.%2BE.%26aulast%3DJeschke%26aufirst%3DG.%2BR.%26aulast%3DSugita%26aufirst%3DM.%26atitle%3DCrenolanib%2520is%2520a%2520selective%2520type%2520I%2520pan-FLT3%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D5319%26epage%3D5324%26doi%3D10.1073%2Fpnas.1320661111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ku, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span> </span><span class="NLM_article-title">Discovery of Pteridin-7 (8 H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) Kinase T790M/L858R mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">7821</span><span class="NLM_x">–</span> <span class="NLM_lpage">7837</span><span class="refDoi"> DOI: 10.1021/jm401045n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401045n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7821-7837&author=W.+Zhouauthor=X.+Liuauthor=Z.+Tuauthor=L.+Zhangauthor=X.+Kuauthor=F.+Baiauthor=Z.+Zhaoauthor=Y.+Xuauthor=K.+Dingauthor=H.+Li&title=Discovery+of+Pteridin-7+%288+H%29-one-based+irreversible+inhibitors+targeting+the+epidermal+growth+factor+receptor+%28EGFR%29+Kinase+T790M%2FL858R+mutant&doi=10.1021%2Fjm401045n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm401045n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401045n%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DKu%26aufirst%3DX.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520Pteridin-7%2520%25288%2520H%2529-one-based%2520irreversible%2520inhibitors%2520targeting%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520Kinase%2520T790M%252FL858R%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7821%26epage%3D7837%26doi%3D10.1021%2Fjm401045n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span><span class="refDoi"> DOI: 10.1038/nature08622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.-H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Padera&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M&doi=10.1038%2Fnature08622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0lg58TNuNQDbqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074%26doi%3D10.1038%2Fnature08622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Song, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ge, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, X.</span><span> </span><span class="NLM_article-title">Challenges and Perspectives on the Development of Small-molecule EGFR Inhibitors against T790M-mediated Resistance in Non-small-cell Lung Cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00840</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00840" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Z.+Songauthor=Y.+Geauthor=C.+Wangauthor=S.+Huangauthor=X.+Shuauthor=K.+Liuauthor=Y.+Zhouauthor=X.+Ma&title=Challenges+and+Perspectives+on+the+Development+of+Small-molecule+EGFR+Inhibitors+against+T790M-mediated+Resistance+in+Non-small-cell+Lung+Cancer&doi=10.1021%2Facs.jmedchem.5b00840"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00840%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DGe%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DShu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DX.%26atitle%3DChallenges%2520and%2520Perspectives%2520on%2520the%2520Development%2520of%2520Small-molecule%2520EGFR%2520Inhibitors%2520against%2520T790M-mediated%2520Resistance%2520in%2520Non-small-cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26doi%3D10.1021%2Facs.jmedchem.5b00840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Walter, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjin, R. T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span> </span><span class="NLM_article-title">Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1404</span><span class="NLM_x">–</span> <span class="NLM_lpage">1415</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1158%2F2159-8290.CD-13-0314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=24065731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1404-1415&author=A.+O.+Walterauthor=R.+T.+T.+Sjinauthor=H.+J.+Haringsmaauthor=K.+Ohashiauthor=J.+Sunauthor=K.+Leeauthor=A.+Dubrovskiyauthor=M.+Labenskiauthor=Z.+Zhuauthor=Z.+Wang&title=Discovery+of+a+mutant-selective+covalent+inhibitor+of+EGFR+that+overcomes+T790M-mediated+resistance+in+NSCLC&doi=10.1158%2F2159-8290.CD-13-0314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span></div><div class="casAuthors">Walter, Annette O.; Sjin, Robert Tjin Tham; Haringsma, Henry J.; Ohashi, Kadoaki; Sun, Jing; Lee, Kwangho; Dubrovskiy, Aleksandr; Labenski, Matthew; Zhu, Zhendong; Wang, Zhigang; Sheets, Michael; St. Martin, Thia; Karp, Russell; van Kalken, Dan; Chaturvedi, Prasoon; Niu, Deqiang; Nacht, Mariana; Petter, Russell C.; Westlin, William; Lin, Kevin; Jaw-Tsai, Sarah; Raponi, Mitch; Van Dyke, Terry; Etter, Jeff; Weaver, Zoe; Pao, William; Singh, Juswinder; Simmons, Andrew D.; Harding, Thomas C.; Allen, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1404-1415</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors.  However, clin. efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation.  CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor.  Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models.  Minimal activity of CO-1686 against the WT EGFR receptor was obsd.  In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of addnl. mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial-mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors.  These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR0CDWQZ5wn7Vg90H21EOLACvtfcHk0lh6Fk-CqqSfrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN&md5=3d111f4bf958f2fda6890fbc0e1d99f5</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0314%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DSjin%26aufirst%3DR.%2BT.%2BT.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520a%2520mutant-selective%2520covalent%2520inhibitor%2520of%2520EGFR%2520that%2520overcomes%2520T790M-mediated%2520resistance%2520in%2520NSCLC%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D1404%26epage%3D1415%26doi%3D10.1158%2F2159-8290.CD-13-0314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Cross, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nebhan, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitzler, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, M. R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span> </span><span class="NLM_article-title">AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&author=D.+A.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+V.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellor&title=AZD9291%2C+an+irreversible+EGFR+TKI%2C+overcomes+T790M-mediated+resistance+to+EGFR+inhibitors+in+lung+cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0lh6Fk-CqqSfrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26atitle%3DAZD9291%252C%2520an%2520irreversible%2520EGFR%2520TKI%252C%2520overcomes%2520T790M-mediated%2520resistance%2520to%2520EGFR%2520inhibitors%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bold, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roesel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guagnano, V.</span><span> </span><span class="NLM_article-title">Aromatic interactions with phenylalanine 691 and cysteine 828: a concept for FMS-like tyrosine kinase-3 inhibition. Application to the discovery of a new class of potential antileukemia agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">4451</span><span class="NLM_x">–</span> <span class="NLM_lpage">4454</span><span class="refDoi"> DOI: 10.1021/jm060368s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060368s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4451-4454&author=P.+Furetauthor=G.+Boldauthor=T.+Meyerauthor=J.+Roeselauthor=V.+Guagnano&title=Aromatic+interactions+with+phenylalanine+691+and+cysteine+828%3A+a+concept+for+FMS-like+tyrosine+kinase-3+inhibition.+Application+to+the+discovery+of+a+new+class+of+potential+antileukemia+agents&doi=10.1021%2Fjm060368s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm060368s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060368s%26sid%3Dliteratum%253Aachs%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DBold%26aufirst%3DG.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DRoesel%26aufirst%3DJ.%26aulast%3DGuagnano%26aufirst%3DV.%26atitle%3DAromatic%2520interactions%2520with%2520phenylalanine%2520691%2520and%2520cysteine%2520828%253A%2520a%2520concept%2520for%2520FMS-like%2520tyrosine%2520kinase-3%2520inhibition.%2520Application%2520to%2520the%2520discovery%2520of%2520a%2520new%2520class%2520of%2520potential%2520antileukemia%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4451%26epage%3D4454%26doi%3D10.1021%2Fjm060368s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Williams, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leahy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span> </span><span class="NLM_article-title">Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">48</span><span class="NLM_x">–</span> <span class="NLM_lpage">55</span><span class="refDoi"> DOI: 10.1038/leu.2012.191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1038%2Fleu.2012.191" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=48-55&author=A.+B.+Williamsauthor=B.+Nguyenauthor=L.+Liauthor=P.+Brownauthor=M.+Levisauthor=D.+Leahyauthor=D.+Small&title=Mutations+of+FLT3%2FITD+confer+resistance+to+multiple+tyrosine+kinase+inhibitors&doi=10.1038%2Fleu.2012.191"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fleu.2012.191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2012.191%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DA.%2BB.%26aulast%3DNguyen%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DBrown%26aufirst%3DP.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DLeahy%26aufirst%3DD.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DMutations%2520of%2520FLT3%252FITD%2520confer%2520resistance%2520to%2520multiple%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DLeukemia%26date%3D2013%26volume%3D27%26spage%3D48%26epage%3D55%26doi%3D10.1038%2Fleu.2012.191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Albers, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leischner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verbeek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Illert, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peschel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Bubnoff, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duyster, J.</span><span> </span><span class="NLM_article-title">The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD<sup>+</sup> AML but retains in vitro sensitivity to PKC412 and Sunitinib</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1416</span><span class="NLM_x">–</span> <span class="NLM_lpage">1418</span><span class="refDoi"> DOI: 10.1038/leu.2013.14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1038%2Fleu.2013.14" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=1416-1418&author=C.+Albersauthor=H.+Leischnerauthor=M.+Verbeekauthor=C.+Yuauthor=A.+L.+Illertauthor=C.+Peschelauthor=N.+von+Bubnoffauthor=J.+Duyster&title=The+secondary+FLT3-ITD+F691L+mutation+induces+resistance+to+AC220+in+FLT3-ITD%2B+AML+but+retains+in+vitro+sensitivity+to+PKC412+and+Sunitinib&doi=10.1038%2Fleu.2013.14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fleu.2013.14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2013.14%26sid%3Dliteratum%253Aachs%26aulast%3DAlbers%26aufirst%3DC.%26aulast%3DLeischner%26aufirst%3DH.%26aulast%3DVerbeek%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DIllert%26aufirst%3DA.%2BL.%26aulast%3DPeschel%26aufirst%3DC.%26aulast%3Dvon%2BBubnoff%26aufirst%3DN.%26aulast%3DDuyster%26aufirst%3DJ.%26atitle%3DThe%2520secondary%2520FLT3-ITD%2520F691L%2520mutation%2520induces%2520resistance%2520to%2520AC220%2520in%2520FLT3-ITD%252B%2520AML%2520but%2520retains%2520in%2520vitro%2520sensitivity%2520to%2520PKC412%2520and%2520Sunitinib%26jtitle%3DLeukemia%26date%3D2013%26volume%3D27%26spage%3D1416%26epage%3D1418%26doi%3D10.1038%2Fleu.2013.14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Barry, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cools, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roesel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span> </span><span class="NLM_article-title">Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">4476</span><span class="NLM_x">–</span> <span class="NLM_lpage">4479</span><span class="refDoi"> DOI: 10.1182/blood-2007-07-101238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1182%2Fblood-2007-07-101238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=17827387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BD1cXot1Wr" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=4476-4479&author=E.+V.+Barryauthor=J.+J.+Clarkauthor=J.+Coolsauthor=J.+Roeselauthor=D.+G.+Gilliland&title=Uniform+sensitivity+of+FLT3+activation+loop+mutants+to+the+tyrosine+kinase+inhibitor+midostaurin&doi=10.1182%2Fblood-2007-07-101238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin</span></div><div class="casAuthors">Barry, Elly V.; Clark, Jennifer J.; Cools, Jan; Roesel, Johannes; Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4476-4479</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Small mol. inhibitors that target fms-like tyrosine kinase 3 (FLT3)-activating mutations have potential in the treatment of leukemias.  However, certain mutations can simultaneously activate the tyrosine kinase, and confer resistance to small mol. inhibitors.  We therefore tested the sensitivity of 8 FLT3 activation loop mutants to midostaurin.  Each mutant conferred IL-3 factor-independent proliferation to Ba/F3 cells, and each resulted in the constitutive activation of FLT3 and its targets, signal transducer and activator of transcription 5 (STAT5) and extracellular stimuli-responsive kinase (ERK).  For each mutant tested, midostaurin inhibited cell growth and phosphorylation of FLT3, STAT5, and ERK.  In contrast, midostaruin did not inhibit Ba/F3 cells stably transduced with FLT3-internal tandem duplications contg. a G697R mutation that confers resistance to midostaurin, demonstrating that midostaurin inhibition of FLT3 activation loop mutants was not due to off-target effects.  We conclude that midostaurin is a potent inhibitor of a spectrum of FLT3 activation loop mutations, and that acute myeloid leukemia patients with such mutations are potential candidates for clin. trials involving midostaurin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdwABqNKHecLVg90H21EOLACvtfcHk0ljiMvJwYuaokA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXot1Wr&md5=a4093ba0c60d4c239226a25eba2a266c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-07-101238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-07-101238%26sid%3Dliteratum%253Aachs%26aulast%3DBarry%26aufirst%3DE.%2BV.%26aulast%3DClark%26aufirst%3DJ.%2BJ.%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DRoesel%26aufirst%3DJ.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DUniform%2520sensitivity%2520of%2520FLT3%2520activation%2520loop%2520mutants%2520to%2520the%2520tyrosine%2520kinase%2520inhibitor%2520midostaurin%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D4476%26epage%3D4479%26doi%3D10.1182%2Fblood-2007-07-101238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Gilliland, D. G.</span><span> </span><span class="NLM_article-title">FLT3-activating mutations in acute promyelocytic leukemia: a rationale for risk-adapted therapy with FLT3 inhibitors</span> <span class="citation_source-journal">Best Practice & Research Clinical Haematology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">409</span><span class="NLM_x">–</span> <span class="NLM_lpage">417</span><span class="refDoi"> DOI: 10.1016/S1521-6926(03)00063-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1016%2FS1521-6926%2803%2900063-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2003&pages=409-417&author=D.+G.+Gilliland&title=FLT3-activating+mutations+in+acute+promyelocytic+leukemia%3A+a+rationale+for+risk-adapted+therapy+with+FLT3+inhibitors&doi=10.1016%2FS1521-6926%2803%2900063-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2FS1521-6926%2803%2900063-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1521-6926%252803%252900063-X%26sid%3Dliteratum%253Aachs%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DFLT3-activating%2520mutations%2520in%2520acute%2520promyelocytic%2520leukemia%253A%2520a%2520rationale%2520for%2520risk-adapted%2520therapy%2520with%2520FLT3%2520inhibitors%26jtitle%3DBest%2520Practice%2520%2526%2520Research%2520Clinical%2520Haematology%26date%3D2003%26volume%3D16%26spage%3D409%26epage%3D417%26doi%3D10.1016%2FS1521-6926%2803%2900063-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Moore, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faisal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Castro, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bavetsias, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atrash, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Haven Brandon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avery, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mair, D.</span><span> </span><span class="NLM_article-title">Selective FLT3 inhibition of FLT3-ITD<sup>+</sup> acute myeloid leukemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1462</span><span class="NLM_x">–</span> <span class="NLM_lpage">1470</span><span class="refDoi"> DOI: 10.1038/leu.2012.52</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1038%2Fleu.2012.52" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=1462-1470&author=A.+S.+Mooreauthor=A.+Faisalauthor=D.+G.+de+Castroauthor=V.+Bavetsiasauthor=C.+Sunauthor=B.+Atrashauthor=M.+Valentiauthor=A.+de+Haven+Brandonauthor=S.+Averyauthor=D.+Mair&title=Selective+FLT3+inhibition+of+FLT3-ITD%2B+acute+myeloid+leukemia+resulting+in+secondary+D835Y+mutation%3A+a+model+for+emerging+clinical+resistance+patterns&doi=10.1038%2Fleu.2012.52"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fleu.2012.52&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2012.52%26sid%3Dliteratum%253Aachs%26aulast%3DMoore%26aufirst%3DA.%2BS.%26aulast%3DFaisal%26aufirst%3DA.%26aulast%3Dde%2BCastro%26aufirst%3DD.%2BG.%26aulast%3DBavetsias%26aufirst%3DV.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DAtrash%26aufirst%3DB.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3Dde%2BHaven%2BBrandon%26aufirst%3DA.%26aulast%3DAvery%26aufirst%3DS.%26aulast%3DMair%26aufirst%3DD.%26atitle%3DSelective%2520FLT3%2520inhibition%2520of%2520FLT3-ITD%252B%2520acute%2520myeloid%2520leukemia%2520resulting%2520in%2520secondary%2520D835Y%2520mutation%253A%2520a%2520model%2520for%2520emerging%2520clinical%2520resistance%2520patterns%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26spage%3D1462%26epage%3D1470%26doi%3D10.1038%2Fleu.2012.52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Yamamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyoi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyawaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yagasaki, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimazaki, C.</span><span> </span><span class="NLM_article-title">Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">2434</span><span class="NLM_x">–</span> <span class="NLM_lpage">2439</span><span class="refDoi"> DOI: 10.1182/blood.V97.8.2434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=10.1182%2Fblood.V97.8.2434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=11290608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivFOgtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2001&pages=2434-2439&author=Y.+Yamamotoauthor=H.+Kiyoiauthor=Y.+Nakanoauthor=R.+Suzukiauthor=Y.+Koderaauthor=S.+Miyawakiauthor=N.+Asouauthor=K.+Kuriyamaauthor=F.+Yagasakiauthor=C.+Shimazaki&title=Activating+mutation+of+D835+within+the+activation+loop+of+FLT3+in+human+hematologic+malignancies&doi=10.1182%2Fblood.V97.8.2434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies</span></div><div class="casAuthors">Yamamoto, Yukiya; Kiyoi, Hitoshi; Nakano, Yasuyuki; Suzuki, Ritsuro; Kodera, Yoshihisa; Miyawaki, Shuichi; Asou, Norio; Kuriyama, Kazutaka; Yagasaki, Fumiharu; Shimazaki, Chihiro; Akiyama, Hideki; Saito, Kenji; Nishimura, Miki; Motoji, Toshiko; Shinagawa, Katsuji; Takeshita, Akihiro; Saito, Hidehiko; Ueda, Ryuzo; Ohno, Ryuzo; Naoe, Tomoki</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2434-2439</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Mutations of receptor tyrosine kinases are implicated in the constitutive activation and development of human malignancy.  An internal tandem duplication (ITD) of the juxtamembrane (JM) domain-coding sequence of the FLT3 gene (FLT3/ITD) is found in 20% of patients with acute myeloid leukemia (AML) and is strongly assocd. with leukocytosis and a poor prognosis.  On the other hand, mutations of the c-KIT gene, which have been found in mast cell leukemia and AML, are clustered in 2 distinct regions, the JM domain and D816 within the activation loop.  This study was designed to analyze the mutation of D835 of FLT3, which corresponds to D816 of c-KIT, in a large series of human hematol. malignancies.  Several kinds of missense mutations were found in 30 of the 429 (7.0%) AML cases, 1 of the 29 (3.4%) myelodysplastic syndrome (MDS) cases, and 1 of the 36 (2.8%) acute lymphocytic leukemia patients.  The D835Y mutation was most frequently found (22 of the 32 D835 mutations), followed by the D835V (5), and D835H (1), D835E (1), and D835N (1) mutations.  Of note is that D835 mutations occurred independently of FLT3/ITD.  An anal. in the 201 patients newly diagnosed with AML (excluding M3) revealed that, in contrast to the FLT3/ITD mutation, D835 mutations were not significantly related to the leukocytosis, but tended to worsen disease-free survival.  All D835-mutant FLT3 were constitutively tyrosine-phosphorylated and transformed 32D cells, suggesting these mutations were constitutively active.  These results demonstrate that the FLT3 gene is the target most frequently mutated to become constitutively active in AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrydJnPT47K17Vg90H21EOLACvtfcHk0lgbFwsUYMETPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivFOgtbk%253D&md5=646e1b1a04c570f4094e7d83723d47fb</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1182%2Fblood.V97.8.2434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V97.8.2434%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DNakano%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DKodera%26aufirst%3DY.%26aulast%3DMiyawaki%26aufirst%3DS.%26aulast%3DAsou%26aufirst%3DN.%26aulast%3DKuriyama%26aufirst%3DK.%26aulast%3DYagasaki%26aufirst%3DF.%26aulast%3DShimazaki%26aufirst%3DC.%26atitle%3DActivating%2520mutation%2520of%2520D835%2520within%2520the%2520activation%2520loop%2520of%2520FLT3%2520in%2520human%2520hematologic%2520malignancies%26jtitle%3DBlood%26date%3D2001%26volume%3D97%26spage%3D2434%26epage%3D2439%26doi%3D10.1182%2Fblood.V97.8.2434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eksterowicz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribble, M. W.,  Jr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alba, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, R.</span><span> </span><span class="NLM_article-title">Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">3430</span><span class="NLM_x">–</span> <span class="NLM_lpage">3449</span><span class="refDoi"> DOI: 10.1021/jm500118j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500118j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktl2itLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3430-3449&author=Z.+Liauthor=X.+Wangauthor=J.+Eksterowiczauthor=M.+W.+Gribbleauthor=G.+Q.+Albaauthor=M.+Ayresauthor=T.+J.+Carlsonauthor=A.+Chenauthor=X.+Chenauthor=R.+Cho&title=Discovery+of+AMG+925%2C+a+FLT3+and+CDK4+Dual+Kinase+Inhibitor+with+Preferential+Affinity+for+the+Activated+State+of+FLT3&doi=10.1021%2Fjm500118j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3</span></div><div class="casAuthors">Li, Zhihong; Wang, Xianghong; Eksterowicz, John; Gribble, Michael W.; Alba, Grace Q.; Ayres, Merrill; Carlson, Timothy J.; Chen, Ada; Chen, Xiaoqi; Cho, Robert; Connors, Richard V.; DeGraffenreid, Michael; Deignan, Jeffrey T.; Duquette, Jason; Fan, Pingchen; Fisher, Benjamin; Fu, Jiasheng; Huard, Justin N.; Kaizerman, Jacob; Keegan, Kathleen S.; Li, Cong; Li, Kexue; Li, Yunxiao; Liang, Lingming; Liu, Wen; Lively, Sarah E.; Lo, Mei-Chu; Ma, Ji; McMinn, Dustin L.; Mihalic, Jeffrey T.; Modi, Kriti; Ngo, Rachel; Pattabiraman, Kanaka; Piper, Derek E.; Queva, Christophe; Ragains, Mark L.; Suchomel, Julia; Thibault, Steve; Walker, Nigel; Wang, Xiaodong; Wang, Zhulun; Wanska, Malgorzata; Wehn, Paul M.; Weidner, Margaret F.; Zhang, Alex J.; Zhao, Xiaoning; Kamb, Alexander; Wickramasinghe, Dineli; Dai, Kang; McGee, Lawrence R.; Medina, Julio C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3430-3449</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors describe the structural optimization of a lead compd. that exhibits dual inhibitory activities against FLT3 and CDK4.  A series of pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidine derivs. was synthesized, and SAR anal., using cell-based assays, led to the discovery of AMG 925 (I), a potent and orally bioavailable dual inhibitor of CDK4 and FLT3, including many FLT3 mutants reported to date.  Compd. I inhibits the proliferation of a panel of human tumor cell lines including Colo205 (Rb+) and U937 (FLT3WT) and induced cell death in MOLM13 (FLT3ITD) and even in MOLM13 (FLT3ITD, D835Y), which exhibits resistance to a no. of FLT3 inhibitors currently under clin. development.  At well-tolerated doses, compd. I leads to significant growth inhibition of MOLM13 xenografts in nude mice, and the activity correlates with inhibition of STAT5 and Rb phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcJdjH0aU8KrVg90H21EOLACvtfcHk0lgbFwsUYMETPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktl2itLg%253D&md5=4047a6ea068dbde57896da520fbdf0d3</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm500118j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500118j%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DGribble%26aufirst%3DM.%2BW.%26aulast%3DAlba%26aufirst%3DG.%2BQ.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DCarlson%26aufirst%3DT.%2BJ.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DCho%26aufirst%3DR.%26atitle%3DDiscovery%2520of%2520AMG%2520925%252C%2520a%2520FLT3%2520and%2520CDK4%2520Dual%2520Kinase%2520Inhibitor%2520with%2520Preferential%2520Affinity%2520for%2520the%2520Activated%2520State%2520of%2520FLT3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3430%26epage%3D3449%26doi%3D10.1021%2Fjm500118j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span>Discovery Studio, version <span class="NLM_edition">2.5</span>; <span class="NLM_publisher-name">Accelrys, Inc.</span>: <span class="NLM_publisher-loc">San Diego, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Discovery+Studio%2C+version+2.5%3B+Accelrys%2C+Inc.%3A+San+Diego%2C+CA%2C+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DDiscovery%2520Studio%26pub%3DAccelrys%252C%2520Inc%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span>Maestro, version <span class="NLM_edition">9.0</span>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York, NY</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Maestro%2C+version+9.0%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+NY%2C+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DMaestro%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span>Prime, version <span class="NLM_edition">2.1</span>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York, NY</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Prime%2C+version+2.1%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+NY%2C+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DPrime%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span>LigPrep, version <span class="NLM_edition">2.3</span>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York, NY</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=LigPrep%2C+version+2.3%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+NY%2C+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DLigPrep%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span>Epik, version <span class="NLM_edition">2.0</span>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York, NY</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Epik%2C+version+2.0%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+NY%2C+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DEpik%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span>Glide, version <span class="NLM_edition">5.5</span>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York, NY</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Glide%2C+version+5.5%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+NY%2C+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DGlide%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbertz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pippin, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvino, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallamo, J. P.</span><span> </span><span class="NLM_article-title">Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5149</span><span class="NLM_x">–</span> <span class="NLM_lpage">5171</span><span class="refDoi"> DOI: 10.1021/jm800475y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800475y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVWmurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5149-5171&author=A.+K.+Ghoseauthor=T.+Herbertzauthor=D.+A.+Pippinauthor=J.+M.+Salvinoauthor=J.+P.+Mallamo&title=Knowledge+based+prediction+of+ligand+binding+modes+and+rational+inhibitor+design+for+kinase+drug+discovery&doi=10.1021%2Fjm800475y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Knowledge Based Prediction of Ligand Binding Modes and Rational Inhibitor Design for Kinase Drug Discovery</span></div><div class="casAuthors">Ghose, Arup K.; Herbertz, Torsten; Pippin, Douglas A.; Salvino, Joseph M.; Mallamo, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5149-5171</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review describing the use of Protein Data Bank (PDB) entries specifically for kinase inhibitor drug discovery.  Topics discussed include: the current state of structure-aided ligand design, kinase structure queries and extn. from the PDB, alignment of protein structures, structural classification of ligands, anal. of ligands and binding modes, and ligand design strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDINDYVE15cbVg90H21EOLACvtfcHk0ljUf1DOqvTjdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVWmurnM&md5=a1afc4d6c7f6fa4dd6aa9da8d78f1ee3</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm800475y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800475y%26sid%3Dliteratum%253Aachs%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DHerbertz%26aufirst%3DT.%26aulast%3DPippin%26aufirst%3DD.%2BA.%26aulast%3DSalvino%26aufirst%3DJ.%2BM.%26aulast%3DMallamo%26aufirst%3DJ.%2BP.%26atitle%3DKnowledge%2520based%2520prediction%2520of%2520ligand%2520binding%2520modes%2520and%2520rational%2520inhibitor%2520design%2520for%2520kinase%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5149%26epage%3D5171%26doi%3D10.1021%2Fjm800475y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA','PDB','3IKA'); return false;">PDB: 3IKA</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG','PDB','1PKG'); return false;">PDB: 1PKG</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB','PDB','1RJB'); return false;">PDB: 1RJB</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i48"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00374">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_33668"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b00374">10.1021/acs.jmedchem.6b00374</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Selectivity profile data for <b>1</b> versus a panel of 26 kinase targets, table and figures presenting validations of FLT3 homology model and docking results, in vitro enzymatic selectivity against FLT3 over EGFR, Western blot results of <b>23</b> in MV4–11 cells, the cell arrest and apoptosis results of <b>23</b> in MV4–11 cells, in vivo effects of <b>31</b> against MV4–11 tumor xenografts via intraperitoneal administration, and details of kinase selectivity of <b>31</b> against a panel of 468 kinases (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00374/suppl_file/jm6b00374_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00374/suppl_file/jm6b00374_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00374/suppl_file/jm6b00374_si_001.pdf">jm6b00374_si_001.pdf (2.22 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00374/suppl_file/jm6b00374_si_002.csv">jm6b00374_si_002.csv (4.24 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00374&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-13%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00374%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00374" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a6e770a193c6a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
